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ABSTRACT
Cannabinoids reported to have analgesic, anti-inflammatory and 
immunosuppressive effects were also shown to reduce joint damage in 
animal models of arthritis, suggesting that they have a potential as anti- 
arthritic agents. Therefore in this thesis, the effects of cannabinoids were 
studied to determine the mechanisms involved in their joint protective effects 
by making use of IL-1a-induced bovine articular chondrocytes and nasal 
cartilage explants.
IL-1a induction of the inducible nitric oxide synthase (iNOS), 
cyclooxygenase-2 (COX-2) and 5-lipooxygenase (5-LOX) pathways and 
effects of cannabinoids on these was studied using immunofluorescence, 
immunoblotting as well as ELISAs. Effects of cannabinoids on IL-1-induced 
activation of nuclear factor-kappa B (NF-kB) as well as p38 mitogen activated 
protein kinase (MAPK) were determined by immunofluorescence and fast 
activated cell-based ELISA (FACE®). Cartilage explant cultures were 
stimulated with IL-1a to resorb and effects of cannabinoids on the release of 
collagen (using hydroxyproline assay), cartilage oligomeric matrix protein 
(COMP) (using an ELISA) and proteoglycan (using dimethylmethylene blue 
assay) were studied as well. Expression of cannabinoid receptors in 
chondrocytes was also determined by immublotting and immunofluorescence.
Cannabinoids inhibited IL-1a-induced iNOS, COX-2 expression, NF-kB and 
p38 MAPK activation in chondrocytes. They also protected the explants from 
resorption stimulated by IL-1. Chondrocytes were also shown for the first time 
to express cannabinoid receptors. The results suggested that cannabinoids 
protected cartilage from cytokine-induced degradation, in part, by inhibiting 
NO and PGE2 production and their pathways. These effects were possibly 
receptor mediated. Cannabinoids appear to have a significant potential as 
anti-arthritic therapeutics.
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CHAPTER 1 
INTRODUCTION
1
General introduction
Arthritis, a term that literally means joint inflammation, is characterised by joint 
pain, swelling and stiffness followed by joint destruction and deformity (Auw 
Yang et a/., 2004; Blumenkrantz et al., 2004). The most common forms of 
arthritis are osteoarthritis and rheumatoid arthritis, the most common 
disabling disease states in which articular cartilage metabolism is altered 
leading to cartilage destruction (Auw Yang et al., 2004; van de Berg, 1998). 
There is no cure for these diseases although there are a number of drugs 
recommended for arthritis treatment such as the non-steroidal anti­
inflammatory drugs and disease modifying anti-rheumatoid drugs (Arjmandi et 
al., 2004; Carter, 1997). These drugs however are either slow-acting or may 
control either pain or inflammation, requiring combination of drugs, and have 
a number of side effects. The search for effective and less toxic anti-arthritic 
agents is still going on. Cannabinoids have potential as anti-arthritic agents. 
There is anecdotal evidence that they are effective in relieving symptoms of 
arthritis. Furthermore they have been shown to have analgesic, 
immunosuppressive and anti-inflammatory effects and to prevent joint 
damage in animal models of arthritis (Bidinger et al., 2003; Burstein, 2000; 
Mafait et al., 2000; Zurier et al., 1998). It is therefore possible that 
cannabinoids have the potential to modify cartilage metabolism in arthritic 
conditions to prevent cartilage destruction. Studies on the effects of 
cannabinoids on cartilage metabolism form the core of this thesis.
1.1 Cartilage
Cartilage is a uniquely specialised connective tissue consisting of cells 
(chondrocytes) and extracellular matrix. There are 3 different types of 
cartilage characterised by composition of extracellular matrix namely: elastic 
cartilage, fibrocartilage and hyaline cartilage. Elastic cartilage is characterised 
by the presence of elastic fibres within the matrix, which increase elasticity in 
tissues such as the external ear and trachea (Saw and Mironowicz, 1991). 
Fibrocartilage is found in intervertebral discs, the pubic symphysis, in menisci 
of joints, and often occurs where tendon and ligament are joined to bones.
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This tissue consists of thick, interlaced collagenous fibres, collagen type I is 
the most abundant collagen in this cartilage. Fibrocartilage provides good 
resistance to shear and compression forces (Saw and Mironowicz, 1991). 
Hyaline cartilage is found lining articular surfaces, and in the nasal septum, 
tracheal rings, costal cartilages, and the epiphyseal cartilage of growing bone. 
Articular hyaline cartilage consists of a glassy and homogenous matrix with 
more collagen than other types of hyaline cartilage (Saw and Mironowicz, 
1991).
1.1.1 Articular cartilage
Articular cartilage is a very important tissue of the diarthrodial joints (also 
known as synovial joints) (Fig. 1.1). These joints have a wide range of 
movement. The joint cavity in these joints is fairly large with the adjacent 
bones widely separated and is filled with synovial fluid which lubricates the 
joints (Stevens and Lowe, 2000). Cavity margins are defined partly by 
articular cartilage covering the ends of the adjacent bones, and partly by a 
tough fibrous capsule (Stevens and Lowe, 2000; Woolf, 1998). The inner 
surface of the capsule is lined by well vascularised connective tissue, 
composed partly of fibrous and partly of adipose tissue. This is lined by 
synovial membrane (synovium), which is a layer or two of type A cells 
(belonging to the macrophage family, producing hyaluronic acid) and type B 
cells (fibroblastic but also producing non-collagenous proteins). There is no 
basement membrane beneath the synovium, hence transfer of water, solutes 
and proteins between the blood and fluid within the cavity is facilitated (Woolf, 
1998).
Articular cartilage has unique material properties that enable it to perform its 
physiological and mechanical functions over a lifetime and under a wide 
range of loading conditions (Muir, 1980; Roughley, 2001). Articular cartilage is 
a tissue in which cells (chondrocytes) are sparsely distributed in rigid 
extracellular matrix (Muir, 1980). The articular cartilage is avascular, aneural 
and alymphatic relying on the process of diffusion to provide nutrients for the
3
chondrocytes (Roughley, 2001). Access to nutrients and elimination of waste 
products occur via diffusion through the extracellular matrix (Roughley, 2001).
Bone
Ligament
Fibrous joint capsule 
Synovium
Joint space (synovial cavity) 
Articular cartilage
Skeletal muscle
Tendon
Figure 1.1: Diagram of a synovial joint showing the features that make up the 
joint and help it to articulate and make a wide range of movements.
1.1.2 Articular cartilage composition
Articular cartilage is primarily made up of water, collagen, proteoglycans, 
other non-collagenous proteins and chondrocytes.
1.1.2.1 Water
Articular cartilage is a highly hydrated material. Water distribution varies; 
making up 65% of wet weight at the deep zone and 80% at the joint surface 
(Muir, 1980; Saw and Mironowicz, 1991). Weight bearing capacity is made
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possible through regional changes in water content which allow deformation 
of the cartilage surface in response to stress (Saw and Mironowicz, 1991). It 
is precisely the presence of water in conjunction with the hydrophilic 
proteoglycans and presence of collagen that makes cartilage tough and 
resilient (Muir, 1980). A random macromolecular mesh (represented here by 
proteoglycans), when placed within a fibrous network (such as collagen) such 
that the macromolecule cannot move, impedes the flow of interstitial water 
within the tissue when an external force is applied. Fluid pressure within 
cartilage rises immediately a load is applied, but cartilage deforms only 
gradually as the water is driven out from the loaded areas. Thus the 
compressive stiffness of cartilage over short time intervals is directly 
correlated with the proteoglycan content measured as glycosaminoglycans 
(GAGs) (Muir, 1980).
Water acts as a medium through which chondrocytes have access to 
nutrients and eliminate wastes and it also provides lubrication of cartilage 
(Saw and Mironowicz, 1991). Water content decreases with normal ageing 
(Saw and Mironowicz, 1991) whilst water content of osteoarthritic cartilage 
increases, particularly in coarse, fibrillated areas where the GAG content is 
markedly depleted (Muir, 1980). Water distribution in the tissue is also 
altered, it is highest near the mid-zone rather than toward the joint surface as 
in normal cartilage (Muir, 1980). It was reported also that unlike normal 
cartilage, osteoarthritic cartilage swells when placed in 0.15 M NaCI and it 
has been suggested that osteoarthritic cartilage imbibes water and swells in 
physiological saline because the collagen network that opposes swelling 
pressure of proteoglycan has been damaged (Muir, 1980).
1.1.2.2 Collagen
Collagen forms the framework that provides the tensile strength and stiffness 
in articular cartilage (Sugimoto et al., 2004). It accounts for about 50% dry 
weight (dw) of the human adult articular cartilage, however articular cartilage 
is not uniform in composition throughout its depth (section 1.1.3). The 
collagen content is higher in the superficial layers. Proteoglycan content
varies inversely with the collagen content since it is highest in the deeper 
layers of the cartilage tissue (Muir, 1980).
Articular cartilage contains a number of genetically distinct types of collagen 
(Eyre, 1991). Type II collagen is the most abundant collagen in mammals, 
however collagens III, VI, IX, X, XI, XII and XIV all contribute to the mature 
matrix (Eyre, 2002). Collagen types II, IX, X, and XI are referred to as 
“cartilage specific”. Collagen types II, IX, and XI are organized into 
copolymeric fibrils, where type II constitutes the bulk of the fibril, type XI 
regulates fibril size, and type IX facilitates fibril interaction with proteoglycan 
macromolecules (Cremer et al., 1998). Stromelysin, a matrix 
metalloproteinase, was recently shown to degrade type IX collagen. This 
action may cause the collagen network swelling seen in articular cartilage in 
early experimental osteoarthritis (OA) (Eyre, 1991). Collagen type X is 
restricted to the thin layer of calcified cartilage that interfaces articular 
cartilage with bone (Eyre, 2002), a zone that exhibits active remodeling in 
joints with OA (Eyre, 1991).
Chondrocytes are surrounded by a pericellular matrix and enclosed within a 
pericellular capsule and it has been suggested that the chondrocyte, its 
pericellular matrix, and capsule together constitute the chondron. Type VI 
collagen is preferentially localised in the chondron (Poole et al., 1992) and 
may help the chondrocytes to attach to the macromolecular framework of the 
matrix (Buckwalter et al., 1998).
Synthesis of collagen takes place in stages at various intracellular and 
extracellular sites. Intracellularly, collagen mRNA is translated into 
polypeptide chains that are released into the cisternae of the rough 
endoplasmic reticulum (rER) where the signal peptide is cleaved. Lysine and 
proline residues are hydroxylated and hydroxylysine residues are 
glycosylated. N-linked sugars are added to the terminal portion of the 
polypeptide (Saw and Mironowicz, 1991). The collagen molecule consists of 
an uninterrupted triple helix of about 300 nm in length and 1.5 nm in diameter. 
This is formed from three component polypeptide chains of repeating
structure G-X-Y, in which G is Glycine; X and Y are frequently the imino acids 
proline and hydroxyproline (Holmes et al., 2001). Thus procollagen is formed 
through intrachain and interchain disulfide bonds that stabilise the 
polypeptides and determine the shape of the molecule. Procollagen is then 
packed into secretory granules, which move along microtubules to be 
released into the extracellular matrix (Saw and Mironowicz, 1991). 
Extracellularly, uncoiled terminal ends of procollagen are cleaved to form 
tropocollagen. Tropocollagen molecules aggregate and lysine and 
hydroxylysine residues are crosslinked to form collagen fibrils, which also 
aggregate to form collagen fibres (Saw and Mironowicz, 1991) (see Fig. 1.2).
Collagen  
Fibril
Collagen
Molecule
Triple Helix
Alpha-chain
Figure 1.2: Diagram showing stages of formation and arrangement of 
collagen. Modified from Saw and Mironowicz (1991).
1.1.2.3 Proteoglycans and other non-collagenous proteins
Collagen molecules and proteoglycans interweave to form cartilage matrix. 
Proteoglycans, due to their-polyanionic charge provided by the sulphated
E M
GlycineHO, HO,
Hydroxyproline
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GAG chains, attract water into the cartilage matrix, thus creating a high 
osmotic pressure resisted by and constrained only by the framework of 
collagen fibres (Little et al., 2002). During joint loading and articulation, the 
proteoglycans dissipate the compressive forces and reversibly deform by 
releasing water to the synovial fluid, and upon relaxation they pull water in 
(Flannery et al., 1999; Sugimoto etal., 2004). This model of osmotic pressure 
and collagen fibres, thus, renders the cartilage resistant to major irreversible 
deformation during load-bearing, and allows cartilage resiliency upon removal 
of load.
Aggrecan
The large aggregating proteoglycan, aggrecan, which is responsible for the 
osmotic swelling capability, and thus the elasticity of the cartilage matrix, is 
the most abundant non-collagenous protein in cartilage (Sugimoto et al., 
2004).
Aggrecan consists of an extended protein core, which can be subdivided into 
several well-defined functional regions: the N-terminal globular G1, G2 
domains and an interglobular domain (IGD) between the G1 and G2 domains, 
the keratan sulfate and chondroitin sulfate attachment region, and the C- 
terminal globular G3 domain (see Fig. 1.3) (Sugimoto etal., 2004).
The G1 domain non-covalently links with hyaluronic acid and a protein called 
link protein stabilises the association of the two molecules (Cawston, 1998). 
The attachment of approximately a hundred aggrecan monomers to a 
hyaluronic acid molecule form the multimolecular proteoglycan aggregates 
(Caterson et al., 2000).
The IGD domain, the short polypeptide region between G1 and G2, is highly 
conserved between mammalian species (Flannery et al., 1999) and it is the 
area on the core protein that is most prone to attack by proteinases.
The three major GAGs found in cartilage in order of abundance are 
chondroitin sulfate, keratan sulfate and hyaluronic acid. Numerous chains of 
chondroitin sulfate and keratan sulfate covalently linked to a core protein 
constitute the aggrecan monomer. Keratan sulphate (KS) attachment domain 
follows the G2 domain on the core protein of aggrecan. In turn, this is 
followed by the chondroitin sulphate (CS) attachment region (Fig. 1.3). Over 
100 CS and KS chains may be present in the GAG attachment domains 
(Roughley, 2001). The C-terminal globular domain, G3, possibly interacts with 
other components of the extracellular matrix, or may be involved in the 
intracellular trafficking during aggrecan synthesis (Roughley, 2001).
KS rich 
region
Link protein
Hyaluronic acid CS rich region
Figure 1.3: Diagram showing an aggrecan molecule linked to hyaluronic acid 
and stabilised by link protein. Modified from Porter etal. (2005).
Small leucine-rich repeat proteoglycans
The small proteoglycans (PGs) of cartilage matrix represent a small fraction 
of the total mass of PGs, but with a small size they can be present in 
equivalent moles to the large PGs. Three types of PGs with a wide skeletal 
and extraskeletal distribution, biglycan (PGI), decorin (PGII) and fibromodulin 
have distinct but homologous core proteins containing leucin-rich sequences. 
Carbohydrate substituents (one or two chondroitin sulphate or dermatan 
sulfate chains for decorin and biglycan respectively, chains of keratan sulfate 
for fibromodulin and oligosaccharides) present variations from tissue to tissue
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and with age and other factors. Decorin and fibromodulin appear to interact 
with collagen and to participate in the regulation of collagen matrices. In vitro 
experiments indicate a role for small PGs in adhesion, multiplication, 
differentiation, and migration of cells (Stanescu, 1990).
Cartilage oligomeric matrix protein (COMP)
The extracellular matrix of cartilage contains numerous proteins that are 
neither collagens nor proteoglycans and most of these are thought to play 
structural roles in the matrix. COMP is probably the most studied of these 
proteins (Roughley, 2001). COMP is a 524 kDa glycoprotein component of 
the matrix. It is composed of 5 100-120 kDa subunits and is secreted by 
chondrocytes from various types of cartilage and chondrosarcoma cells 
(Newton et al., 1994). It is the fifth member of the thrombospondin (TSP) 
gene family with a bouquet-like molecular structure (Fig. 1.4) (Posey et al., 
2004).
%- U - . %
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Figure 1.4: A diagram of COMP pentamer showing the bouquet arrangement 
with the globular domains at the ends of each monomeric unit. Modified from 
Posey et al. (2004)
Functional studies have shown that COMP binds types II and IX collagens but 
the role of COMP in the extracellular matrix remains to be defined (Posey et 
al., 2004). COMP also binds to fibronectin. Confocal microscopy
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demonstrated punctate binding on the cell surface, which is indicative of 
possible binding to cell surface receptors. It has been found that 
chondrocytes bind to fibronectin by an integrin receptor and that this complex 
is in turn anchored to the collagen matrix by a complex network mediated by 
COMP (DiCesare et al., 2002).
1.1.2.4 Chondrocytes
Structural integrity and cartilage function are maintained by the resident, 
sparsely distributed chondrocytes that rely on the diffusion of oxygen and 
nutrients from the synovial fluid or capillaries in the subchondral bone (Bigg 
and Rowan, 2001). Chondroprogenitor cells which are derived from 
mesenchymal cells differentiate into chondrocytes enclosed within small 
cavities called lacunae, often in groups of 2, 4, or 6  cells as a result of mitosis 
and restricted cellular movement (Saw and Mironowicz, 1991).
Chondrocytes are important in the control of matrix turnover through 
production of collagen, proteoglycans and enzymes for cartilage metabolism 
The available evidence indicates that normal matrix turnover depends on the 
ability of chondrocytes to detect alterations in the matrix composition and 
organization, including the presence of degraded molecules, and to respond 
by synthesizing appropriate types and amounts of new molecules (Bulkwalter 
and Mankin, 1998).
1.1.3 Articular cartilage zonal arrangement
The articular cartilage contains different zones with respect to depth from the 
articular surface and has a regional organization around the chondrocytes. Its 
composition varies regionally and zonally in its collagen and proteoglycan 
contents and those of other matrix molecules (Poole et al., 2001). Beginning 
with the articulating surface, mature cartilage can be separated into the 
superficial, middle, deep, and calcified zones (Fig. 1.5). The first 10-20% of 
the full-thickness articular cartilage contains densely packed collagen II fibrils 
and flattened, discoid or elongated flattened cells, oriented parallel to surface
in the direction of shear stress and is classified as the superficial zone (Saw 
and Mironowicz, 1991; Darling etal., 2004). The middle zone (40-60% of full 
thickness) contains round cells arranged singly or in pairs and collagen fibres 
that are thick and obliquely or randomly arranged. It serves as a transition 
between the superficial and deep zones (Darling et ai, 2004). Columns of 
ellipsoid cells distributed between radially oriented collagen fibres 
characterize the deep zone. The collagen fibrils extend into the calcified zone 
to reinforce the bond between cartilage and bone. The deep zone is 
separated from the calcified zone by a distinct tidemark, an undulating barrier 
tangential to the surface, which represents a plane of weakness, which is 
often considered the boundary between cartilage and bone. The calcified 
zone contains cells trapped within a calcified matrix and it contains 
hydroxyapatite crystals that anchor the cartilage to the subchondral bone 
(Darling etal., 2004; Saw and Mironowicz, 1991).
Articular surface
Superficial zo n e |# _ ~ v
Middle zone
Deep zone
I
Territorial
matrix
Tidemark viBB 
Calcified zone
Figure 1.5: Diagram showing different zonal layers of articular cartilage. 
Adapted from Darling et al. (2004).
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Through the depth of cartilage, water content falls linearly, from approximately 
84% wet weight (ww) to 40-60% ww. The collagen content falls from 8 6 % dw 
in the superficial zone to 67% dw in the deep zone. The proteoglycan content 
increases from around 15% dw in the superficial zone to a peak of 25% dw in 
the middle zone, then falls to 20% in the deep zone Darling et al. (2004).
1.2 Cartilage Metabolism
Chondrocytes maintain cartilage tissue homeostasis, sustaining the crucial 
balance between the rate of biosynthesis and incorporation of matrix 
components, and the rate of their degradation and subsequent loss from the 
cartilage into the synovial fluid (Steinmeyer and Daufeldt, 1997). Under 
physiologic conditions, chondrocytes show steady-state equilibrium between 
anabolic and catabolic activities that maintains the structural and functional 
integrity of the cartilage extracellular matrix (Goidring et al., 2004). Any 
change in this steady state will rapidly affect the healthy function of the 
cartilage (Cawston, 1998). Active proteinases such as aggrecanases and 
matrix metalloproteinases (MMPs) are involved in cartilage resorption by 
degrading major components of cartilage extracellular matrix, collagen and 
proteoglycan, mostly type II collagen and aggrecan, respectively (Cawston, 
1998). The MMPs are secreted from the cells in a latent form (zymogens), 
requiring activation extracellularly. They and aggrecanases are inhibited by 
tissue inhibitors of metalloproteinases (TIMPs) (Steinmeyer and Daufeldt, 
1997). In arthritic conditions such as osteoarthritis and rheumatoid arthritis 
there is a disparity between the proteinases and TIMPs that accounts at least 
in part for the observed cartilage destruction (Steinmeyer and Daufeldt, 1997; 
Cawston, 1998). Proteoglycan breakdown is an early event in cartilage 
resorption process, while substantial degradation of collagen occurs later and 
may represent the point of irreversible cartilage damage (Little et al., 2 0 0 2 ).
1.2.1 Cytokines in Cartilage Metabolism
Cytokines such as interleukin-1 (IL-1), IL-6 , oncostatin M (OSM), tumour 
necrosis factor (TNF-a) and IL-17 have been reported to induce cartilage
breakdown (Amer et a i, 1998; Flannery et ai, 2000; Lubberts, 2003), whilst 
protective effects against cartilage breakdown were shown by IL-4, IL-1 0, IL- 
13, transforming growth factor-pi (TGF-pi) and insulin-like growth factor-1 
(IGF-1) (Cawston e ta i, 1996; Lubberts e ta i, 1998; Koshy etal., 2002).
1.2.1.1 Catabolic Cytokines
Key proinfiammatory cytokines, IL-1 and TNF-a
IL-1 was originally known as lymphocyte-activating factor (Saklatvala et ai, 
1985). Around the same time, a soluble factor, termed catabolin, released 
from living synovial and other connective tissues was reported to be capable 
of stimulating chondrocytes to degrade totally both proteoglycan and collagen 
(Dingle, 1981). The synovial catabolin was later believed to be a form of IL-1 
(Yodlowski et a i, 1990) and two immunologically distinct forms of IL-1 were 
purified and found to have identical molecular weight, demonstrate the same 
range of biological activity, but differ in isoelectric point. These isoforms were 
identified as IL-1 a and IL-1 p (Saklatvala et ai, 1985). IL-1 is the prototype of 
the pro-inflammatory cytokines in that it induces the expression of a variety of 
genes and the synthesis of several proteins that, in turn, induce acute and 
chronic inflammatory changes. IL-1 is also the prototypic cytokine that brings 
about increases in a variety of defense mechanisms, particularly immunologic 
and haematologic responses (Dinarello, 1991). The IL-1 family includes two 
agonist proteins, IL-1 a and IL-1 p, which are able to trigger cell activation upon 
interaction with specific receptors on the membrane of target cells (Boraschi 
et ai, 1996). Both members are first synthesized as 31 kDa precursor 
proteins, prolL-1a and prolL-1p respectively (Boraschi et al., 1996). The pro- 
IL-la and the enzymatically cleaved mature 17 kDa IL-1 a are both biologically 
active. Approximately 10-15% of the IL-la is myristoylated. It is believed that 
this form is transported to the cell surface where it is attached to the 
membrane and is called membrane IL-1 (Dinarello, 1994; Boraschi et ai, 
1996). In contrast, prolL-1p is relatively inactive and requires cleavage to a 17 
kDa peptide for optimal biological activity (Dinarello, 1994). An intracellular
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cysteine protease known as Interleukin 1-Converting Enzyme (ICE also 
known as caspase-1) is highly specific for cleaving prolL-1 p but does not 
cleave the IL-la precursor. Other enzymes have been found that do cleave 
the IL-1 precursors but these seem less specific than ICE (Boraschi et al., 
1996). IL-1 proteins lack a signal peptide and thus are not secreted through 
classical pathways and are unglycosylated proteins (Boraschi et al., 1996). 
The third member of the IL-1 family is IL-1 Ra, a pure receptor antagonist, 
which is a glycosylated secretory protein of about 23 kDa (Boraschi et al., 
1996; Dinarello, 1994). IL-1Ra is also first produced as a precursor with a 
leader sequence (peptide signal), which is cleaved to produce the mature 
form therefore IL-1Ra is secreted like most proteins (Boraschi et al., 1996). 
Although IL-1Ra is secreted (slL-1Ra), another form of the IL-1Ra gene is 
retained inside cells: intracellular (ic) IL-1Ra. icIL-IRa results from alternate 
mRNA splicing of the IL-1Ra transcript replacing the first exon coding for the 
signal peptide. However, both forms of IL-1Ra are functionally 
indistinguishable. IL-1Ra functions primarily to block IL-1 receptors and thus 
acts as a natural inhibitor of IL-1 activity (Dinarello, 1994).
Activation of target cells by IL-1 depends on the interaction with specific 
receptors on the cell membrane. Two types of IL-1 receptors (IL-1R) have 
been identified, IL-1 R| and IL-1 Rn.The second type of IL-1 R, IL-1 R h, shares 
many structural characteristics of IL-1 R|. The main difference between IL-1Rn 
and IL-1Ri lies in the intracellular domain, which is extremely short for IL-1 Rn 
and is apparently unable to initiate signal transduction. Thus, the functional 
role of IL-1 Rn apparently is that of binding and sequestering IL-1, thus 
avoiding its interaction with IL-1R| and consequent cell triggering. IL-1 Rn can 
therefore act as another natural inhibitor of IL-1 activity, complementing the 
function of IL-1Ra (Boraschi etal., 1996).
TNF-a is a proinflammatory cytokine that contributes to a variety of disease 
states and is produced mainly by monocytes and macrophages (Shankar and 
Handa, 2004). The protein exists as a membrane-bound precursor of relative 
molecular mass of 26 kDa which can be processed by a TNF-alpha- 
converting enzyme (TACE also known as ADAM17), to generate secreted 17
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kDa mature TNF-a (Moss et al., 1997). TNFa binds to its receptors on a 
variety of target cells, transducing a signalling cascade in those cells. There 
are two TNF-alpha receptors; the 55 and 75 kDa TNF-a receptors (TNF-R55 
and TNF-R75, respectively) (Gallea-Robache et al., 1997) also referred to as 
p55 and p75 TNF receptors (Webb et al., 1997). Expression of p55 TNF-a 
receptor has been localised in cells at sites of focal loss of cartilage 
proteoglycan in OA patients (Webb, et al., 1997) providing evidence for role of 
TNFa in pathogenesis of human OA. TNF-a triggers production of other 
cytokines, induces endothelial adhesion molecules, stimulates collagenase 
and stromelysin production, and stimulates osteoclast differentiation thus its 
blockade has a more global effect on inflammation than the blockade of other 
cytokines (Shankar and Handa, 2004).
A number of studies showed that effects of TNFa were similar to IL-1 or 
synergistic with it and thus suggested a role for the cytokines in cartilage 
destruction (Goldring, 2000). IL-1 is one of the key mediators by which the 
chondrocytes and synoviocytes enhance their protease production 
(Steinmeyer and Daufeldt, 1997) and inflammatory factors. Chondrocytes 
produce large quantities of nitric oxide (NO) from L-arginine oxidation by 
inducible nitric oxide synthase (iNOS or NOS-II), when stimulated by IL-1 
alone or in combination with TNFa (Amin and Abramson, 1998; Goldring, 
2000). IL-1 alone or in combination with TNFa has also been shown to be 
capable of stimulating chondrocytes to express cyclooxygenase-2 (COX-2) 
which results in production and secretion of prostaglandin E2 by the cells 
(Hardy et al., 2002; Martel-Pelletier et al., 2003). These pro-inflammatory 
mediators have been implicated in the pathogenesis of osteoarthritis (Goggs 
et al., 2003; Mendes et al., 2002; Studer et al., 1999). They have different 
effects in articular cells that may lead to cartilage resorption. These effects 
include inhibition of matrix synthesis, upregulation of MMP production and 
induction of chondrocyte apoptosis (Goggs et al., 2003; Henrotin et al., 2003; 
Studer et al., 2003). Apoptosis induced by PGE2 in chondrocytes is linked 
with the cAMP-dependent pathway (Miwa et al., 2000). Both IL-1 and TNFa 
are found at enhanced levels in synovial fluid from inflamed joints and are 
thought to play important roles in the destruction that ensues (Manicourt et
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al., 2 0 0 0 ). Through use of animal models of arthritis and cytokine-specific 
neutralising antibodies as well as cytokine specific knockout conditions, it was 
found that TNFa is sufficient to drive the early aspect of joint inflammation as 
well as the acute cellular infiltrate in the synovial tissue, while IL-1 has a 
pivotal role in sustaining both inflammation and erosive cartilage damage (van 
den Berg et al., 1999). Persistent joint inflammation and erosive joint damage 
are the characteristics of chronic arthritis thus both cytokines need to be 
targeted to achieve optimal treatment in arthritis (van den Berg et al., 1999).
Other proinflammatory cytokines 
IL-6
IL- 6  is one of the regulatory cytokines that influences IL-1- and TNFa-induced 
catabolic processes (Goldring, 2000). IL- 6  is involved in diverse biological 
processes such as final maturation of B cells into plasma cells, T cell 
activation, induction of the acute-phase response, stimulation of growth and 
differentiation of haematopoietic precursor cells and proliferation of synovial 
fibroblasts (Shankar and Handa, 2004). IL-1 and TNFa can stimulate its 
synthesis in chondrocytes (Goldring, 2000). IL- 6  alone is not capable of 
stimulating cartilage degradation directly. Recently it has been reported that 
soluble IL- 6  receptor (slL-6 Ra) is required for full response to IL- 6  in 
chondrocytes in vitro and was also found to potentiate the inhibitory effects of 
IL- 6  on proteoglycan synthesis, but this effect was moderate compared with 
that of IL-1 (Goldring, 2000). IL- 6  and its soluble receptor also augment 
aggrecanase-mediated proteoglycan catabolism in articular cartilage 
(Flannery et al., 2000).
IL-17
IL-17 is one of the potent inducers of catabolic responses in chondrocytes. It 
increases the expression of IL-1 [3, IL-6 , stromelysin, iNOS and COX-2 in 
human articular chondrocytes (Goldring, 2000). IL-17 is produced by 
activated T lymphocytes, predominantly of CD4+ sub-type, in RA synovial
fluid and tissue (Goldring 2000). Interleukin 17 induces cartilage collagen 
breakdown in cartilage and shows synergistic effects in combination with 
other proinflammatory cytokines (Koshy et al., 2002) and IL-17 has a role in 
the pathogenesis of arthritis (Lubberts, 2003).
IL-18
IL-18 is a cytokine that was originally identified as Interferon-gamma (IFN-y)- 
inducing factor (IGIF) (Ghayur et al., 1997). IL-18 has structural similarities 
with the IL-1 family of proteins. IL-18 is also synthesized as a biologically 
inactive precursor and cleaved by the ICE. Macrophages and other cells 
produce it. The human IL-18R was purified and its sequence was found to be 
identical to the previously known IL-1R-related protein (Olee et al., 1999). IL- 
18 augments natural killer (NK) activity in spleen cells and may be involved in 
the development of Th1 cells and also in mechanisms of tissue injury in 
inflammatory reactions (Okamura et al., 1995). IL-18 stimulates the 
expression of several genes and their proteins in normal human articular 
chondrocytes including iNOS, COX-2, IL-6 , and stromelysin and treatment of 
normal human articular cartilage with IL-18 increased proteoglycan 
degradation (Olee et al., 1999). This suggests that IL-18 regulates 
chondrocyte responses and contributes to cartilage pathophysiology. Synovial 
tissue IL-18 expression was also shown to correlate with disease activity in 
inflammatory arthritis (Rooney et al., 2004). After treatment, tissue levels 
changed in parallel with changes in serum IL-18 and with changes in the 
acute phase response. These observations support a role for IL-18 in the 
pathophysiology of inflammatory arthritis (Rooney et al., 2004).
Oncostatin M
Oncostatin M (OSM), a T cell or monocyte cytokine, closely related to IL-6 , 
stimulates proteoglycan release and inhibits its synthesis in cartilage 
explants. Elevated levels of OSM were detected in synovial fluid from arthritic 
patients (Hui etal., 1997). When in combination with IL-1 a, OSM promoted an 
enhanced release of proteoglycan and collagen from cartilage explants. This
18
was accompanied by an enhanced upregulation of active and pro- 
collagenases and a reduction in TIMP-1 (Hui et al., 2000). Unlike IL-6 , OSM 
stimulated aggrecan catabolism and when combined with IL-1 enhanced 
release of collagen in nasal cartilage explants (Manicourt etal., 2000).
1.2.1.2 Immunomodulatory and anti-inflammatory cytokines
IL-4
IL-4 is a 20 kDa glycoprotein that has a broad spectrum of biological activities 
including growth and differentiation of T cells, B cells, mast cells, 
haematopoietic cells and non-haematopoietic cells, such that it is referred to 
as the prototypic immunoregulatory cytokine (Brown and Hural, 1997; Noma, 
1992). It is produced only by a subset of activated hematopoietic cells, 
including T cells, mast cells and basophils and has an important role in 
regulating antibody production, haematopoiesis and inflammation, and the 
development of effector T-cell responses (Brown and Hural, 1997). The 
biological effects of IL-4 are induced by binding to specific membrane IL-4 
receptors (IL-4R) on target cells (Noma, 1992). IL-4 blocks the release of 
collagen fragments from bovine nasal cartilage treated with cytokines 
(Cawston et al., 1996), suggesting its therapeutic potential in arthritis. IL-4 
also enhances the effects of IL-10 in reducing joint inflammation and cartilage 
destruction in murine streptococcal cell wall (SCW) arthritis (Lubberts et al., 
1998) producing more therapeutic benefits.
IL-10
IL-10, an immunoregulatory cytokine produced by T cells and monocytes, 
inhibits the expression of inflammatory and hemopoietic cytokines as well as 
its own expression (Daftarian et al., 1996). IL-10 inhibits the antigen- 
presenting capacity of synovial fluid (SF) macrophages, importantly, IL-10 is 
able to downregulate the antigen presenting function of SF macrophages 
even when they are efficiently activated, which further emphasizes the anti­
inflammatory potential of IL-10 in RA (Mottonen et al., 1998). IL-10 is
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spontaneously produced in RA and OA and is an important immunoregulatory 
component in the cytokine network of RA (Katsikis et al., 1994) and has been 
shown to play a role in RA as an anti-inflammatory cytokine (Isomaki et al., 
1996). Neutralization of endogenously produced IL-10 in RA synovial 
membrane cultures resulted in a two- to threefold increase in the protein 
levels of proinflammatory cytokines (IL-1 p and TNFa) (Katsikis et al., 1994). 
IL-10 also enhances IL-4 suppression of inflammatory cytokine production by 
rheumatoid synovial cells (Sugiyama et al., 1995).
IL-13
Interleukin 13 (IL-13) is a recently described cytokine secreted by activated T 
cells (Zurawski and de Vries, 1994). IL-13 has profound effects on monocytes 
in vitro, acting not simply to deactivate them but rather in a complex manner 
to change monocytic morphology, phenotype, function, and cytokine 
production (Woods et al., 2000). IL-13 shares biological activities with IL-4, 
their genes are closely linked and there is sequence homology between IL-13 
and IL-4 proteins. Although the cloned IL-4 receptor protein (IL-4R) does not 
bind IL-13, it appears that the functional IL-4R and IL-13R share a common 
subunit that is important for signal transduction (Zurawski and de Vries, 
1994). IL-13 is potentially useful in the therapeutic treatment of OA, as it could 
regulate the major pathological process of this disease by reducing the 
production of proinflammatory cytokines (IL-1 p and TNFa) and 
metalloproteases (e.g. stromelysin-1), and favoring the production of IL-1Ra 
(Jovanovic et al., 1998). Increased expression of IL-13 via gene therapy 
decreased RA-associated inflammation by reducing secretion of 
proinflammatory cytokines and PGE2 in RA synovial tissue explants (Woods 
et al., 2000). In animal models of collagen induced arthritis (CIA), vector cells 
engineered to secrete interleukin-13 attenuated CIA in mice and this effect 
coincided with a decreased TNF-a mRNA expression in the spleen of treated 
animals (Bessis et al., 1996), suggesting therapeutic potential of IL-13 in the 
treatment of autoimmune diseases such as RA.
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In one study, effects of IL-4, IL-10, and IL-13 were compared in the 
interruption of two major inflammatory pathways in RA (i.e. overexpression of 
proinflammatory cytokines and cytokine-mediated fibroblast growth). All the 
cytokines were able to significantly inhibit the production of proinflammatory 
cytokines by freshly isolated RA synovial tissue cells; however IL-10 was the 
most potent. The IL-1 receptor antagonist was enhanced by IL-4 and IL-13, 
but only slightly enhanced by IL-10. Addition of anti-IL-10 neutralizing 
antibody to RA synovial tissue cells resulted in a substantial increase in IL-1 p 
and TNF-a levels, whereas neither anti-IL-4 nor anti-IL-13 antibody had a 
significant effect. IL-1(3-stimulated proliferation of RA synovial fibroblast cell 
lines was inhibited by IL-4 and IL-13, but not by IL-10; IL-4 was over tenfold 
more effective than IL-13. The results indicate that cytokines, IL-4, IL-10, and 
IL-13, have the therapeutic potential to regulate the disease activity mediated 
by proinflammatory cytokines in RA, but each cytokine may have different 
potencies (Morita et al., 2001).
1.2.1.3 Growth factors in cartilage
Transforming growth factor-beta (TGF-ps)
The TGF family includes a number of polypeptides involved in the regulation 
of cell growth and differentiation and in wound healing. The TGF-p, first 
identified by its ability to stimulate normal cells to grow and differentiate in soft 
agar, is found throughout the body and binds to at least three membrane 
receptors common to most cells. Three isoforms, TGF-p1, TGF-p2, and TGF- 
p3, have been isolated from cartilage in mammals (Holland and Mikos, 2003).
TGF-p1 has been shown to promote the differentiation of stem cells to 
osteoblasts, osteoclasts, and chondrocytes. In articular cartilage, TGF-pi 
promotes protein synthesis and cell proliferation and inhibits the actions of 
MMPs (Holland and Mikos, 2003). In addition to these protective effects on 
articular cartilage, it is also known to promote chemotaxis and activation of 
inflammatory cells and, at high concentrations, has been implicated in fibrosis
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and osteophyte formation in articular cartilage defects (Holland and Mikos,
2003).
IGFs
Insulin-like growth factors 1 and 2 (IGF-1 and IGF-2), which exhibit close 
homologies to insulin, have been isolated from a number of tissues, including 
articular cartilage. These growth factors were initially discovered as sulfation 
factors or somatomedins, which promote sulfate incorporation into 
proteoglycans. In articular cartilage, these growth factors act primarily in an 
anabolic fashion to increase proteoglycan and type II collagen synthesis. IGF- 
1 also appears to influence cellular differentiation and specific integrin 
expression (Holland and Mikos, 2003). Although IGF-1 is nearly ubiquitous, 
its bioavailability in cartilage is controlled by IGF-1 binding proteins (IGFBPs) 
secreted by chondrocytes. IGFBPs are part of a complex system, termed the 
IGF-1 axis that tightly regulates IGF-1 activities. For the most part, IGFBPs 
block IGF-1 activity by sequestering IGF-1 from its cell surface receptor 
controlling its bioavailability in human articular cartilage (Martin et al., 2000). 
The damage-induced proteinases may subsequently liberate IGF-1 from such 
pools and cause greatly enhanced anabolic processes, contributing to 
cartilage repair (Purple et al., 2002). It has been suggested that this 
mechanism may have an important role in maintenance and repair of articular 
cartilage and that age-related failure to organize this system may contribute to 
progressive articular cartilage degeneration (Martin et al., 2000).
1.2.2 Extracellular matrix proteinases
Degradation of cartilage is a major feature of OA and RA. Major activities 
responsible for catabolism of proteoglycan (mainly aggrecan) and collagen 
(mainly Type II collagen) are attributable to zinc-dependent 
metalloproteinases (Flannery et al., 2000) in particular the MMPs and 
aggrecanases.
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1.2.2.1 Matrix metalloproteinases
The MMPs (Table 1.1) play an important role in the digestion of the 
extracellular matrix in both normal and degenerative articular cartilage. These 
enzymes target specific components of the extracellular matrix such as 
collagen, aggrecan, fibronectin, laminin, and elastin and may be activated 
through a number of signaling pathways (Holland and Mikos, 2003).
MMPs share a common domain structure comprising of a predomain, which is 
a signal peptide for secretion, a prodomain to maintain latency, a catalytic 
domain containing a highly conserved zinc-binding site, a hinge region, and a 
C-terminal also known as a hemopexin-like domain (Fig. 1.6). Two family 
members, MMP-2 and MMP-9, have a gelatin-binding domain containing 
three fibronectin-type II repeats inserted into the catalytic domain (Szabo et 
al., 2004).
Key to domains
I signal peptide propeptidecatalytic (metalloproteinase) domain 
Zinc active site
Figure 1.6: Diagram showing the domain structure of matrix
metalloproteinases (MMPs). Some MMPs have additional domains located 
up- and/or down-stream of the catalytic domain such as: fibronectin domain; 
Type I and type II transmembrane domain; cytoplasmic domain; cysteine 
array region; and IgG-like domain. Modified from Visse and Nagase (2003).
Most MMPs are secreted as proenzymes into the extracellular milieu (Leppert 
et al., 2001). However, six members of MMPs referred to as membrane-type 
MMPs (MT-MMPs) have recently been defined and were categorized in a
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new subfamily due to their unique feature of a C-terminal anchor sequence 
(transmembrane domain) after the hemopexin domain that keeps them 
attached to the cell membrane (Leppert et al., 2001). All MMPs are functional 
at neutral pH and are produced by a variety of cells including fibroblasts, 
neutrophils, eosinophils, macrophages, T-cells, chondrocytes and osteoblasts 
in response to inflammatory cytokines (Szabo et al., 2004).
Physiology and pathology of MMPs
The modeling, disassembly and remodelling of connective tissue matrices by 
one or more MMPs involves secretion and proteolytic activation of the 
precursor MMPs (Szabo et al., 2004). MMPs are synthesized as zymogens 
containing an N-terminal inhibitory propeptide sequence with a cysteine (Cys) 
that chelates the zinc (Zn2+) ion and keeps the enzyme in a latent pro-form. 
Various factors can activate MMPs via a conformational change that disrupts 
the Cys-Zn2+ binding (cysteine switch) and leads to intermediate activation 
followed by autocatalytic cleavage of the propeptide from the core protein 
rendering the enzyme fully active (Leppert etal., 2001; Szabo et al., 2004). 
Most MMPs are expressed only on demand through the action of cytokines, 
eicosanoids, growth factors and components of infectious pathogens, among 
others (Chien et al., 2005; Leppert et al., 2001) and the most prominent of 
these inducers are the pro-inflammatory cytokines IL-1a/(3 and TNF-a/(3.
MMPs contribute to joint destruction in at least two ways. First, they can 
directly enhance proteolytic degradation of the ECM of the cartilage and 
bone. The major MMPs implicated in the process are MMP-1, -2, -3, -9, -13 
and -15, wherein MMP-15 activates proMMPs-2 and -13 and MMP-14 plays 
an important role in the activation of pro-MMP-2 in the rheumatoid synovial 
lining cell layer, suggesting involvement in the cartilage destruction of RA. 
Secondly, MMPs are important during angiogenesis, which is a prominent 
feature of RA (Szabo etal., 2004).
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Table 1.1: Summary of MMPs proteins
Group MMP Other
name(s)
Special
feature(s)
Function (s)
Collagenases MVIP-1 
MVIP-8 
MVIP-13 
MVIP-18 
(Zenopus)
Specific cleavage 
site oncolla gens 3/41' from II- 
teririnus
Cleavage of 
collagens 1, II 
and III; digestion 
of other E CM 
and other non- 
ECMGelatin a ses MVIP-2 Gelatinase A 3 repeats of type BintfingtoMMP-9 GelatinaseB II fibronectin 
domain inserted in the catalytic 
domain
collagens, 
gelatins and laminin; digestion of 
denatured 
collagens and 
gelatins; Osteogenesis
Stromelysins MVIP-3 Stromelysin 1 MVIP-3 more Activation of a
MVIP-10 Stromelysin 2 efficacious than MVIP-10 number of proMVPs; 
digestion of ECM
Matrilysins MMP-7 Matrilysin-1 Lack of a D igestion of
MVIP-26 Matrilysin-2;Endometase hemopexindomain
E CM; processing 
of surface molecules (e.g. 
Fas-ligand, pro- 
THF-c)
MT-WMPsType Itrartsmembrane MVIP-14 MTT1-MM> Transmembrane Activation of
proteins MVIP-15 MVIP-16
MT2-MIVP
MT3-MM>
domain proMvP-2;Angiogenesis;
MVIP-24 MT5-MIVP MT5-MIVP is brain digestion of ECM
Glycosylphosphatidylinositol MVIP-17 MT4-MMP specific and molecules
<GPI) anchored proteins MVIP-25 MT6-MMP expressed mainly in the cerebellum
including collagens 1, II 
and III
Other MMPs
MMP-12 
MVIP-19
Metalloelastase Expressed in macrophages
Identified in the 
liver as cD I1A and 
as a T cell- derived
arltoantigen inRA
Macrophage 
migration; Digestion of 
elastin and other 
proteins
MMP-20
MMP-22
MVIP-23
E namely sin
Cysteine a i t  ay 
MMP
Located vuthin newly formed 
tooth enamel
First cloned from
chicken
fibroblasts andhuman
homologue
identified
Expressed mainly in reproductive tissues; lacks 
‘cysteine switch' 
motif and 
hemopexin domain; instead it 
has cysteine-rich 
domain followed 
by ig-like domain
D igestion of 
amelogenin
Unknown
MVIP-28 Epilysin E xpressed in keratinocytes
Tissue
homeostasis and wound healing
Modified from Visse and Nagase (2003).
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1.2.2.2 Aggrecanase proteins
Aggrecanases are members of ADAMTS (a disintegrin and metalloprotease 
with thrombospondin motifs) gene family (Tang, 2001). This is a novel group 
of extracellular proteases found in mammals including humans (Table 1.2). 
Although the existence of ‘aggrecanase’ was known for more than ten years 
based on its unique cleavage-site, it is only recently that two aggrecanases 
have been isolated from cartilage, cloned and expressed, designated 
ADAMTS-4 and ADAMTS-5 (aggrecanase-1 and -2, respectively) (Arner,
2002). The ADAMTS proteins consist of an N-terminal signal peptide and pro­
domain and have the characteristic ADAM (a disintegrin and metalloprotease) 
-like catalytic domain with the zinc-binding motif, a disintegrin-like and a 
cysteine-rich domain (Arner, 2002; Tang, 2001). However, they differ from 
conventional ADAMs in that they lack the transmembrane and cytoplasmic 
domains exhibited by many of these proteins. They have a distinct feature, a 
thrombospondin type 1 (TSP-l)-repeat between the disintegrin-like and the 
cysteine-rich domain, a spacer region, followed by a varying number of TSP- 
1 -like repeats at the C-terminus (Fig. 1.7). Since ADAMTS proteins lack 
transmembrane domains, they are therefore secreted into the ECM (Tang,
2001).
ADAMTS-4 
ADAMTS-5
Key to domains:! signal peptide pro domainmetalloproteinase domain 
disintegrin domain 
thrombospondin type 1 motif 
■  cysteine-rich domain 
—J spacer regionFigure 1.7: Diagram showing the domain structure of ADAMTS-4 
(Aggrecanase-1) and ADAMTS-5 (Aggrecanase-2). Modified from Porter et 
al. (2005).
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Both recombinant ADAMTS-4 and ADAMTS-5 cleave aggrecan within the 
IGD at a site not sensitive to MMPs. they also cleave aggrecan preferentially 
at four sites located in the CS-rich region between G2 and G3 (Tortorella et 
al., 2000). ADAMTS-4 and/or ADAMTS-5 are the aggrecanases responsible 
for aggrecan catabolism following IL-1 and TNF treatment of bovine articular 
cartilage (Tortorella etal., 2001).
Table 1.2: The human ADAMTS names and their function
ADAMTS Other Names Number of 
Tsp Motifs
Function
AD/WTS-1 METH-1; Aggrecanase-3; 
KIAA1346
3 Inflammation, angiogenesis, organ 
m orphogenesis, turn our invasion
ADAMTS-2 Procollagen N-proteinase 4 Procollagen processing
AD/WTS-3 KIAA0366 4 Procollagen processing
ADAMTS-4 Aggrecanase-1; KIM0688 1 Aggrecan, brevican.versican 
cleavage
ADAMTS-5 Aggrecanase-2; ADAMTS-11; 
Implantin
2 Aggrecan cleavage
ADAM TS-6 2 Unknowi
ADAMTS-7 2 Unknowi
ADAMTS-8 METH-2 2 Angiogenesis
ADAMTS-9 KIAA1312 13-15 Aggrecan, versican cleavage
ADAMTS-10 5 Unknowi
AD/WTS-12 8 Unknowi
ADAMTS-13 \WF-cleaving protease 8 von Willebrand factor cleavage
ADAMTS-14
ADAMTS-15
ADAMTS-16
AD/WTS-17
ADAMTS-18
ADAMTS-19
ADAMTS-20
4 Procollagen processing
Aggrecan cleavage
Unknowi
Unknowi
Unknowi
Unknowi
Unknowi
M o d ifie d  fro m  A rn e r , 2 0 0 2 ;  P o rte r  et a l . , 2 0 0 5 ;  an d  T a n g , 2 0 0 1
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1.2.2.3 Inhibitors of extracellular matrix metalloproteinases
The activity of MMPs is strictly regulated by a group of inhibitors. Two known 
natural sources of MMP inhibition are the a2-macroglobulin (a large protein 
(=750 kDa), produced by the liver) and the tissue inhibitors of matrix 
metalloproteinases (TIMPs) (Szabo et al., 2004). TIMPs are more specific 
endogenous inhibitors of MMPs that consist of at least four members (TIMP- 
1, -2, -3 and -4) (Holland and Mikos, 2003; Szabo etal., 2004). TIMPs control 
MMP activity by binding to the active site of MMPs. TIMPs may also bind to 
additional sites on latent MMPs (Holland and Mikos, 2003). TIMPs form 
noncovalent binding complexes in a 1 : 1  stoichiometry with pro and activated 
forms of MMPs and inhibit enzymatic activity. Although TIMPs bind tightly to 
most MMPs and are highly similar in their quaternary structure, their tissue 
distribution, regulation, and function are diverse. Aggrecanase activity is 
specifically inhibited by TIMP-3 (Kashiwaya et al., 2001). Similar to the 
metalloproteinases, TIMPs are also regulated by a network of different 
signaling molecules. The TIMPs inhibit the MT-MMPs, however, unlike the 
soluble MMPs, the MT-MMPs exhibit significant differences in affinities for the 
various TIMPs (Szabo et al., 2004). Elevated levels of MMPs and TIMPs are 
found in patients with OA and RA (Holland and Mikos, 2003).
1.3 Arthritis
1.3.1 Rheumatoid arthritis
RA is the commonest chronic inflammatory arthropathy (joint disease) of 
unknown origin with several extra-articular features suggesting systemic 
involvement and autoimmunity (Moller et al., 2001; Scott et al., 1998). RA 
affects about 1 % of the population, with a marked female predominance 
(Sayah and English, 2005). The disease can occur at any age, but it is most 
common among those aged 40-70 years, its incidence increasing with age. 
The geographic distribution of rheumatoid arthritis is worldwide, with a notably 
low prevalence in rural Africa and high prevalence in specific tribes of Native 
Americans (Pima and Chippewa) (Lee and Weinblatt, 2001; Sayah and
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English, 2005). In childhood, RA is rare and overlaps with other forms of 
chronic arthritis; it has a low incidence of 5/100 000 children/year and the 
prevalence of established disease is equally low (Scott et al., 1998). The 
costs of managing RA are high and may cost the individual with the disease 
an average of £4000 p.a. in the UK (Scott et al., 1998). There is no clear 
association between prevalence of rheumatoid arthritis and socioeconomic 
status (Lee and Weinblatt, 2001). Progressive bone and cartilage destruction, 
chronic synovial inflammation and extracellular matrix degradation leading to 
gross crippling joint deformation and pain characterize the disease (Szabo et 
al., 2004).
1.3.1.1 Aetiology and pathology of RA
RA is a multi-system disorder with a complex aetiology (Carter, 1997). The 
most obvious manifestation is a destructive inflammatory arthritis but other 
systemic features contribute significantly to morbidity (Harney et al., 2003). 
An inflamed synovium is central to the pathophysiology of RA (Fig. 1.8). 
Macrophages, fibroblast-like synoviocytes (FLS) and lymphocytes are the 
predominant cell types involved in RA synovitis (Moller et al., 2001). It is 
histologically striking, showing pronounced angiogenesis; cellular hyperplasia; 
an influx of inflammatory leucocytes; and changes in the expression of cell- 
surface adhesion molecules, proteinases, proteinase inhibitors, and many 
cytokines. The synovial changes vary with disease progression (Lee and 
Weinblatt, 2001). The formation of locally invasive synovial tissue, pannus, is 
a characteristic feature of rheumatoid arthritis. This tissue is involved in the 
joint erosions (Fig. 1.8). Pannus is histologically distinct from other regions of 
the synovium and shows phases of progression. Initially, there is penetration 
of the cartilage by synovial pannus composed of mononuclear cells and 
fibroblasts with high-level expression of matrix metalloproteinases by synovial 
lining cells. In later phases of the disease, cellular pannus can be replaced by 
fibrous pannus comprised of a minimally vascularised layer of pannus cells 
and collagen overlying cartilage. The pannus cells are thought to arise from 
fibroblast-like cells (type B synoviocytes) (Lee and Weinblatt, 2001).
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Figure 1.8: Diagrams showing pathological changes in RA. (a) Early stages 
of RA, the synovium are inflamed and the capsule and soft tissue around the 
joint are swollen. Lymphocytes, macrophages and synoviocytes are involved 
in synovitis, (b) Pannus is formed and it destroys the cartilage at the periphery 
of the joint, (c) Later stages there is continued inflammation and thickening of 
capsule and synovium as well as erosion of the cartilage and bone by the 
pannus and other catabolic factors. Joint deformity and loss of bone density 
may ensue. Modified from Stevens and Lowe (2000).
Cytokine-stimulated T cells, interacting with macrophages in the rheumatoid 
synovial membrane, may contribute to the continuous excessive production of
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TNF-a observed in the RA joint, and to the imbalance of pro-inflammatory 
cytokines over anti-inflammatory cytokines (Sebbag et al., 1997). Targeting 
the action of individual cytokines, for example, using antibody against TNF-a 
has been shown to be very effective in the treatment of RA. Blockage of TNF- 
a activity results in deactivation of the endothelium, manifested as reduced 
expression of adhesion molecules and chemoattractant cytokines, leading to 
diminished trafficking of inflammatory cells to synovial joints. In addition anti- 
TNF-a decreases circulating levels of the potent angiogenic cytokine vascular 
endothelial growth factor (VEGF), suggesting that new blood vessel 
formation, and hence the supply of nutrients to the growing synovial lesion, is 
also affected. These observations lend further support to the hypothesis that 
interruption of a component of the cytokine network in RA may modulate 
disease progression, and point the way towards the development of new 
therapeutic strategies for the treatment of chronic inflammatory disease states 
(Paleolog, 1997).
1.3.1.2 Clinical features of RA
1. Constitutional symptoms (fatigue, anorexia, weight loss, fever)
2. Symmetric polyarthritis-primarily of peripheral joints (joints of the hand- 
usually sparing the distal interphalangeal joints, almost any diarthrodial 
joint)
3. Morning stiffness-greater than 1 hr
4. Erosive arthritis (loss of marginal aspects of the bones
5. Deformity and decreased range of motion (ROM)
6 . Rheumatoid nodules (subcutaneous masses - most common site being 
the olecranon bursa [elbow] however they can occur elsewhere and
. usually indicative of an active or more severe disease
7. Extraarticular manifestations in RA may involve organs such heart 
[pericarditis], lungs [pleuritis], eyes, blood vessels and nervous 
system).
(Carter, 1997)
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1.3.1.3 Genetics of RA
Over the years, the only area consistently shown to be associated with RA 
has been the major histocompatibility complex (MHC), which is located on 
chromosome 6  (6p21.3). This region contains about 220 genes, and about 
40% of these have an immune function. The MHC is made up of three 
regions known as class I, II and III. Human leukocyte antigens (HLA) DR and 
DQ are located in the class II region and present antigens to T cells (Comelis, 
2003; Harney et al., 2003). HLA-DR alleles associated with RA include those 
belonging to the HLA-DR4; HLA-DR1 and HLA-DR10 (Comelis, 2003). It has 
also been known for years that HLA-DQ3 and DQ5 alleles are associated 
with RA (Harney et ai, 2003). DR4 alleles and related haplotypes are 
associated with severe, persistent, rheumatoid factor-positive polyarthritis 
with extraarticular manifestations. However, the question whether DR4 
influences disease severity or susceptibility is still a matter of debate. Even 
less understood is the actual contribution of DR1 and DR10 alleles and 
related haplotypes to RA (Zanelli et al., 2000). However increased 
frequencies of DR4 were observed in males and DR1 in females with RA 
(Sherritt etal., 1996).
Genetic factors however appear to make a limited contribution to the 
development of RA as implied by the statistics that state that first-degree 
relatives of RA patients have an estimated risk of approximately 4 % and 
identical twins have approximately 12% risk rate. This suggests a role for 
other factors, probably related to the environment (Sayah and English, 2005).
1.3.1.4 Disease management
The previous therapeutic approach, termed the therapeutic pyramid, involved 
initial management of RA with the non-steroidal anti- inflammatory drugs 
(NSAIDs) for several years until clear evidence of erosions was seen. The 
disease modifiying anti-rheumatic drugs (DMARDs) were then added 
individually in slow succession as the disease progressed. This kind of 
treatment has been replaced with early initiation of DMARDs and combination
32
DMARD therapy in patients with the potential for progressive disease (Sayah 
and English, 2005). DMARDs slow the disease process by modifying the 
immune system and thus decreasing inflammation, however they have 
significant side effects. DMARDs include methotrexate (MTX), gold, 
hydroxychloroquine, sulfasalazine, cyclosporine, and azathioprine. MTX is 
now being used as base for combination therapy regimens with gold, 
hydroxychloroquine, sulfasalazine, cyclosporine, azathioprine and newly 
approved drugs such as leflunomide (anti-inflammatory), etanercept and 
infliximab (antibodies against TNF-a), and celecoxib (selective COX-2 
inhibitor) (Sayah and English, 2005).
The efficacy of fish oils such as cod liver oil, in the diet has been 
demonstrated in several clinical trials, animal feeding experiments and in vitro 
models that mimic cartilage destruction in arthritic disease (Curtis et al., 
2004). A variety of other agents, such as glucocorticoids and nutraceuticals 
such as glucosamine, chondroitin sulfate, hyaluronic acid, green tea, also 
appear to modify the symptoms and course of arthritis (Ulrich-Vinther et al.,
2003). However, in most cases, scientific studies are still being carried out to 
identify their mechanisms of action at the cellular and molecular levels (Curtis 
etal., .2004).
1.3.2 Osteoarthritis
Although osteoarthritis (OA) is generally more benign than RA, it is still the 
most common joint disorder and a major contributor to disability in the elderly 
(Arjmandi et al., 2004; Scott et al., 1998). It is more common in women than 
men (Scott et al., 1998). OA has high prevalence (6-12% of the adult 
population) (Auw Yang et al., 2004) although true prevalence is difficult to 
measure as clinical definitions rely on the presence of pain and as such many 
cases of asymptomatic disease are missed (Salter, 2002). Its prevalence 
increases with age (Fautrel et al., 2005) but age perse does not cause OA 
(Salter, 2002). Radiographic assessments suggest that OA affects roughly 
80% of the population over 75 years (Blumenkrantz et al., 2004; Salter, 
2002). The efficacy of articular cartilage repair also decreases with increasing
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age. Martin and Bulkwalter (2003) reported that chondrocytes as they age, 
synthesize smaller, less uniform aggrecan molecules and less functional link 
proteins, their mitotic and synthetic activity decline, and their responsiveness 
to anabolic mechanical stimuli and growth factors decreases. Therefore 
chondrocyte senescence contributes to the age-related increase in the 
prevalence of OA and decrease in the efficacy of cartilage repair (Martin and 
Bulkwalter, 2003).
Although there is a lack of agreement regarding the definition of OA, it is 
generally viewed as a degenerative disorder (Arjmandi et al., 2004) in which 
bone and cartilage morphological and biochemical changes cause abnormal 
biomechanical loading patterns, leading to joint deformity, progressively 
increasing pain, (morning) stiffness, crepitus, and decreased mobility or 
limited range of motion of the joint involved (Auw Yang et al., 2004; 
Blumenkrantz et al., 2004). Typically, the degenerative changes are 
accompanied by a local inflammatory component that accelerates the joint 
destruction (Arjmandi et al., 2004), although rather limited due to the 
avascular nature of the cartilage tissue (Salter, 2002).
1.3.2.1 OA aetiology and pathology
OA is usually classified as primary (idiopathic) or secondary when it follows 
some clearly defined predisposing disorder. Mechanical factors play a role in 
all types of primary, as well as secondary OA. Joint failure results from an 
imbalance between the combinations of mechanical stresses and catabolic 
processes acting on the joint and the capacity of its tissues to withstand the 
strains and repair the damage. It is likely that in the majority of patients with 
primary, idiopathic OA multiple genetic and environmental factors are 
contributing to the pathogenesis and progression of joint failure (Blanco et al.,
2004). Risk factors for OA include factors that increase joint vulnerability 
(malalignment, muscle weakness, genetic and ethnic predispositions, ageing) 
and those that cause excessive loading (obesity; certain physical activities) 
(Felson and Schurman, 2004). Excessive mechanical stresses and major 
trauma are recognized as being important causes of disease. There is an
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increased incidence of degenerative joint disease in certain occupations such 
as farmers, coalminers and shipyard workers and following injuries to joints 
such as cruciate ligament rupture in sportsmen (Salter, 2002). Mechanical 
factors, when optimally applied, are important in maintaining cartilage in a 
healthy state and moderate regular use of a joint has a negligible risk of 
osteoarthritis (Salter, 2002). This may help explain why strenuous repetitive 
usage of joints for short periods is likely to increase the incidence of OA when 
there is associated injury and loss of the normal joint biomechanics (Salter,
2002). Articular cartilage has a limited ability to heal after trauma or maintain 
its function with increasing age due to the avascular nature of the tissue and 
the limited ability of chondrocytes to migrate within the tissue (Auw Yang et 
al., 2004). Obesity has also been found to be associated with an increase in 
OA and although this may be explained by biomechanical factors, a metabolic 
role for fat in disease pathogenesis has been suggested (Salter, 2002).
At the molecular level, OA is characterized by an imbalance between 
chondrocyte anabolism and catabolism. Disruption of chondrocyte 
homeostasis primarily affects the cartilage ECM, which is responsible for the 
biomechanical properties of the tissue (Malemud, 2004). Morphological 
changes observed in OA include cartilage erosion as well as a variable 
degree of synovial inflammation (Fernandes et al., 2002) (Fig. 1.9). The 
disease processes not only affect the articular cartilage, but involve the entire 
joint, including the subchondral bone, ligaments, capsule, synovial 
membrane, and periarticular muscles. Ultimately, the articular cartilage 
degenerates with fibrillation, fissures, ulceration and full thickness loss of the 
joint surface (Salter, 2002). As cartilage function is compromised, the loading 
of the underlying bone is altered. This is followed by an increase in bone 
remodelling resulting in bone thickening and joint deformity occurs caused by 
benign hypertrophic reactions at the edges of the joints (osteophytes) (Fig. 
1.9) (Auw Yang et al., 2004). Loss of cartilage leads to bone-to-bone 
articulation (Fig. 1.9) which is associated with much pain. Pain in OA usually 
increases after exercise and decreases at rest and in more severe cases, 
pain can even occur after minimal usage or at rest (Auw Yang et al., 2004). 
OA can also occur without pain (Felson and Schurman, 2004). Stiffness
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occurs mainly in the morning after sleep and after prolonged rest. It usually 
disappears within 10min after minimal motion (Auw Yang et al., 2004). 
Decreased mobility is caused by pain; joint destruction and inflammation of 
the soft tissue surrounding the involved joint (Auw Yang et al., 2004).
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Figure 1.9: Diagrams showing pathological changes in OA. (a) Normal joint, 
(b) In the early stages of OA, the joint capsule and the synovium are inflamed 
and swollen (oedema). Cartilage disintegrates and is eroded leading to 
narrowed joint space, (c) In the later stages of the disease, inflammation of 
synovium leads to hyperplasia, loss of cartilage leads to bone-to-bone 
articulation (eburnation). The deformation of subchondral bone follows as 
seen in its thickening and development of osteophytes (bone outgrowths) and 
bone cysts. Modified from Stevens and Lowe (2000).
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A number of pro-inflammatory cytokines have been implicated in the OA 
process of cartilage destruction including IL-1, TNF-a, IL-6 , and IL-17 
(Fernandes etal., 2002; Malemud, 2004). The primary role of these cytokines 
is to modulate the expression of matrix metalloproteinases and cartilage ECM 
proteins. IL-1 and TNF-a produced by activated synoviocytes, mononuclear 
cells or by articular cartilage itself significantly up-regulate MMP gene 
expression. The cytokines were shown to significantly up-regulate MMP-3 
steady-state mRNA derived from human synovium and chondrocytes 
(Fernandes et a/., 2002). Cytokines also impair chondrocyte compensatory 
synthesis pathways required to restore the integrity of the degraded ECM. 
Chondrocytes in OA cartilage appear unable to respond to anabolic factors 
such as IGF-1 (Malemud, 2004). IL-1 a was found to increase the expression 
of IGFBPs and also reduce the IGF-I bioactivity, suggesting that locally 
produced IGFBPs mediated the reduction of the IGF-I activity (Sunic et a!., 
1998). IGFBP-3 and -5 expression and production has been shown to be 
elevated in osteoarthritic cartilage and they sequester IGF-I in osteoarthritic 
cartilage, thus reducing the anabolic stimulation of this tissue and contributing 
to the net loss of cartilage in this disease (Olney etal., 1996). Furthermore, in 
OA synovium, a relative deficit in the production of natural antagonists of the 
IL-1 receptor, IL-1Ra, has been demonstrated and it has been suggested this 
may be related to an excess production of nitric oxide in OA tissues. This, 
coupled with an upregulation in the receptor level, has been shown to be an 
additional enhancer of the catabolic effect of IL-1 in this disease (Fernandes 
etal., 2 0 0 2 ).
Elevated levels of nitrite, a stable end-product of NO metabolism were found 
in serum and synovial fluid samples from arthritis patients, including OA 
patients (Jang and Murrell, 1998). In OA tissue, iNOS is the enzyme that is 
responsible for the increased production of NO (Alderton et a i, 2001). In 
articular chondrocytes and cartilage, NO plays a regulatory role in the 
activation of metalloproteinases (Murrell et a i, 1995) and thus may be 
involved in cartilage catabolism. In addition, induction of synovial and 
chondrocyte COX-2/ mPGES-1 -produced PGE2 has been shown to be one 
mechanism by which IL-1 modulates cartilage proteoglycan degradation in
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OA (Hardy et al., 2002). This synthesis was shown to be regulated by IL-1 
acting via the ERK-1/2 and p38 MAPK signalling pathways (Masuko-Hongo et 
al., 2004) and perhaps, cAMP-dependent protein kinase (Faour et al., 2001). 
The synthesis of cyclo-oxygenases, nitric oxide synthase, and neutral 
proteinases is increased in inflammatory synovitis, and these enzymes might 
mediate parts of the disease process (Lee and Weinblatt, 2001).
Decreased proteoglycan content and increased water content in articular 
cartilage, as well as, elevated concentrations of proteoglycans and fibronectin 
fragments in the synovial fluid are characteristic of osteoarthritis due to the 
upregulation of MMPs production by chondrocytes (Holland and Mikos, 2003).
There is a chronic, inflammatory form of osteoarthritis which involves both the 
proximal and distal rows of finger joints and leads ultimately to marked 
deformity of the digits. This is referred to as erosive OA (EOA) and some of 
its clinical features include abrupt onset of pain, swelling, redness, warmth 
and limited function of interphalangeal joints of the hands (hallmarks of 
inflammation) (Punzi et al., 2004). EOA may lead to joint deformities such as 
formation of Heberden's and Bouchard's nodes which are present at distal 
and proximal interphalangeal joints, respectively (Greenspan, 2003; Punzi et 
al., 2004).
1.3.2.2 Genetic influences in OA
Genetic factors are important in some forms of OA as has been recognized 
for some time in cases of idiopathic OA associated with Heberden’s nodes 
(nodal OA) (Salter, 2002) Sisters of females with Heberden’s nodes in the 
distal and proximal interphalangeal joints, and carpometacarpal joints of the 
hand, were three times more likely than the general population to exhibit 
nodal OA at age 50 (Simonet, 2002). In subsequent studies of generalised 
OA of the hand, the frequency of OA was nearly twice as high in OA 
pedigrees compared with the general population. Familial studies reveal a 
higher incidence of OA among monozygotic versus dizygotic twins, a higher 
prevalence of OA in siblings of affected individuals than in the normal
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population, and a higher prevalence of OA in first-degree relatives (siblings, 
parents, and offspring) of affected individuals than in the normal population. 
Together, these studies confirm a strong genetic influence on the disease
(Simonet, 2002). Type II collagen mutations have been demonstrated in some
families with early onset OA and associations with the vitamin D receptor 
gene, the type I collagen gene COL1A1, and the oestrogen receptor gene in 
idiopathic osteoarthritis are being studied (Salter, 2002). It is likely that 
common OA, like some other diseases of ageing, is a polygenic disease, 
where common alleles of multiple genes each contribute to a small increased - 
risk either individually or by interaction with each other or with environmental 
factors (Simonet, 2002).
1.3.2.3 OA management
Goals are to prevent or retard further damage to joints, to manage pain and 
stiffness, and maintain mobility. First, protection of joints from additional 
trauma is important- in particular eliminating those activities that increase the 
load-bearing strain to an affected joint. Canes and walkers can significantly 
decrease the weight load on knees and hips. Weight reduction if the person 
is overweight, can greatly decrease the load placed on knees and hips. 
Secondly, physical therapy is important for relieving pain and preserving 
muscle strength and range of motion (ROM). Use of ice and heat on involved 
joints may also provide temporary relief of pain. Drug therapy designed to 
control pain and any synovitis is also one of the means of managing OA. 
Over-the-counter (OTC) analgesic drugs such as aspirin and ibuprofen are 
usually adequate for pain relief. The drugs have the added advantage of 
controlling the synovitis. Other NSAIDS are used as well for pain and 
synovitis control. Adverse effects of the drugs are generally common in older 
persons so drug therapy should be considered carefully since many in the 
age group have OA. DMARDs are not used in OA because it is not a 
systemic disorder. Oral corticosteroids are contraindicated, since they are 
generally not effective in improving symptoms and their toxic potential make 
their use risky. Intraarticular injections can provide relief of synovitis but if
39
used too frequently, the agents deplete the components of the cartilage and 
can accelerate the arthritic progression.
A final option is surgical treatment that is designed to remove loose bodies; 
repair damaged supporting tissues or to replace the entire joint (Arjmandi et 
a/., 2004; Carter, 1997)
1.4 Inflammatory mediators associated with arthritis
As mentioned above, in OA proinflammatory cytokines including IL-1 have 
been implicated as important mediators in the disease. In response to IL-1, 
chondrocytes upregulate the production of nitric oxide (NO) and prostaglandin 
E2 (PGE2 ), two factors that have been shown to induce a number of the 
cellular changes associated with OA (Hedbom and Hauselmann, 2002).
1.4.1 Nitric Oxide
NO is a very small molecule of 30 Da (Coleman, 2001) synthesized from the 
L-arginine by a family of enzymes, the NO synthases. Its size and its unpaired 
electron make it a highly reactive and locally diffusible free radical (Murrell et 
al., 1996). Research on the biological roles of nitric oxide has revealed that it 
functions as an important signal and effector molecule in a variety of 
physiologic and pathologic settings (Stuehr, 1997).
Synthesis
NO is synthesised universally from L-arginine and molecular oxygen by an 
enzymatic process that utilises electrons donated by NADPH. The NO 
synthase (NOS) enzymes convert L-arginine to NO and L-citrulline via the 
intermediate A/-hydroxy-L-arginine. One molecule of L-arginine produces one 
molecule of NO, the nitrogen atom of the latter deriving from a terminal 
guanidino group of the arginine side chain (Coleman, 2001). There are three 
known isoforms of the enzyme, named neuronal NOS (nNOS), inducible NOS 
(iNOS), and endothelial NOS (eNOS), which differ in their dependence on 
Ca2+, as well as in their expression and activities. These unique features give
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rise to the distinct subcellular localisations and mechanistic features which 
are responsible for the physiological and pathophysiological roles of each 
isoform (Andrew and Mayer, 1999). The NOS isoforms are all dimeric, bi­
domain enzymes that contain iron protoporphyrin IX, flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN), and tetrahydrobiopterin 
(BH4) as bound prosthetic groups (Stuehr, 1997). Cytokine-inducible NO 
synthase (iNOS) contains an oxygenase domain that binds haem, BH4, and 
L-arginine, and a reductase domain that binds FAD, FMN, calmodulin, and 
NADPH. Dimerisation of two oxygenase domains allows electrons to transfer 
from the flavins to the haem irons, which enables 0 2 binding and NO 
synthesis from L-arginine (Siddhanta et al., 1998). The haem is essential for 
dimerisation as well as NO production and the BH4 also affects dimerisation 
and electron transfer, although its full role in catalysis remains to be 
determined (Andrew and Mayer, 1999). NO presence in cells or tissue can be 
determined indirectly, through the measurement of its stable metabolites, 
nitrite (N02‘) and nitrate (NO3') which act as marker molecules (Jang and 
Murrell, 1998).
NO and cGMP production
Cyclic guanosine 3 ',5-monophosphate (cGMP) is an important second 
messenger molecule, which is formed from guanosine triphosphate (GTP) in 
a reaction catalyzed by guanylyl cyclase (GC). There are two families of 
cGMP-producing GCs, the transmembrane receptor class and the soluble 
class. NO increases the activity of soluble GC by binding to its haem iron and 
thereby raising the cGMP levels in the cell, which was the first signalling 
function of NO to be discovered (Schindler and Bogdan, 2001).
NO and cartilage metabolism
The iNOS is thought to play a role during host defense and immunological 
reactions (Murrell etal., 1995). Articular chondrocytes are the major source of 
inducible nitric oxide synthase and nitric oxide during inflammation or infection 
of a joint. NO plays a regulatory role in the activation of metalloproteinases
(Murrell et al., 1996). Involvement of NO in arthritis was first demonstrated 
when elevated levels of nitrite, a stable end product of NO metabolism were 
found in serum and synovial fluid samples from RA and OA patients (Jang 
and Murrell, 1998)
1.4.2 Eicosanoids
Prostaglandins and other structurally related molecules, prostacyclins, 
thromboxanes and leukotrienes are referred to as eicosanoids because they 
contain 20 carbon atoms. They act locally or near site of synthesis in the 
body. They are derived from a common precursor arachidonic acid (Hames 
and Hooper, 2000). Prostaglandins are not stored in cells but are synthesized 
and released immediately (Foegh and Ramwell, 2004). Prostaglandins 
produce a number of pharmacological effects. One of the most important 
effects is their activity as natural mediators of inflammation. Administration of 
PGE2 induces signs of inflammation that include: redness, heat, swelling and 
oedema; and in the presence of histamine and bradykinin, enhances both 
intensity and duration of pain caused by these two agents (Glew, 2002). L T B 4  
regulates neutrophil and eosinophil function and is a mediator of 
hypersensitivity, inflammation, secretion (e.g. insulin), cell movement, cell 
growth and calcium fluxes (Glew, 2002).
1.4.2.1 Prostaglandin E2
Prostaglandin E2 biosynthesis
Two unique cyclooxygenase (COX) isoenzymes convert arachidonic acid into 
prostaglandin G2 (PGG2), namely prostaglandin Synthase-1 (PGS-1 ) also 
known as COX-1 and PGS-2 also referred to as COX-2. COX -1 is 
constitutively expressed, widely distributed and has "housekeeping" functions 
whilst COX-2 expression depends on stimulus and is an immediate early 
response gene product in inflammatory and immune cells. COX-2 expression 
is stimulated by growth factors, tumour promoters, cytokines and 
lipopolysaccharide (LPS) (Foegh and Ramwell, 2004).
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The PGSs catalyse both the oxygenation of arachidonic acid to PGG2  and the 
reduction of PGG2 to prostaglandin endoperoxide H2 (PGH2) (Glew, 2002; 
Masuko-Hongo et al., 2004). Prostaglandin E synthase (PGES) in turn 
converts PGH2 to prostaglandin E2 (PGE2) (Glew, 2002; Hames and Hooper, 
2000; Masuko-Hongo et al., 2004) (Fig. 1.10). Three distinct types of PGES 
have been identified and characterised to date namely: the cytosolic type, 
cPGES and two membrane-associated PGES-1 and -2 (mPGES-1 and 
mPGES-2, respectively) (Masuko-Hongo etal., 2004).
PGE2 production and cartilage metabolism
Tanioka et al. (2000) identified cPGES, the terminal enzyme of the 
cyclooxygenase (COX)-1-mediated PGE2 biosynthetic pathway. Thus, 
functional coupling between COX-1 and cPGES/p23 may contribute to 
production of the PGE2 that plays a role in maintenance of tissue 
homeostasis. Tanikawa etal. (2002) identified and characterised the mPGES 
with a molecular weight of approximately 33 kDa. The mPGES-1 is the 
inducible terminal synthase in the COX-2-dependent PGE2 production 
pathway (Claveau et al., 2003). The production of mPGES is stimulated by 
proinflammatory agents in several cells and tissues including rheumatoid 
synovial cells (Masuko-Hongo et al., 2004). The mPGES-1 has been shown 
to be up-regulated throughout the development of adjuvant-induced arthritis 
and it has been suggested that it plays a major role in the elevated production 
of PGE2 in this arthritis model (Claveau et al., 2003). IL-1 stimulates the 
expression of secreted phospholipase A2 and COX-2 genes in articular 
chondrocytes, resulting in increased PGE2 production (Masuko-Hongo et al.,
2004). The Masuko-Hongo group (2004) also reported overexpression of 
mPGES-1, but not cPGES, in OA cartilage and in human articular 
chondrocytes stimulated with IL-1. Chondrocytes from OA cartilage were also 
shown to synthesize mPGES-1, and that this synthesis is regulated by IL-1 
acting via the ERK-1/2 and p38 MAPK signaling pathways (Masuko-Hongo et 
al., 2004). Although PGE2 can be produced by both COX-2/mPGES and 
COX-1/cPGES pathways, the COX-2/mPGES pathway could be of
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importance for increased PGE2  production at sites of inflammation (Kojima et 
al., 2003).
1.4.2.2 Leukotriene B4 biosynthesis
Lipoxygenase (LOX) is a dioxygenase, one of which is 5-LOX that produces 
leukotrienes that are important in humans and are involved in mediation of 
inflammatory disorders. Leukotrienes contain at least 3 conjugated double 
bonds. 5-LOX oxygenates AA to form 5-hydroperoxyeicosatetraenoic acid (5- 
HPETE). 5-HPETE is converted to LTA4  which in turn is converted to LTB4  
catalysed by LTB4  synthase (LTA4 hydrolase) which adds water to the double 
bond between C11 and C12 (Glew, 2002; Hames and Hooper, 2000) (see 
Fig. 1.10).
Phospholipids
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Figure 1.10: Pathways for PGE2 and L T B 4  biosynthesis
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1.5 Cannabinoids
1.5.1 History of Cannabis sativa and cannabinoids use
Cannabis sativa (Fig. 1.11), a plant belonging to the family of Cannabinceae 
(Pars and Howes, 1977) represents one of the oldest cultivated, economic 
plant providing fibre, edible seeds and drug resin (Philippe, 2004).
Figure 1.11: The Cannabis sativa plants. Adapted from Brown (1998).
Cannabis sativa appears to have originated from Central Asia, north of the 
Himalayas (Peters and Nahas, 1999). It was cultivated in China for its fibre 
and oil in its seeds (Peter and Nahas, 1999). The first evidence of the 
medicinal use of Cannabis comes from China. In 2737 BC, the Chinese 
emperor Shen-nung published a pharmacobotanical compendium, the Pen- 
ts'ao Ching, describing the use of Cannabis in the treatment of a variety of 
diseases including malaria, constipation, rheumatic pains, 
“absentmindedness” and female disorders (Calixto et al., 2000; Guzman et 
al., 2001; Straus, 2000). Shen-nung in his monograph concluded that 
cannabis "undoes rheumatism" (Straus, 2000). From China its use spread to 
Persia and Assyria in the 8th century BC (Peters and Nahas, 1999). The
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Greeks and Romans also cultivated Cannabis for its fibre and manufactured 
ropes and sails (Peters and Nahas, 1999). Cannabis was also used for 
medicinal purposes in the ancient Egyptian civilisation (Guzman etal., 2001).
The next widespread use of Cannabis occurred in India where it was also 
cultivated. Its use spread further to the Middle East. It started in the wake of 
the rise of Islam and met little cultural opposition, since Muhammad forbids 
the use of wine but not explicitly the Cannabis derivatives -  hashish (Arabic 
name for “grass”) (Peters and Nahas, 1999). The Arabs introduced Cannabis 
preparations into North Africa from Egypt to Tunisia in the 9th -  20th centuries. 
During these centuries, studies done by the Muslim scholars and debates 
through the centuries led to prohibition of Cannabis, except for legitimate 
medicinal purposes. This religious prohibition still prevails in Islamic countries 
under penalty of law, which in some countries include the death sentence 
(Peters and Nahas, 1999).
In Europe, Cannabis was introduced by Napoleon Bonaparte’s troops when 
returning from Egypt (Berdyshev, 2000). In England, the history of the 
therapeutic use Cannabis dates as far back as the 1500s. It was reported 
then, that “water of hempe” freshly prepared from dried leaves of the plant 
were recommended for headaches and “for all here wheresoe’er it be” 
(Crawford, 2002). This was later supported by the founding father of modern 
English herbalism, Culpeper. He also commented on the usefulness of 
Cannabis to those with jaundice accompanied by a fever and recommended 
its use for diarrhoea, colic and rheumatic pain. He also recommended fresh 
Cannabis root mixed with oil and butter for burns and its seeds “seethed in 
milk" for coughs (Crawford, 2002). William O’Shaughnessy, an army 
physician in Calcutta, India during the 1830s found Cannabis to be effective in 
the treatment of rabies, rheumatism, epilepsy, and tetanus and as an 
analgesic (Calixto et al., 2000; Peters and Nahas, 1999). Following the 
experiments carried out by O’Shaughnessy and as a result of the publication 
of his extensive article on the use of Cannabis in various medical conditions 
(Calixto et al., 2000; Crawford, 2002), Cannabis was introduced into
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European medicine and subsequently into other areas of western medicine 
including the US (Calixto et al., 2000).
The medicinal use of Cannabis switched from the leaves, roots and seeds to 
the concentrated resin, rich in delta-9-tetrahydrocannabinoid (A9-THC) and 
other cannabinoids, from the Indian variety of the plant (Crawford, 2002). 
Cannabis preparations such as ‘tincture and extract of Cannabis’ were 
recognised for a long time as official drugs and were included in the British 
and US pharmacopoeias from the 1850s (Berdyshev, 2000; Calixto et al., 
2000). In Britain, Cannabis continued to be regarded as a benevolent 
therapeutic plant capable of soothing pain, calming anxiety, promoting 
appetite and digestion and relieving both headaches and nervous convulsions 
(Crawford, 2000). According to the records, dosages given were not strong 
enough to produce psychoactive effects. However many of the physicians 
noted the extreme variability in potency of Cannabis extracts and the difficulty 
in obtaining replicable results (Peters and Nahas, 1999). Thus Cannabis 
started to lose medical attention as new, pure pharmaceutical drugs began to 
appear such as aspirin and barbiturates that could be given in standard doses 
with reliable effects (Berdyshev, 2000).
As the medicinal use of Cannabis dwindled, its recreational use increased. In 
western countries, this abuse and perceived behavioural and addictive effects 
of Cannabis led to withdrawal of its preparations from the US pharmacopoeia 
and laws were passed prohibiting its use in the 1930s and 1940s (BMA 
report, 1997; Straus, 2000). In Britain, it remained permissible for doctors to 
prescribe Cannabis preparations until 1971 (BMA report, 1997).
Cannabis is by far the most widely used illegal drug in the Western world, with 
an estimated 20 million regular users in North America and Europe. Many 
thousands of patients with AIDS, multiple sclerosis, and other illnesses are 
also illegally self-medicating with Cannabis in the belief that it provides them 
with a therapeutic benefit (Iversen, 1999). The scientific study on Cannabis 
however, did not commence until the early 1960s, when Mechoulam and his 
colleague identified A9-THC (Guzman et al., 2001). This led to growth in the
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production of synthetic cannabinoid analogues and the discovery of 
cannabinoid receptors (Berdyshev, 2000).
1.5.2 Cannabinoid receptors
In the 1980s, studies on cannabinoids revealed that: the effects of 
cannabinoids are stereoselective; the psychoactivity of cannabinoids is not 
related to their lipophilicity, thus ruling out the hypothesis that states that 
cannabinoids because of their high hydrophobicity act by disrupting the 
membrane integrity; and the cannabinoid concentrations that are able to 
disrupt membranes integrity are excessively high. Hence these data 
suggested that the cannabinoids mediate their action through specific 
receptors (Guzman et al., 2001). The first pharmacological evidence for 
cannabinoid receptors was reported by Devane et al. (1988) who showed the 
binding of the radioactive synthetic cannabinoid CP-55,940 to rat brain 
homogenates. In 1990, the first cannabinoid receptor was isolated and cloned 
from a cortical rat brain cDNA library (Matsuda et al., 1990). Subsequently, 
human and mouse brain-type cannabinoid receptors were cloned (Berdyshev,
2000). A second subtype of cannabinoid receptors was subsequently isolated 
and cloned from a human promyelocytic HL-60 cell line (Munro et al., 1993). 
According to the International Union of Pharmacology Subcommittee on 
Cannabinoid Receptors, these two cannabinoid receptors are termed, CBi 
and CB2 , respectively (Howlett et al., 1998). Both receptors are members of 
the 7 -transmembrane-helices, G-protein coupled receptor superfamily, and 
share 44% homology with each other (6 8 % nucleotide identity within 
transmembrane regions) (Guzman etal., 2001) (Fig. 1.12).
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Figure 1.12: The diagram showing CBi and CB2 cannabinoid receptors. The 
small circles represent amino acid residues. Modified from Joy et al. (1999).
In spite of this difference between the two types of cannabinoid receptors, 
most natural cannabinoids as well as endogenous ligands for cannabinoid 
receptors showed similar binding affinity to both receptor subtypes (Pertwee, 
1999). Tissue expression of these receptors is rather different. CBi 
cannabinoid receptor also known as a central cannabinoid receptor is 
primarily found in the central nervous system; although it is detected at low 
levels in several peripheral tissues as well. CB2 cannabinoid receptor also 
known as a peripheral cannabinoid receptor is found in the immune tissues. It 
is not found in the brain. It is detected at levels of about 10-100 times higher 
than the CB-i receptor in the peripheral tissues. High levels of CB2 receptors 
found in the immune system suggest that it could have a significant role in 
immunoregulation by its ligands (Galiegue, 1995). Blood cell subpopulations 
differ in the degree of CB2 receptor expression and are ranked in the following 
order: B cells > natural killer (NK) cells > monocytes > polymorphonuclear 
(PMN) cells (neutrophils) > CD8 + T cells > CD4+ T cells (Berdyshev, 2000).
Cannabinoid receptors are also expressed in high density in many areas 
related to pain. They are found in brain areas involved in descending pain 
modulation, in the superficial layers of the spinal dorsal horn, in the dorsal 
root ganglion and on both central and peripheral terminals of primary afferent
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neurons. These areas provide peripheral, spinal, and central targets through 
which cannabinoids modulate pain (Walker and Huang, 2002). The 
cannabinoid receptors are involved in signal transduction mechanisms that 
include inhibition of adenylyl cyclase, activation of mitogen-activated protein 
kinase, and regulation of calcium and potassium channels (Howlett, 2 0 0 2 ).
There are indications also that other cannabinoid receptor sub-types may 
exist that are yet to be identified (Porter and Felder, 2001).
1.5.3 Cannabinoid receptor ligands
Cannabinoids are divided into 5 different chemical classes (see Fig.1.13 for 
structures).
Classical cannabinoids
The first is the classical cannabinoids. This class consists of natural 
cannabinoids such as THCs and some cannabinoids synthesized at Hebrew 
University in Israel (HU series) such as HU-210 (Guzman et al., 2001) as well 
as the synthetic selective CB2 cannabinoid receptor agonist, JWH-133. These 
are dibenzopyran derivatives (Brown, 1998). The most relevant plant-derived 
cannabinoids are A9-THC, A8-THC (almost as active as A9-THC but much 
less abundant in the plant), cannabinol and cannabidiol (both produced in 
significant amount but are much less potent as cannabimimetic agents). HU- 
210 is the most potent of these cannabinoids (Guzman et al., 2001). HU-210 
has 100-800 times greater potency than A9-THC (Pertwee, 1995). Because 
binding values differ due to experimental conditions, data from different 
laboratories may vary considerably, but the general trend is apparently 
retained (Howlett et al., 2002). The pharmacophoric elements that appear to 
be important for cannabimimetic activity are the phenolic hydroxyl group, 
which can be substituted by an amino group; the alkyl chain, elongation of the 
chain increases biological activity and; the para aliphatic hydroxyl 
(Goutopoulos and Makriyannis, 2002).
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Figure 1.13: Structures of representatives of the cannabinoids [1], [2] and [3] 
are representatives of the classical cannabinoids; [4] and [5] are non-classical 
cannabinoids; [6 ] and [7] are representatives of the aminoalkylindoles; [8 ] and 
[9] are CB>| and CB2 cannabinoid receptor antagonists (inverse agonists) 
respectively; and [1 0 ] and [1 1 ] are representatives of the endocannabinoids 
(Hanus and Mechoulam, 2005)
Non-classical cannabinoids
The second class is the non-classical cannabinoids. This is comprised of 
different synthetic bi- and tricyclic analogues of classical cannabinoids lacking 
the pyran ring. Its main representative is CP-55,940, widely used in its
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tritiated form (Brown, 1998). It was the binding assays performed with [3 H] 
CP-55,940 that demonstrated the presence of the cannabinoid receptors 
(Devane et al., 1988). CP-55,940 is a non selective cannabinoid receptor 
agonist. CP-55,940 binds to CBi and CB2 receptors with similar affinity and 
displays high activity in vivo as well, being 10 to 50 times more potent than A9- 
THC in mouse experiments (Howlett et al., 2002). HU-308 is also a member 
of this class and it is a CB2 cannabinoid receptor agonist. The side chain and 
the phenolic hydroxyl of this class of cannabinoids are important for activity.
Aminoalkylindoles
The third group are the aminoalkylindoles, represented by synthetic 
cannabinoids, Win-55,212 and AM1241. This class is considerably less 
lipophilic (Goutopoulos and Makriyannis, 2002). Although quite different in 
structure to the other cannabinoids, these compounds bind to both 
cannabinoid receptors (Brown, 1998) and are chemically related to cyclo- 
oxygenase inhibitors, although the latter do not bind to the cannabinoid 
receptors (Guzman etal., 2001).
Endocannabinoids
The fourth class are the endocannabinoids, also known as the eicosanoid 
group. These are the endogenous cannabinoid receptor ligands, the best 
known being arachidonylethanolamide (AEA) also known as anandamide, 2- 
arachidonylglycerol (2-AG) and palmitoylethanolamide (PEA). Anandamide 
was the first endocannabinoid to be described. It produces similar effects to 
A9-THC but is less potent with a short half-life (Devane et al., 1992). It is a 
ligand for both CBi and CB2 receptors, with less CB2 than CB<| efficacy 
(Pertwee, 1999). Studies by Sugiura and his colleagues (2000) strongly 
suggest that the CB2 receptor is originally a 2-AG receptor and that 2-AG is 
the intrinsic natural ligand for the CB2 receptor that is abundant in the immune 
system. PEA has been reported to bind to a yet unidentified CB2-like receptor 
(Kumar etal., 2001). In general, endocannabinoids mimic the effects of plant-
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derived and synthetic cannabinoids although they are different structurally 
(Guzman et al., 2001).
Diarylpyrazoles
The last group are the diarylpyrazoles, the cannabinoid receptor antagonists 
represented by SR141716A and its analogue AM 281; as well as SR144528 
and its analogue AM 630, selective CBi and CB2 antagonists (inverse 
agonists) respectively (Guzman et al., 2 0 0 1 ).
1.5.4 The mode of action of cannabinoids
The discovery of cannabinoid receptors and their endogenous ligands 
suggested the existence of an endogenous cannabinoid system. Apart from 
receptors and ligands, specific systems for cannabinoid synthesis and 
degradation have been described. The synthesis of endogenous 
cannabinoids is believed to be mediated by Ca2+-dependent mechanisms 
involving the activation of a phospholipase D. This enzyme hydrolyses 
phospholipid precursors releasing anandamide or 2-AG. The degradation 
system comprises a specific transporter for endocannabinoid uptake and an 
enzyme that degrades endogenous cannabinoids, fatty acid amide hydrolase 
(FAAH) (Guzman etal., 2001).
One of the most extensively studied properties of cannabinoid receptors is the 
ability of the activated receptors to block the accumulation of intracellular 
cyclic adenosine 3', 5'-monophosphate (cAMP) through inhibition of activation 
of adenylyl cyclase (AC). The receptors are coupled to AC through the G j/0- 
proteins. The inhibitory effect of cannabinoid receptor to accumulation of 
cAMP is abrogated by cell pre-treatment with pertussis toxin which ADP- 
ribosylates the G-Proteins, thus confirming the G-protein linkage to 
cannabinoid receptors. The intracellular cAMP level is critical for protein 
kinase A (PKA)-mediated signalling since cAMP regulates PKA activation. 
Activated PKA phosphorylates a number of intracellular targets including 
transcription factors, activator protein-1 (AP-1); the nuclear factor for
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immunoglobulin kappa chain in B cells (NF-kB) and; the nuclear factor of 
activated T cells (NF-AT) (Berdyshev, 2000). G-proteins also link cannabinoid 
receptors to mitogen-activated protein (MAP) kinase signalling cascades 
(Guzman et al., 2001). The regulation of MAP kinases by cannabinoids is 
complex and may differ depending on cell type, agonist and experimental 
conditions (Berdyshev, 2000; Bouaboula et al., 1995; Derocq et al., 1998). 
Cannabinoid receptor-mediated signalling is regulated by the availability of 
the receptors. Following activation, cannabinoid receptors were shown to 
undergo phosphorylation and internalisation, which may be followed by 
recycling back to the membranes (Berdyshev, 2000).
Cannabinoids exhibit a variety of pharmacological properties making them 
potential candidates for therapeutic development and use in a variety of 
disorders (Kumar et al., 2001).
1.6 Cannabinoids and the immune system
Effects of cannabinoids on immune function are not obvious; they are fairly 
complex and appear to be modulatory in nature (Baczynski et al., 1983). The 
possible existence of a relationship between cannabinoids and immunity was 
first raised by Juel-Jensen (1972) who reported that marijuana smokers have 
more frequent recurrences of Herpes simplex virus infection. This report gave 
rise to a large number of further studies on the effect of cannabinoids on 
immune function (Guzman et al., 2001). Various experimental models have 
been used employing the drug-abusing human subjects, experimental 
animals exposed to cannabis smoke or injected with cannabinoids, and in 
vitro models employing immune cell cultures treated with various 
cannabinoids (Klein et al., 1998). The findings suggested that cannabinoids 
modulate the function of B and T cells, macrophages, NK cells and mast 
cells; host resistance to various infectious agents of viral and bacterial origin, 
especially the secondary immune response; and production and function of 
cytokines and chemokines (Cabral and Pettit, 1998; Klein etal., 1998).
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In most cases, both in vitro and in vivo studies have shown that cannabinoids 
have immunosuppressive properties. Contrary to the reports above, 
cannabinoids were also found to have some immunostimulatory effects; at 
nanomolar concentrations (10-100nM) (Derocq et al., 2000) and some of the 
effects were confirmed to be CB2 receptor-mediated (Jbilo etal., 1999).
This variation in drug effects is a result of different experimental factors such 
as drug concentration (main factor), timing of drug delivery, and type of cell 
and cell function being examined (Klein etal., 1998; Guzman etal., 2001).
1.7 Cannabinoids in Pain and inflammation 
Link of pain to inflammation
Tissue damage initiated by trauma, infection, allergy or autoimmune reaction 
may induce production or secretion of inflammatory mediators such as 
cytokines, prostanoids and neuropeptides (Richardson and Vasko, 2002). 
These inflammatory mediators produce vascular effects including vasodilation 
which leads to redness (rubor) and heat (calor), increase in vascular 
permeability leading to swelling (oedema) and increase in expression of 
adhesion molecules leading to recruitment of inflammatory cells (Goldsby et 
al., 2000). Inflammatory mediators also produce neural effects involving 
activation of nociceptors, free nerve endings which act as receptors for pain 
(Costigan and Woolf, 2000). Pain and inflammation are very closely linked. 
For instance, expression of receptors such as neuropeptide and bradykinin 
receptors is upregulated during inflammation (Schaible et al., 2 0 0 2 ) and this 
may lead to potentiation of activation of the nociceptors which may result in 
increased detection of noxious stimuli and the subsequent transmission of 
encoded information to the brain (nociception) (Kidd and Urban, 2001).
Pain definition
Pain is an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage or described in terms of such damage, 
according to the International Association for the Study of Pain (IASP).
Noxious stimuli activate nociceptors, the myelinated A5 fibres which produce 
fast, sharp pain sensation since they are fast conductors of the pain signals 
and the unmyelinated C fibres which produce slow, dull pain sensation 
because they conduct pain signals slowly. These receptors innervate 
cutaneous as well as deep somatic tissues and have high activation 
thresholds (Costigan and Woolf, 2000; Stucky et al., 2001). The activated 
nociceptors, the primary afferent neurons, transduce (detect) noxious stimuli, 
conduct and transmit the pain signal to the dorsal horn of the spinal cord via 
the dorsal root ganglion. The neurons and interneurons pass the encoded 
message via dorsal horn up to the brain where site and type of pain are 
identified. Thus the pain signal in the brain is processed and induces visceral, 
emotional and behavioural reactions to the pain (Stucky et al., 2001; and 
Saladin and Porth, 1998). Repeated exposure of nociceptors to the noxious 
stimuli leads to increased responsiveness (sensitisation). Associated with this 
sensitization is a decreased activation threshold such that normally innocuous 
stimuli may produce pain (allodynia), increased response magnitude to 
noxious stimuli (hyperalgesia), and increased recruitment of receptive fields 
(Kidd and Urban, 2001; Winkelstein, 2004).
Effects of cannabinoids in pain states
Cannabinoids have been reported to have anti-nociceptive, analgesic, anti- 
hyperalgesic, anti-allodynic, anti-inflammatory effects and have potential as 
therapeutic agents in neuropathic pain (refer to Table 1.3 for a summary of 
these effects).
These reports of beneficial effects of cannabinoid receptor agonists against 
the three entities of pain namely: nociceptive, inflammatory and neuropathic; 
suggest a unique therapeutic role of this group of compounds in pain and 
inflammation.
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Table 1.3: Summary of some of the effects of cannabinoids in pain and 
inflammation.
Cannabinoid Receptor
type
Effect Reference
2-Arachidonyl 
glycerol (2-AG)
CB1/CB2 Produced cerebroprotective effects, inhibited 
vasoconstrictor endothelin (ET-1)
Panikashvili et al., 
2001
AM1241 c b 2 Inhibited C-fibre mediated nociception 
Reversed sensory hypersensivity in 
neuropathic pain model (topically administered)
Malan et al., 2003 
De Petrocellis et 
al., 2000
Anandamide CB1/CB2 Inhibited capsaicin-induced CGRP release Karst et al., 2003
Ajulemic acid (CT- 
3)
CB1/CB2 Produced anti-allodynic effects and reduced 
chronic neuropathic pain 
Produced analgesia in mouse models of pain, 
equipotent to morphine but with greater 
duration of action
Inhibited IL-1 production, enhanced T cell 
apoptosis
Dajani etal., 1999; 
Burstein, 2000
Zurier et al., 2003; 
Bidinger et al.
2003
BAY 38-7271 CB1/CB2 Exhibited neuroprotective properties in 
traumatic brain injury TBI
Mauler et al., 2003
Cannabidiol CB1/CB2 Anti-inflammatory and anti-arthritic Malfait et al., 2000
Cannabinol CB1/CB2 Inhibited expression of Th2 cytokines in allergic 
reactions
Jan et al., 2003
Dexanabinol (HU- 
211)
Exhibited antioxidant and anti-inflammatory 
properties and was cerebroprotective in TBI, 
prevented secondary degeneration and 
promoted regeneration
Pop, 2000
Zalish and 
Lavie,2003
HU-308 c b 2 Inhibited C-fibre mediated nociception Malan et al., 2003
HU-320 CB1/CB2 Inhibited TNF-a and prevented joint damage Sumariwalla et al., 
2004
Win-55,212-2 CB1/CB2 Dose-dependent anti-nociception (topically and 
intrathecally administered)
Reversed hyperalgesia (0.1 mg/kg, s.c) by 
abolishing increases in PGE2, NO and nNOS
Reversed development of allodynia and 
hyperalgesia in neuropathic pain models
Inhibited Th1 differentiation and ameliorated 
MS in mouse model
Reduced microglial activity, abrogated MHC 
class II antigen expression, inhibited 
proliferation of CD4+ T cells in MS
Drogul et al., 2003
Costa et al., 2004
Bridges et al., 
2001
Croxford and 
Miller, 2003
Arevolo-Martin et 
al., 2003
SR141716A 
(antagonist/ 
inverse agonist)
CBi
Enhanced nociception 
Produced hyperalgesia
De Petrocellis et 
al., 2000
Richardson et al., 
1998
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1.8 Unwanted effects of Cannabis and cannabinoids
Cannabis and cannabinoids can also produce unwanted (adverse) effects, 
but these have often been overstated according to Vaughan and Christie 
(2000). The acute toxicity of cannabinoids is very low and no deaths have 
been directly attributable to their recreational or therapeutic use (Kumar et al.,
2001). For a list of some of the adverse effects of cannabis and cannabinoids 
refer to Table 1.4.
Table 1.4: Unwanted effects of cannabis and some cannabinoids.
Central nervous system
Effects on mood
Effects on Perception 
Sedative effects
Effects on cognition and psychomotor 
performance
Tolerance
Dependence and withdrawal syndromes
Cardiovascular system
Heart rate
Peripheral circulation 
Eye
Imm une system  
Respiratory system
Reproductive system
Euphoriant effects (janxiety, I  alertness, J, 
depression, I  tension, |  sociability - if taken 
in friendly surrounding), dysphoric reactions 
(anxiety, panic, paranoia, transient 
psychosis), exacerbation of psychotic states 
e.g. schizophrenia and f  risk of suicide 
t  sensory perception, distortion of spatial 
perception and time sense, delusions, 
hallucinations
Generalised CNS depression, drowsiness, 
sleep, additive effect with other CNS  
depressants
Slow reaction time, motor in-coordination, 
fragmented thoughts, mental clouding, subtle 
impairment of short-term memory and 
attention, impairs road-driving performance 
Develops for many effects including the 
'high' and many systemic effects 
Potential for development but rare, 
manifested in restlessness, insomnia, 
anxiety, aggression, anorexia, muscle tremor 
and autonomic effects
Dose-related tachycardia, bradycardia with 
chronic use
Vasodilation, conjunctival redness, postural
hypotension
I  intraocular pressure
Impaired immunity thus J. resistance to
infection
Chronic bronchitis (e.g. coughing, production 
of sputum and wheezing) and emphysema, f  
incidence of rare forms of oropharyngeal 
cancer in chronic young cannabis users 
jsperm count and motility, suppression of 
ovulation, fobstetric risks, low birth weight.
[f = increased/enhanced and I  = decreased/lowered] (Ashton, 2001; Hall and Solowij, 1998; 
Kumar et al., 2001; Vaughan and Christie, 2000).
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1.9 Cannabinoids in animal models of arthritis
Cannabinoids such as A9-THC and other natural cannabinoids were shown to 
possess significant anti-oedema activity in rats (Sofia et al., 1974). A9-THC 
was shown to be orally effective not only as an anti-oedema but as analgesic 
as well and effectively inhibited adjuvant-induced arthritis and suppressed 
further development of the established disease in rats (Sofia etal., 1973).
Oral administration of ajulemic acid (AjA), a cannabinoid acid devoid of 
psychoactivity, also reduced joint tissue damage in rats with adjuvant-induced 
polyarthritis, a model of chronic inflammation and joint tissue injury (Zurier et 
al., 1998). AjA significantly reduced the severity of adjuvant-induced 
polyarthritis, histopathologic studies showed attenuation of pannus formation 
and joint tissue injury (Zurier et al., 1998). In another study, peripheral blood 
and synovial fluid monocytes (PBM and SFM) were isolated from healthy 
subjects and patients with inflammatory arthritis, respectively, treated with AjA 
(0-30 pM) in vitro, and then stimulated with lipopolysaccharide. Addition of 
AjA to PBM and SFM in vitro reduced both steady-state levels of IL-1 (3 mRNA 
and secretion of IL-1 p in a concentration-dependent manner. Reduction of IL- 
1 (3 by AjA may be responsible for the therapeutic effects of AjA in the animal 
model of arthritis (Zurier et al., 2003).
Growth of synovium as pannus which invades and destroys cartilage and 
bone in joints of patients with RA depends on activation of several cell types. 
It has been argued that activated T lymphocytes initiate and govern the 
process through their failure to undergo apoptotic cell death and thus, 
induction of T-cell apoptosis may offer a new approach to treatment of 
diseases such as RA which are characterized by chronic T-cell-driven 
inflammation (Bidinger et al., 2003). Studies by Bidinger et al. (2003) showed 
that addition of AjA in vitro induces apoptosis of human T lymphocytes. This 
depletion of T cells by AjA may also be responsible, in part, for AjA 
suppression of joint tissue injury in the rat model of arthritis above.
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Cannabidiol (CBD), the major non-psychoactive component of cannabis has 
various pharmacological actions of clinical interest and has been shown to be 
of therapeutic potential as an anti-inflammatory and anti-arthritic in murine 
collagen-induced arthritis (CIA). It was found that CBD exerted a dose- 
dependent suppressive action, both on the clinical arthritis and joint damage 
(Malfait et al., 2000).
1.10 Aim and objectives of the study 
Aim
Cannabinoids have been known for centuries to have medicinal properties 
(section 1.5.1). They have been shown to have immunomodulatory, analgesic 
and anti-inflammatory effects (sections 1. 6  and 1.7). Cannabinoids have also 
been reported to reduce inflammation and inhibit joint destruction in animal 
models of arthritis (section 1.9). These reports together suggest that 
cannabinoids have a potential as anti-arthritic drugs. The mechanisms behind 
the effects displayed by cannabinoids in animal models of arthritis are not 
fully elucidated. Therefore the aim of this study was to determine whether 
cannabinoids have effects on chondrocyte metabolism, which may reduce 
cartilage breakdown. Since IL-1 has been shown to be a key pro- 
inflammatory cytokine in arthritis, chondrocytes and cartilage explants were 
stimulated with IL-1. The effects of cannabinoids on IL-1a-stimulated cartilage 
resorption and the production of inflammatory mediators, including NO and 
eicosanoids were studied and the potential mechanisms for any changes 
observed. In addition the expression of cannabinoid receptors by bovine 
chondrocytes was studied.
Objectives
The objectives of the study were to investigate: the toxicity of cannabinoids in 
chondrocytes; the effect of the drugs on NO, LTB4 and PGE2 production; the 
effect of drugs on protease expression; the effect of drugs on cartilage 
breakdown; cannabinoid receptor expression in chondrocytes and find out if 
any of the effects were receptor mediated and; signal transduction pathways 
involved in chondrocyte metabolism and effects of cannabinoids on these.
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CHAPTER 2 
GENERAL MATERIALS AND METHODS
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2.1 Materials
Reagents 
Active Motif
(B-1330 Rixensart, Belgium)
FACE™ p38 MAPK kit
Alexis Biochemical, UK (now AXXORA (UK) Ltd)
(Nottingham, UK)
L T B 4  and PGE2 EIA kits; COX- 1  and COX- 2  rabbit polyclonal antibodies; 
mPGES-2 rabbit polyclonal antibody; iNOS polyclonal antibody produced in 
rabbit
Invitrogen Ltd /Molecular Probes
(Paisley, UK)
Antibiotics: Penicillin/Streptomycin; Collagenase Type I; Dulbecco's modified 
Eagle's medium (DMEM); Foetal bovine serum (FBS); Fungizone: 
Amphotericin B; L-Glutamine; Normal goat serum (NGS); Phosphate buffered 
saline (PBS) without calcium and magnesium; SlowFade anti-fade mounting 
medium with DAPI; Trypsin (0.25 %); Trypsin-EDTA; Western Blot kit 
(including pre-cast gels, buffers and membranes); WesternBreeze detection 
kit; Zymogram gels and buffers.
Santa Cruz Biotechnology
(Santa Cruz, California, USA)
All antibodies used except for those purchased from Alexis and Sigma- 
Aldrich; Fluorescein isothiocyanate (FITC)-conjugated secondary goat anti­
rabbit IgG; Rabbit polyclonal antibodies to CB1 (H-150) and CB2 (H-60); 
Rabbit polyclonal anti-NF-xB p65; RIPA lysis buffer.
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Sigma-Aldrich Company Ltd
(Gillingham, Dorset, UK)
Absolute Ethanol; Acetic acid; Bichiniconic acid (BCA) solution; Boric acid; 
Cannabinoids: Cannabidiol, Cannabinol, A8 -THC acid, Win-2 and Win-3; 
Chloramine T; Citric acid; Crystal violet; Cysteine HCI; p- 
Dimethylaminobenzaldehyde; 1, 9, Dimethylmethylene Blue; DMSO; EDTA, 
disodium salt; Glycine; Griess reagent (modified); HCI; 2-isopropanol; LDH 
assay Kit; Methanol; MTT; n-Propanol; Papain; Perchloric acid; R-250 
coomassie brilliant blue; Rat polyclonal anti-cannabinoid receptor -1; Rabbit 
polyclonal anti-cannabinoid receptor-2; Shark chondroitin sulphate; Sodium 
acetate trihydrate; Sodium hydroxide; Sodium Nitrite; Trypan Blue.
Tocris Cookson Ltd
(Avonmouth, Bristol, UK)
Cannabinoids: ACEA, AM281, AM630, Anandamide, 2-AG, HU-210, 
Methanandamide, NADA, N-AG, JWH-133; Glacial acetic acid; NS-398; 
ODQ; PDTC.
Other sources
Copper sulphate pentahydrate (Cupric sulphate); MK- 8 8 6  
Equipment
Fluorescence microscope coupled with a coolsnap digital camera; Light and 
Inverted microscopes; UVP Biolmaging system with Labworks software (Utra- 
Violet Products Ltd); Victor Wallac multi-plate reader; XCell SureLock™ Mini- 
Cell and XCell II™ Blot Module Kit (Invitrogen)
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2.2 Methods
All the experiments carried out in this study were repeated atleast twice, 
except where indicated in the figure legend.
2.2.1 Chondrocyte culture
2.2.1.1 Preparation
Bovine ankles were obtained fresh from the abattoir, kept at 4 °C and were 
used within 24 hrs of slaughter. First the ankles were scrubbed clean under 
running tap water. Skin around the ankle joint was slit and cut, being careful 
not to cut the faschia. The joint area was sprayed with 70 % ethanol and 
wiped with medical tissues. The ends of the joints were wrapped in foil, 
leaving just the joint exposed. Then the rest of procedures were done in a 
sterile laminar flow cabinet.
The metacarpophalangeal joint was opened up exposing the articular 
cartilage by sectioning through the faschia and ligament. The bovine articular 
cartilage (BAC) was cut from the. metacarpophalangeal joint with the aid of a 
scalpel. The cartilage pieces were washed in phosphate buffered saline 
(PBS).
The cartilage pieces were sequentially digested enzymatically, first by 
incubation with 0.25 % trypsin at 37 °C for 30 min, followed by a wash in 
complete DMEM [supplemented with glutamine (2 mM), penicillin (100 U/ml), 
streptomycin (100 pg/ml), amphotericin B (2.5 pg/ml) and 10% heat- 
inactivated FBS (FBS incubated for 30 min in a waterbath set at 56 °C)] to 
inhibit the activity of the trypsin. Further digestion was accomplished by 
incubation in sterile filtered type I collagenase (3 mg/ml in complete DMEM) 
at 37 °C overnight.
The supernatant in the digested tissue was transferred carefully into a sterile 
tube using a syringe, avoiding the tissue residues. The residues were washed
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with PBS and the supernatants were combined and centrifuged at 200 x g 
(1000 x rpm) for 7 min. The supernatant was discarded and pellets were 
washed 3-4X with PBS. The cells were then resuspended in complete DMEM 
and counted. Cell viability was checked using 0.4 % trypan blue solution. 
Cells were seeded to 2 x 105 cells per cm2 (Buttle et al., 1997). The 
chondrocytes were plated and cultured in 24-well plates in a humidified 
incubator at 37°C in an atmosphere of 5 % CO2 .
2.2.1.2 Culture
The chondrocytes were used as primary cultures. The chondrocytes were 
incubated in complete DMEM for 5 days and the medium was changed. After 
5-10 days, the chondrocytes were incubated with or without cannabinoids ± 
IL-1a (100 U/ml = 1 ng/ml = 0.06 nM) for 48 hrs in DMEM with the 
supplements except FBS at 37°C in an atmosphere of 5 % CO2 .
2.2.2 Cartilage explant culture
2.2.2.1 Preparation
Bovine noses were obtained as above (section 2.2.1). Bovine nasal cartilage 
(BNC) (Buttle et al., 1993) was prepared by dissecting the septum from the 
nasal bony hard palette. The septum was sprayed with ethanol and 
transferred to a sterile laminar flow cabinet and put in a Petri dish. The 
septum was cleaned carefully by removing the mucous membrane and 
washing in PBS a few times. Slices (approximately 3 mm) were cut using a 
sterilized Mandolin. BNC discs (3mm in diameter) were prepared using the 
sterile leather-belt punch. The discs were washed 3X in PBS.
2.2.2.2 Culture
The BNC explants were incubated in complete DMEM for at least 24 hrs. 
Before the experiments were set up, the medium was changed to DMEM
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without FBS. Discs were plated out in 96-well plate (1 disc/well/200 pi 
medium) or 24-well plate (1 or 3 discs/well/600 or 1000 pi medium). The BNC 
explants were incubated with or without cannabinoids ± IL-1a (500 U/ml = 5 
ng/ml = 0.3 nM) (Buttle et al., 1997) for 4 days or 21-35 days at 37 °C in an 
atmosphere of 5 % C02. The conditioned medium was removed and stored at 
-20 °C until assay and the explants were also stored the same way prior to 
digestion.
2.2.3 Cytotoxicity assays
2.2.3.1 MTT assay
This is colorimetric assay that is used as a measure viable cell number as the 
formation of the coloured product depends on cell metabolic activity. This is 
used for quantification of cell proliferation as well as cell cytotoxicity.
Principle
MTT is water soluble producing a yellowish solution. This is converted to 
insoluble blue formazan salt by cleavage of the tetrazolium ring by 
dehydrogenases of mitochondria of living cells. Acid-isopropanol or other 
solvents is added to the wells to dissolve the formazan crystals. Absorbance 
is read at 570 nm using the multi-plate reader. The absorbance is determined 
as measure of cell number (Mossman, 1983).
Procedure
Filter sterilised MTT (5 mg/ml in PBS), 10 pi per 100 pi medium, was added to 
all the wells of the assay, and the plate was incubated at 37 °C for 4 hrs. The 
medium was removed and acid-isopropanol was added, 1 0 0  pi per well, to 
dissolve the blue formazan crystals in the cell layer. Dissolution took about 30 
min and absorbance was read at 570 nm.
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2.2.3.2 Crystal violet assay
Principle
The cells, following culture were fixed and stained with crystal violet. The 
stain bound to the DNA of the cells. Excess stain was washed away with 
water. Acetic acid was then used to dissolve the bound stain. Absorbance of 
the stain was measured and was related to cell number.
Procedure
The assay was carried modified from (Kaeffer et al., 1997). Culture medium 
was removed and cells were washed in 200 pi of PBS. Cells were fixed with 
200 pi of methanol for 15 min. Methanol was removed and the plates were air 
dried in a fume cupboard. The plates were stained with 0.1 % crystal violet (in 
200 mM boric acid), 200 pi/ well for 20 min. The plates were washed with 
distilled water and the stained cell layer was solubilised in 50 pi of 10 % 
glacial acetic acid. The plate was incubated at 37 °C for 30 min to achieve 
dissolution. Absorbance was read at 550 nm.
2.2.3.3 LDH release assay
LDH assay was used as a means of measuring membrane intergrity, 
determined by measuring lactate dehydrogenase (LDH) in the extracellular 
medium. This enzyme is normally present in the cytosol, and cannot be 
measured extracellularly unless cell damage has occurred.
Principle
LDH activity is determined in an enzymatic test. In the first step, NAD+ is 
reduced to NADH/H+ by the LDH-catalyzed conversion of lactate to pyruvate.
In the second step, the H/H+ are transferred from NADH/H+ to a tetrazolium 
salt which is reduced to formazan. The formazan dye is water soluble and 
shows a broad absorption maximum at about 500 nm, whereas the 
tetrazolium salt shows no significant absorption at this wavelength. 
Absorbance indicates the degree of cytotoxicity. Amount of LDH activity can 
be used as an indicator of relative cell viability as well as a function of 
membrane integrity (Legrand etal., 1992).
Procedure
The assay was performed according to the manufacturer's instructions. 
Briefly, LDH assay enzyme preparation was reconstituted and the assay 
mixture was prepared containing substrate, enzyme and dye according to the 
manufacturer’s (Sigma-Aldrich) instructions. 100 pi of conditioned medium 
from each well was transferred into a clean plate. Then 50 pi of assay mixture 
was added to the conditioned medium in the wells. The plate was covered 
with foil and incubated at room temperature for 20-30 min. The reaction was 
stopped by adding 1/10 of total volume (in the well) of 1 M HCI to each well. 
Absorbance was read at 490 nm.
2.2.4 NO production assay
NO gas has an extremely short half-life (<10 s), which makes it difficult to 
detect and study directly. However, because NO is metabolized to nitrite and 
nitrate, quantification of these stable anions can be used to indirectly 
determine the amount of NO originally present. In this study NO was 
measured as one of its stable metabolites, nitrite.
Principle
Nitrite reacts with sulfanilamide releasing water to produce an intermediate 
product which then reacts with N-(l-Naphthyl) ethylenediamine to form a 
coloured Azo-product that absorbs light at wavelength approximately around 
550 nm (Fig. 2.1).
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Figure 2.1: Chemical reactions in a Nitrite Assay. Two step conversion of 
nitrite to a colored azo-product by chemically reacting with sulfanilamide and 
N-(l-naphthyl) ethylenediamine.
Procedure
NO production was measured as nitrite using the Griess reagent (Green et al. 
1982). Equal amounts (100 pi) of each of Griess reagent (Sigma-Aldrich) and 
conditioned medium or standard (0-100pM) or blank (culture medium alone) 
were added to a 96-well plate, adding Griess reagent last. The plate was 
allowed to stand at room temperature for 1 0  min for colour to develop. 
Absorbance was read at 550 nm. Nitrite concentration in the sample was 
calculated from a standard curve, 0 -100 pM sodium nitrite (Fig. 2.2).
Nitrite assay std curve
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Figure 2.2: A typical nitrite assay standard curve
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2.2.5 PGE2 and LTB4 production assays
PGE2 and LTB4 production was measured using Enzyme ImmunoAssay (EIA) 
kits, following the instructions from the manufacturers (Alexis. Biochemical).
Contents of the Kits
Table 2.1: EIA kit contents
Number Item 96 wells Quantity/Size
1 P G E 2 m ono c lona l an tibod y/ 1 v i a l / 1 0 0  determ inations
L T B 4 antiserum (dtn)
2 P G E 2/ L T B 4 E IA  A C h E  tracer 1 v i a l / 1 0 0  dtn
3 P G E 2/  L T B 4 E IA  standard 1 v i a l / 1 eac h
4 E IA  buffer concentra te 2  v i a l / 1 0  ml
5 W a s h  buffer concentrate 1 v ia l /5  ml
5 a T w e e n  2 0 1 v ia l /3  ml
6 G oat an ti-m ouse  IgG
coated  plate 1 p l a t e / 1 each
7 Plate  c o ve r 1 c o v e r / 1 e a c h
8 E llm an 's  re ag en t 3  v i a l s / 1 0 0  dtn
14 E IA  trac e r  dye 1 v i a l / 1 each
15 E IA  antiseru m  dye 1 v ia l /1  each
Principle of the Assay
The assay is based on the competition between PGE2/ LTB4 and a PGE2/ 
LTB4-acetylcholinesterase (AChE) conjugate (tracer) for a limited amount of 
PGE2 monoclonal antibody/ LTB4 antiserum. The concentration of the tracer 
is held constant while concentration of PGE2/ LTB4 in the samples varies; 
therefore the amount of tracer that is able to bind to the antibody will be 
inversely proportional to the concentration of PGE2/ LTB4 in the wells.
This antibody- PGE2/ LTB4 complex binds to goat polyclonal anti-mouse IgG 
that has been previously attached to the wells. The plate is washed to remove 
any unbound reagents and then Ellman’s reagent (which contains the 
substrate to AChE) is added to the wells. The product of this enzymatic 
reaction has a distinct yellow colour which absorbs strongly at 412 nm. The
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intensity of this colour, determined spectrophotometrically, is proportional to 
the amount of tracer bound to the wells, which is inversely proportional to the 
amount of free PGE2/ LTB4 present in the wells during the incubation. For a 
summary of the assay process refer to Figure 2.3.
2. W a s h e d  the plate  
to remove all unbound  
reagents
Plate pre-coated with 
mouse monoclonal 
antibody and blocked 
with proteins
1. Incubated with 
tracer, antiserum, and 
either Std or sam ples,  
overnight.
3. D eveloped the 
wells with Ellman's  
reagent. Read  
Absorbance at 4 0 5  
nm
Figure 2.3: Schematic drawing of the EIA process.
Biochemistry of the ElAs
AChE is a stable enzyme that hydrolyses acetylthiocholine. In the enzyme 
immunoassays, a molecule of the analyte (in this case, PGE2 or LTB4) 
covalently bound to a molecule of AChE serves as the tracer. The 
quantification of the tracer is achieved by measuring its AChE activity with 
Ellman’s reagent. This reagent consists of acetylthiocholine and 5,5’-dithio- 
b/s-(2-nitrobenzoic acid). Hydrolysis of acetylthiocholine by AChE produces 
thiocholine. The non-enzymatic reaction of thiocholine with 5,5’-dithio-b/s-(2- 
nitrobenzoic acid) produces 5-thio-2-nitrobenzoic acid, which has a strong 
absorbance at 412 nm. See Figure 2.4.
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Figure 2.4: The Biochemical reactions in the ElAs
Pre-assay preparations
EIA buffer was prepared by diluting the contents of one vial of EIA buffer 
concentrate with 90 ml deionised and sterilised water. Wash buffer was 
prepared by diluting the vial (5 ml) of wash buffer concentrate with deionised 
water to a total volume of 2 L and 1 ml Tween 20 was added to it. To prepare 
1 L of wash buffer, 2.5 ml of wash buffer concentrate was diluted to 1 L, and 
0.5 ml Tween 20 was added. Conditioned media was used immediately at the 
end of the cell culture. No dilution was done.
Preparation of assay-specific reagents
The PGE2 standard was reconstituted with 1 ml of EIA buffer making the 
stock solution (10 ng/ml). The standard curve was diluted with culture media 
because the samples were not diluted. Serial dilutions were prepared for the 
standard curve. Eppendorf tubes were set aside, numbered 1 to 8. 900 pi of 
culture medium was aliquoted to tube 1 and 500 pi of culture medium was 
aliquoted to tubes 2 to 8.100 pi of stock solution (10 ng/ml) was transferred to 
the tube 1 and mixed thoroughly. The standard was then serially diluted by 
transferring 500 pi from tube 1 to tube 2, and from tube 2 to tube 3 and so on,
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mixing thoroughly prior to each transfer. The diluted standards were not 
stored for more than 24 hrs.
LTB4 standard preparation started with equilibration of the pipette tip used in 
ethanol by repeatedly filling and expelling the tip with ethanol several times.
Using the equilibrated pipette tip, 100 pi of LTB4 standard was transferred into
a clean Eppendorf tube, and 900 pi was then added to this tube using 
deionised, sterilised water to make a stock solution (5 ng/ml). The standard 
curve was diluted with culture media because the samples were not diluted. 
Serial dilutions were prepared for the standard curve as for the PGE2 
standards (Fig. 2.5).
500 |il 500 |il 500 |il 500 |il 500 |il 500 |il 500 |il
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Figure 2.5: Standards serial dilution
PGE2/LTB4 AChE Tracer (1 vial) was reconstituted with 6 ml EIA buffer. 
PGE2/LTB4 antiserum was also reconstituted with 6 ml EIA buffer.
Assay procedure
Each plate or set of strips contained a minimum of 2 blanks (Blk), 2 non­
specific binding (NSB) wells, 2 maximum binding (B0), and an 8 point Std 
curve run in duplicate. 50 pi of culture medium was added to NSB and B0 
wells and 50 pi EIA buffer to NSB wells. 50 pi was added to the Std wells, 
starting with the lowest concentration continuing with this procedure until all 
the Stds were aliquoted. 50 pi of sample was added per sample well. Each 
sample was assayed at least in duplicate. PGE2/ LTB4 AChE tracer was
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added (50 jjI) to each well except the Total Activity (TA) and the Blk wells. 
PGE2 monoclonal antibody/ LTB4 antiserum was added (50 pi) to each well 
except the TA, NSB and Blk wells. The plate was covered with plastic film and 
incubated overnight at 4°C.
For the development of the plate, Ellman’s reagent was reconstituted with 20 
ml of deionised and sterilised water and was used the same day since it is 
unstable. It was also protected from light by covering the tube containing the 
reagent with aluminium foil. The wells were emptied and rinsed 5X with wash 
buffer (1X). 200 pi of Ellman’s reagent was added to each of the wells and 5 
pi of tracer was added to the TA wells. The plate was covered with plastic film 
and protected from light by covering with aluminium foil. The plate was placed 
on a shaker for optimal development. The assays developed (i.e. B0 wells 
read a minimum of 0.3 at 405 nm, with the Blk subtracted) in 90-120 minutes. 
The plate was read at a 405 nm, when the Bo wells were in the range 0.3-0.8 
(Blk subtracted). If the absorbance of the wells exceeded 1.5, the plates were 
washed and fresh Ellman’s reagent was added and plate was developed 
again.
Calculation of the results
The absorbance readings from the NSB wells were averaged. The 
absorbance readings from the B 0 wells were also averaged. The NSB 
average was subtracted from the Bo average. This is the corrected Bo or 
corrected maximum binding. The % B/Bo (% sample or Std bound/maximum 
bound) for the remaining wells was calculated. To do this, the average NSB 
absorbance was subtracted from the Std 1 absorbance and divided by the 
corrected B0 (from step 3). This was then multiplied by 100 to obtain % B/B0. 
The calculation was repeated for Std 2-8 and all sample wells. The standard 
curve was prepared by plotting % B/B0 for Std 1-8 vs PGE2/ LTB4 
concentration (in pg/ml) on semi-log scale. Actual PGE2/ LTB4 concentration 
was calculated using the equation of the plot (Fig. 2.6). The detection limit 
(80% B/Bo) for PGE2 EIA assays was generally approximately 0.05 pg/ml, and 
for LTB4 EIA assays was in general around 0.002 pg/ml.
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STD Curve for PGE2 Assay
y = -5.8914Ln(x) + 36.164 
R2 = 0.974
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Figure 2.6: A typical standard curve for the PGE2 assay
2.2.6 Cartilage resorption assays
2.2.6.1 Collagen release assay
Bovine nasal catilage explants when incubated in the presence of IL-1 a (0.3 
nM) were stimulated to undergo extracellular matrix resorption and this 
included breakdown and release of collagen later in the resorption process. 
Collagen breakdown was measured as hydroxyproline (Hpro) released in the 
conditioned media using the Hpro assay described by Reddy and Enwemeka 
(1996).
Principle of the assay
The method was based on alkaline hydrolysis of samples (conditioned media 
or residual cartilage digests) and subsequent quantification of free Hpro in the 
hydrolysates. It involved 3 main steps: (a) hydrolysis to free Hpro using NaOH 
(2 M final concentration), (b) oxidation of Hpro by chloramine T reagent, and 
(c) chromophore development by the Ehrlich’s reagent.
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Assay reagents
Acetate-citrate buffer (pH 6.5)
Sodium acetate trihydrate (120 g), citric acid (46 g), acetic acid (12 ml) and 
NaOH (34 g) were dissolved in 1 L in distilled water with pH adjusted 
accordingly to 6.5.
Chloramine T reagent (0.056 M)
Chloramine T (1.27 g) was dissolved in 20 ml 50 % n-propanol and brought to 
100 ml with acetate-citrate buffer.
Ehrlich’s reagent (1 M)
p-Dimethylaminobenzalaldehyde (15 g) was dissolved in n- 
propanol/perchloric acid (2:1, v/v) and brought to 100 ml. Since this reagent is 
not stable, it was prepared freshly before each assay.
The residual cartilage was digested using papain solution containing 25 
mg/ml papain in 0.1 M phosphate buffer (pH 6.5); 50 mM EDTA disodium salt 
and 50 mM cysteine HCI. Sodium hydroxide (10 M) in distilled water was 
prepared as a stock solution. L-hydroxyproline was used for standard curve. 
A solution containing 1 mg/ml of Hpro in distilled water was prepared as a 
stock solution.
Assay procedure
For residual cartilage digestion, cartilage from each well was digested in an 
Eppendorf tube with a total volume of 700 pi containing: 490 pi phosphate 
buffer, 70 pi EDTA disodium salt, 70 pi cysteine HCI and 70 pi papain. The 
papain used was fairly insoluble therefore the digestion buffer mix was filtered 
prior to addition to the tubes containing the discs. The capped tubes were 
incubated at 65 °C in a water bath for 2 hrs to digest the discs.
Hydroxyproline content was determined in the conditioned media as well as in 
digests following the procedure below:
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10 |jl of standard (0-50 pg/ml) and samples (conditioned media and digests) 
were mixed with NaOH (2 M final concentration) in a total volume of 50 pi. 
The samples were autoclaved at 120 °C for 20 min (for hydrolysis) in O-ring 
screw-capped polypropylene (PP) tubes (2 ml). 450 pi of chloramine T was 
added to the hydrolysates and standards were mixed gently followed by 
incubation at room temperature for 25 min to allow oxidation to take place. 
500 pi of Ehrlich’s reagent was added to each sample and standard and 
mixed gently. Chromophore was allowed to develop by incubating at 65 °C for 
20 min. Absorbance was read at 550 nm in 96-well plate using a Victor- 
Wallac plate reader. The equations obtained from the prepared standard 
curves (see Fig. 2.7) were used to determine the actual concentration of the 
released hydroxyproline, taking into consideration the dilution factors. The 
results were expressed as a percent cumulative hydroxyproline released (as 
a percentage of total hydroxyproline in the explants per well).
STD Curve for Hydroxyproline Assay
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R2 = 0.99910.50 -
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Figure 2.7: A typical hydroxyproline assay standard curve.
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2.2.6.2 Cartilage Oligomeric Matrix Protein (COMP) release assay
This assay was used to measure the release of COMP fragments into the 
conditioned media, as one of the markers of extracellular matrix degradation. 
COMP is one of the biomarkers of cartilage resorption (Neidhart etaL, 1997). 
It can also be used prognostically for cartilage destruction in inflammatory 
arthropathies such as RA and OA (Forslind et al., 1992) since quantitative 
relation has been found between COMP concentration in serum and the 
degree of cartilage destruction. This animal COMP ELISA from AnaMar 
Medical (Sweden) provides a method for the determination of COMP in 
animal serum including that of bovine. The assay was carried out following 
the manufacturer’s instructions. Conditioned medium was used in place of 
serum.
Assay kit reagents
(See Table 2.2 below)
Table 2.2: COMP ELISA kit reagents
Item Quantity Preparation
COMP coated plate 
(COMP of bovine origin) 
Calibrators (rat origin) 
(0.055 U/L-0.9 U/L) 
Sample buffer 
Polyclonal antibody 
Enzyme conjugate 11X 
peroxidase conjugated 
antibody (donkey origin) 
Conjugate buffer 
Stop solution 0.5M H2SO4 
Washing tablet
Enzyme substrate (TMB)
1 plate
5 vials (0.5 ml)
1 vial (7.5 ml)
1 vial (7 ml)
1 vial (1.2 ml)
1 vial (12 ml)
1 vial (7 ml)
2 tablets
2 vials (6 ml)
Ready for use, stored at 4° C
Ready for use
Ready for use 
Ready for use 
Concentrate, prepared by 
diluting 11X in conjugate buffer
Ready for use 
Ready for use
Dissolved in 500 ml deionised 
water
Ready for use
Principle of the procedure
In the competitive COMP ELISA, the wells of the 96-well plate were provided 
coated with bovine COMP. Sera from rats were used as calibrators. A
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polyclonal antiserum from rats directed against COMP was used as the 
primary antibody. This antibody was incubated together with samples and 
calibrators directly in the wells, so the antibody would competitively bind to 
either the COMP coated to the well or to one added as sample or calibrator. 
After washing, donkey anti-rat peroxidase conjugate was added to the wells 
so it could bind to primary antibody. The peroxidase enzyme usually 
catalyses the oxidation of a chromogen that can be measured following 
termination of the reaction. A chromogen widely used for this purpose is 
S.S'^S'-tetramethylbenzidine (TMB). The two electron oxidation of 
tetramethylbenzidine yields a component with an absorbance maximum at 
450 nm. If the enzyme reaction is terminated by lowering of the pH (less than 
1.0), an additional increase of the absorbance at 450 nm is observed (Bally 
and Gribnau, 1989). Therefore after washing, the enzyme substrate TMB was 
added. The product of this enzymatic reaction changed colour to yellow when 
the stop solution (sulphuric acid) was added. The absorbance of the colour 
developed was read at 450 nm. This response was inversely proportional to 
the concentration of COMP in the sample.
Assay procedure
The samples (conditioned media) were diluted 1/10 in sample buffer. Sample 
buffer (blank) and Std 0.9 U/ml -  0.055U/ml in 50 pi aliquots were added to 
the Std wells. 50 pi of conditioned medium were added to the sample wells 
followed by addition of 50 pi polyclonal antibody to all the wells. The plate was 
sealed and incubated on a shaker for 2 hrs at room temperature. After the 
incubation, the plate was washed 6 times. After the final wash, the plate was 
inverted and tapped firmly against a paper towel. 50 pi of conjugate was 
added to each well. The plate was sealed and incubated on a shaker for 1 hr 
at room temperature after which the plate was washed 6 times. After the final 
wash, the plate was inverted and tapped firmly against the paper towel. 100 pi 
of enzyme substrate was added to each well. The plate was incubated for 15 
min at room temperature. 50 pi stop solution was added and the plate was 
placed on a shaker for approximately 5 seconds to ensure mixing of substrate 
and stop solution. The absorbance was then read at 450 nm. The calibrator
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curve was prepared by plotting absorbance versus calibrator concentration on 
a semi-log scale (Fig. 2.8). The equation from this plot was used to work out 
the actual COMP concentration in the samples, multiplying the result by 
dilution factor (x10).
COMP Assay STD Curve
0.91
y = -0.1284Ln(x)- 0.5181
[COMP] U/ml
Figure 2.8: A typical COMP assay standard curve 
2.2.6.3 Proteoglycan release assay
Bovine nasal cartilage explants when incubated in the presence of IL-1a (0.3 
nM) underwent extracellular matrix resorption (Buttle et al., 1997) that 
included the breakdown and release of proteoglycan earlier in the catabolic 
process. Proteoglycan breakdown was measured as release of sulphated 
glycosaminoglycans (sGAGs), such as chondroitin sulphate, using the 
dimethylmethylene blue assay (Farndale etal. 1986).
Assay principle
1,9-dimethylmethylene blue binds with the sGAGs causing an increase in 
absorbance at 520 nm dependent on the amount of sGAGs present. This was 
used to quantify cartilage resorption in terms of proteoglycan breakdown.
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Assay reagents
Dimethylmethylene blue solution was prepared containing 16 mg 1,9- 
dimethylmethylene blue in 1 L of Glycine buffer (3.04 g glycine, 2.37 g NaCI 
and 95 ml 0.1 M HCI in 1 L; adjusted to pH 3.0 using HCI or NaOH). The 
absorbance of the solution was checked at 520nm and was expected to be 
around 0.31. The solution was stored in a brown bottle (to protect from light) 
at room temperature and was stable for several months. This solution was 
used to determine the amount of sGAGs measured as chondroitin sulphate in 
conditioned media and cartilage digests.
The residual cartilage was digested using papain solution containing 25 
mg/ml papain in 0.1 M phosphate buffer (pH 6.5), 50 mM EDTA disodium salt 
and 50 mM cysteine HCI.
Chondroitin sulphate stock solution, 4 mg/ml chondroitin sulphate (shark or 
bovine trachea) (Sigma-Aldrich) was made up in either DMEM or phosphate 
buffer (pH 6.5) depending on whether sGAGs were being measured in 
conditioned media or digests. Standard was kept at -20 °C in aliquots.
Procedure
Residual cartilage digestion was carried out as explained under section 
2.2.6.1. Standard stock solution of 4 mg/ml chondroitin sulphate was diluted 
to 40 pg/ml working solution and standard curve was constructed using 0-40 
pg/ml chondroitin sulphate. The test samples (conditioned media and digests) 
were diluted 100X.
Aliquots, 40 pi, of the standard or test samples were added to wells of a 96- 
well plate. Dimethylmethylene blue solution, 250 pi, was added to the wells 
and absorbance was read immediately at 520 nm using Victor-Wallac plate 
reader spectrophotometer.
81
The equations obtained from the prepared standard curves (Fig. 2.9) were 
used to determine the actual concentration of the released sGAGs, taking into 
consideration the dilution factors. The results were expressed as a percent of 
cumulative sGAGs released (as a percentage of total sGAGs in the explants 
per well).
sGAGs Assay Std Curve
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Figure 2.9: A typical proteoglycan release assay standard curve.
2.2.7 Immunoblot analysis 
Principle
Immunoblot analysis also known as western blotting is a method for the 
identification of a specific protein that involves: sample protein separation by 
size using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE); transfer of separated proteins to a membrane; and specific 
identification by labeled antibodies. The first step in immunoblot analysis was 
gel electrophoresis, in which the proteins of the sample were separated 
according to size on a gel using SDS-PAGE. SDS coats the protein and gives 
it an overall negative charge such that when a current is applied, the proteins 
migrate towards the positive electrode, being separated in the process 
according to the molecular weight. The proteins in the gel were then
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transferred onto a membrane made of polyvinylidene difluoride (PVDF), by 
applying an electric current (electroblotting). The membrane binds proteins 
non-specifically. This process is necessary in order to expose the proteins for 
detection and the membrane is used because it is more manageable than a 
gel. The membrane was then blocked, in order to prevent non-specific protein 
interactions between the membrane and the antibodies used to detect the 
protein. Without the blocking, the antibodies would bind to the membrane 
instead of binding to the protein of interest only. The membrane was 
incubated in primary antibody. The primary antibody should recognise only 
the protein of interest on the membrane. After washing the membrane to 
remove unbound primary antibody, the membrane was incubated with a 
secondary antibody, goat anti-rabbit antibody conjugated to alkaline 
phosphatase. The unbound secondary antibodies were washed away, and 
the membrane incubated with the enzyme substrate so that the positions of 
membrane-bound secondary antibodies could be visualised in this case as 
purple band(s). In principle, the protein bands on the membrane that are 
stained represent the protein(s) of interest. The size of the protein was 
confirmed using the protein markers run on the same gel as the samples..
Whole cell lysate preparation
Cells were maintained as primary cultures and stimulated using IL-1a 
(0.06nM) following 30 min pre-treatment with Win-55,212-2 and incubated for 
48 hrs. The cells were washed in PBS and kept on ice. Complete lysis buffer 
was prepared by mixing radioimmuno precipitation assay (RIPA) lysis buffer 
(5ml), phenylmethylsulfonyl fluoride (PMSF) (50pl), sodium orthovanadate 
(50pl) and protease inhibitor cocktail (100pl) according to the manufacturer’s 
instruction (Santa Cruz). The cells were incubated with the complete lysis 
buffer for 1 hr on ice. The whole cell lysates were centrifuged at 10,000xg for 
10 min at 4 °C. The supernatant was stored at -20 °C until further analysis.
Protein concentration determination
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This was done to determine protein concentration of samples. The reagent 
was prepared by mixing: Bichinichonic acid solution- BCA reagent (Sigma); 
Copper (II) sulphate pentahydrate solution (4 % v/v), BSA (1 mg/ml) in lysis 
buffer. The working reagent was prepared by adding 1 ml of copper (II) 
sulphate solution to 49 ml of BCA reagent. BSA was used as a standard and 
its stock solution was prepared at 1 mg/ml. Standard curve was prepared in 
the range of 0-25pg/ 25 pi.
25 pi of standards or sample were added to a 96 well plate. 200 pi of working 
reagent was added to the wells and the plate was placed on a shaker for 1 
min. Thereafter the plate was incubated for 30 min at 37 °C. Absorbance was 
read at 570 nm. Protein concentration for the samples was in the range of 9- 
14 pg/ 25pl.
2.2.7.1 Sodium dodecyl sulphate - polyacrylamide gel 
electrophoresis (SDS-PAGE)
Running buffer
NUPAGE® Novex Bis-Tris (3-(N-morpholino) propanesulfonic acid (MOPS)) 
running buffer was used. 500 pi of antioxidant was added to 200 ml of the 1X 
running buffer and this was used to fill the upper chamber of the XCell 
SureLock® Mini-Cell.
Sample preparation
5 pi lithium dodecyl sulphate (LDS) sample buffer and 2 pi of reducing agent 
(dithiothreitol (DTT)) were added to samples. Samples were heated at 70 °C 
for 10 min, according to the manufacturer’s instructions (Invitrogen).
Gel cassette’s preparation and electrophoresis
1.0 mm and 1.5 mm thick pre-cast 4-12 % NuPAGE® Bis-Tris mini-gels were 
used. Gel cassettes were removed from their pockets, rinsed with deionised
water. The slot at the bottom was stripped open, on one side of the gel. The 
comb was removed and gel wells were washed 3X and filled with the running 
buffer containing antioxidant. The gel cassette was loaded into the 
electrophoresis module of XCell SureLock® Mini-Cell, with the slot facing out 
and wells facing toward the upper chamber core. The upper chamber was 
filled with approximately 200 ml of the running buffer containing antioxidant, 
covering the wells of the gel. SeeBlue plus2 pre-stained protein standards 
were used for easy and clear band identification. Up to 5pl of the marker as 
well as up to 35 pi of samples were loaded into the wells of the gel. The lower 
chamber of the electrophoresis module was filled with approximately 600 ml 
of the running buffer without the antioxidant. 2 gels were normally run 
simultaneously. The electrophoresis running conditions were set at 200V, 
125mA, 35 W for 1 hr in MOPS buffer.
2.2.7.2 Protein transfer
The electrophoresed proteins on NuPAGE® gels were electroblotted onto 
Invitrolon® PVDF membranes using the XCell II™ Blot Module. Invitrolon™ 
PVDF is a 0.45 pm membrane which is particularly suitable for high sensitivity 
and low background immunblotting. NuPAGE® transfer buffer (1X) was 
prepared by adding 50 ml 20X NuPAGE® transfer buffer and 200 ml 
methanol to 750 ml deionised water. 1ml NuPAGE® antioxidant was added to 
the buffer for the reduced samples.
Blotting pads were soaked in the transfer buffer and bubbles in the pads were 
removed. The PVDF membrane was washed in methanol for 30 sec, rinsed 
with deionised water. The membranes as well as filter papers were 
equilibrated in the transfer buffer for 5 min. The gels were removed from the 
cassettes for transfer by following manufacturer’s instructions (Invitrogen). 
Briefly, the cassettes were opened using a gel knife. The gel rested on one of 
the plates of the cassette. Pre-soaked filter paper was placed on the gel and 
bubbles were removed by rolling a pipette on the filter paper. The filter paper 
was soaked with the transfer buffer to prevent the gel form drying. The wells 
part of the gel was removed using the gel knife. The assembly was turned
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upside-down over a clean flat surface covered with parafilm. The gel was 
allowed to free fall from the cassette plate, the foot was cut off. Pre-soaked 
transfer membrane was placed on the gel and air bubbles were removed. 
Another pre-soaked filter paper was placed on top of the membrane and any 
air bubbles were removed. The filter paper was wet with transfer buffer. Two 
gel/membrane sandwiches were prepared for each transfer.
Two pre-soaked blotting pads were placed on the cathode (-) core of the blot 
module. This was followed by the first gel/membrane sandwich, with the gel 
closest to the cathode core. Another blotting pad was placed on the first 
assembly followed by the second gel/membrane assembly, again with the gel 
closest to the cathode core. Two more pre-soaked blotting pads were placed 
on top of the second assembly, followed by the anode (+) core. The blot 
module was held together firmly and slid into the guide rails on the lower 
buffer chamber. The module was locked into position. The blot module was 
filled with the 1X transfer buffer until the gel/membrane assembly was 
covered. The outer chamber was filled with 650 ml of deionised water. 
Transfer was performed using 30V for at least 1 hr, 170mA; or 15V overnight 
at 4° C.
2.2.7.3 Immunodetection
WesternBreeze® Chromogenic Western Blot Immunodetection kit (Invitrogen) 
was used to detect primary antibodies immobilised on PVDF membrane, 
following the manufacturer’s instructions. For contents of kit (see Table 2.3 
below).
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Table 2.3: The contents of the immunodetection kit
Item Description
Blocker/Diluent (part A) Concentrated buffered saline solution 
containing detergent
Blocker/Diluent (part B) Concentrated Hammersten casein solution
Antibody wash (16X) Concentrated buffered saline solution 
containing detergent
Chromogenic substrate Ready-to-use solution of BCIP/NBT substrate 
for alkaline phosphatase
Secondary antibody solution Ready-to-use solution of alkaline 
phosphatase-conjugated, affinity purified, 
anti-rabbit IgG: goat conjugate
5-bromo-4-chloro-3-indolyl-1 -phosphate (BCIP, i and nitro blue tetrazolium (NBT)
Membrane preparation
After protein transfer from the gels to the PVDF membranes, the membrane 
was washed 2X for 5 min with deionised water to remove gel and transfer 
buffer components and some weakly bound proteins. If the membrane was 
water-washed and dried, the membrane was re-wet in methanol followed by 
2X water washes for 5 minutes before proceeding to immunodetection.
Solution preparation
Table 2.4: Table showing the components and the amounts used to prepare 
solutions for immunodetection assay
Solution Components Am ounts (ml)
Blocking solution Deionised water 5
Blocker/diluent (part A) 2
Blocker/diluent (part B) 3
Total 10
Primary antibody diluent Deionised water 7
Blocker/diluent (part A) 2
Blocker/diluent (part B) 1
Total 10
Antibody wash Deionised water 150
Antibody washing solution
(16X) 10
Total 160
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Immunodetection procedure
The membrane was placed in 10 ml blocking solution (Table 2.4) in a covered 
dish and incubated for 30 min on a shaker, followed by rinsing 2 X with 
deionised water for 5 min. The membrane was incubated in 10 ml of primary 
antibody solution (containing 1:50 -  1:200 antibody) for 1 hr followed by 
washing 4X (5 min each) with 20 ml of prepared antibody wash (Table 2.4). 
The membrane was then incubated in 10 ml of secondary antibody for 30 min 
followed by washing 4X (5 min each) with 20 ml of prepared antibody wash 
and 3X with deionised water. The membrane was then incubated in 5 ml of 
the chromogenic substrate until purple bands developed on the membrane -  
at least 1 hr. This was followed by washing of the membrane 2X with 
deionised water. The membrane was then dried on a clean piece of filter 
paper to open air. After drying, the membrane was imaged using UVP 
Biolmaging system using Labworks or scanned using EPSON scanner.
2.2.8 Zymography
Principle
The protease sample is denatured in SDS buffer and electrophoresed on a 
zymogram substrate containing gel using Tris-Glycine SDS running buffer. 
Following the run, the protease is renatured by incubating the gel in 
zymogram renaturing buffer containing a non-ionic detergent (Triton X-100). 
The gels are the equilibrated and incubated in zymogram developing buffer in 
order to add the divalent metal cation required for enzymatic activity. During 
this incubation, the protease degrades the substrate impregnated in the gel, 
in this case gelatin. This is followed by staining and destaining of the gel such 
that protease bands appear as clear bands against a dark background. The 
dye used penetrates the entire gel, but only binds permanently to the 
proteins. Excess dye is washed by destaining, with first destaining solution 
acting by shrinking the gel thus squeezing out the liquid from the gel, and the 
final destaining solution swells the gel and enhances clearing of the gel.
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Reagents and materials
Zymogram gelatin pre-cast gels (10 % Tris-Glycine gel with 0.1 % gelatin 
incorporated as a substrate); protein molecular weight marker; Tris-Glycine 
SDS sample buffer; 10X Tri-Glycine SDS running buffer (diluted 10X in 
deionised water prior to use); 10X Zymogram renaturing buffer (diluted 10X in 
deionised water prior to use); and 10X Zymogram developing buffer (diluted 
10X in deionised water prior to use) (all purchased from Invitrogen) were used 
in the zymography studies.
Gel preparation
The gel cassettes were removed from the pockets and washed with deionised 
water, the slot on the gel was stripped open and the comb was removed. The 
wells were washed with the Tris-Glycine running buffer 3X and filled with the 
buffer.
Sample preparation and electrophoresis
Conditioned media from chondrocytes or explant cultures were used. 5 pi of 
Novex® Tris-Glycine SDS sample buffer was added to the samples. No 
reducing agent was added to the samples so that proteases would maintain 
their subunit assemblies that they might need for activity. The samples were 
not boiled prior to electrophoresis.
When loading samples into the wells, the marker was separated from the 
sample lanes by one or two lanes to prevent diffusion of reducing agent which 
may interfere with the protease activity. The same marker as in the 
immunoblotting experiments was used and so were the loading volumes. The 
gel cassettes were loaded onto the electrophoresis module of the XCell 
SureLock® Mini-Cell. The 1X Tri-Glycine SDS running buffer was used to fill 
both the upper (200 ml) and lower chamber (600 ml). The gels were run at 
125 V and 40 mA for 90 minutes. The gels were removed from the cassettes 
after electrophoresis by opening the cassettes using a gel knife. The gel
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rested on one of the plates of the cassette and the gel was wetted with the 
renaturing buffer to avoid drying. A piece of clean parafilm was placed on the 
gel and it was turned over so the gel rested on the piece of parafilm. The gel 
was then transferred to a dish for development.
Developing zymogram gels
After electrophoresis, the gel was incubated in 1X zymogram renaturing 
buffer for 30 min at room temperature on a shaker. The renaturing buffer was 
decanted and the gel was equilibrated in 1X developing buffer for 30 min at 
room temperature on a shaker. The buffer was decanted and fresh 1X 
developing buffer was added and the gel was incubated overnight at 37 °C.
Staining zymogram gels
Staining solution
0.1 g Coomassie Brilliant Blue -  R-250 (0.1%); 50 ml methanol (50 %) and 10 
ml glacial acetic acid (10%) were combined and made up to 100 ml with 
deionised water. The solution was filtered prior to use.
Destaining solution
50 ml methanol (50 %) and 10 ml glacial acetic acid (10%) were combined 
and made up to 100 ml with deionised water.
Final destaining solution
7 ml methanol (7 %) and 10 ml glacial acetic acid (10%) were mixed and 
made up to 100 with deionised water.
Procedure
After development, the gels were washed in a solution containing 50 % 
methanol and 10 % acetic acid for 30 min at room temperature. The gels 
were placed in the staining solution about 3 hrs or overnight on a shaker. The
gels were removed from the staining solution and placed in destaining 
solution for a few hours (changing the solution as necessary) until the 
protease activity bands were clear. Destaining was finished with the solution 
containing 7 % methanol and 10 % acetic acid. Finally the. gels were washed 
in deionised water. The gel was then placed between two pieces of parafilm 
and was imaged using the UVP Biolmaging system using Labworks software 
or scanned using EPSON scanner.
2.2.9 Immunofluorescence
Basic principle
Immunofluorescence, which is immunocytochemistry with fluorescence 
detection, is a technique whereby an antibody labelled with a fluorescent 
molecule is used to detect the presence of an antigen in or on a cell or tissue 
by the fluorescence emitted by the bound antibody. This could be done 
directly or indirectly. In this study, the indirect immunofluorescence was used, 
in which the antibody specific for the antigen was unlabeled and a second 
anti-immunoglobulin antibody directed toward the first antibody was 
conjugated to the fluorochrome, fluorescein isothiocyanate (FITC). 
Fluorescence was detected using a fluorescence microscope. The sample 
was excited with a blue light; and following the excitement, the cell target 
protein labelled with FITC emitted a bright green (fluorescent) colour. This 
analysis was carried out as described by Smith etal. (1985)
Cell fixation
At the end of culture period, cells grown on coverslips or chamber slides were 
washed with PBS. The cells were fixed in 4 % paraformaldehyde for 20 min to 
preserve them and their cellular architecture. The cells were washed and 
stored in PBS at 4 °C until further analysis. To prepare 4 % 
paraformaldehyde, PBS (without Ca2+ and Mg2+) was added to 8 g of 
paraformaldehyde and made up to 100 ml. The mixture was heated in a water 
bath at 70 °C until the solution became clear. The solution was filtered,
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allowed to cool at room temperature and kept at 4 °C. It was diluted 2X in 
PBS prior to use.
Immunostaining
The cells were washed in PBS and permeabilised with 0.1 % Triton X-100 (in 
PBS) for 15 min at room temperature, followed by washing in PBS. Non­
specific binding sites were blocked with 2 % normal goat serum (NGS) in PBS 
for 1 hr at 37 °C. The cells were covered with primary antibody diluted in 2 % 
NGS (in PBS) overnight at 4 °C. Following the overnight incubation the cells 
were washed in PBS (containing 0.05 % Tween 20) once quickly and for 20 
min on a shaker. The fluorescently labelled secondary antibody diluted 1:100 
in 2 % NGS (in PBS) was added to the cells and they were incubated covered 
with aluminium foil for 1 hr at room temperature. The cells were washed in 
PBS (containing 0.05 % Tween 20) once quickly and for 20 min on a shaker 
and they were equilibrated with a buffer provided with the slow anti-fade 
mounting kit and mounted in slow anti-fade mounting medium (Molecular 
Probes). The coverslips were sealed with clear nail polish. The cells were 
viewed and imaged using a fluorescence microscope coupled to a Coolsnap 
digital camera.
2.2.10 The Fast Activated Cell-based ELISA (FACE®) for p38 Mitogen- 
Activated Protein Kinase (MAPK)
Principle of the assay
In FACE®, cells were cultured in 96-well plates and stimulated to induce the 
p38 MAPK pathway. Following 15-30 min stimulation, the cells were fixed 
rapidly to preserve activation-specific protein modifications. Each well was 
then incubated with a primary antibody specific for the activated p38 MAPK. 
Subsequent incubation with secondary HRP-conjugated antibody and 
developing solution produced a coloured (blue) product. The reaction was 
stopped using sulphuric acid which turned the blue solution to yellow one, the 
absorbance of which at 450 nm was related to the amount of p38 MAPK. The
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number of cells in each well was normalized with the crystal violet solution 
provided. FACE® p38 Kit also contained a primary antibody specific for the 
native inactive p38 MAPK, so both native and activated protein levels were 
monitored in the same experiment.
Components of the FACE® p38 MAPK kit (see Table 2.5)
Table 2.5: Components of the FACE p38 MAPK kit
Reagents Quantity (per plate) Preparation
Phospho-p38 antibody 9 pi 1 >500 dilution in 
antibody dilution buffer
Total-p38  antibody 9 pi 1 5 0 0  dilution in 
antibody dilution buffer
Anti-rabbit HRP- 
conjugated IgG
11 pi 1 /2 0 00  in antibody 
dilution buffer
1X antibody blocking 
buffer
22 ml R eady to use
1X antibody dilution 
buffer
30 ml R eady to use
10X PBS 120 ml 1 /10  dilution with 
deionised w ater
10X Triton X -10 0 9 ml 1 /100 dilution with PBS  
(0 .1%  Triton X -10 0 )
Crystal violet solution 22 ml R eady to use
Developing solution 22 ml R eady to use
Stop solution 22 ml R eady to use
1 % S D S  solution 22 ml R eady to use
96-w e ll tissue culture 
plate
2 R eady to use
Plate sealing tape 2 R eady to use
Additional Reagents
10 % hydrogen peroxide 
(H 2O2)
3 ml 1 /10  dilution with wash  
buffer (quenching 
buffer)
4 %  paraform aldehyde 2.5 ml
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Procedure for the FACE® p38 assay
Cells were seeded in the 96-well plate at 2 x 105 cells/cm2. The chondrocytes 
were grown for 5 days in complete medium. The medium was changed to one 
without FBS. The cells were stimulated for 15 or 30 min with IL-1a (0.06nM) 
with or without Win-55,212-2 (1-10 pM). The cells were fixed by replacing 
culture medium with 100 pi of 4 % paraformaldehyde in PBS and the plate 
was incubated for 20 min at room temperature. This was followed by washing 
3X with 200 pi wash buffer. Each wash was done for 5 min on a shaker. 100 
pi quenching buffer (wash buffer with 1 % H20 2) was added to the cells and 
incubated for 20 min at room temperature. The cells were washed 2X, 5 min 
each, with 200 pi wash buffer. 100 pi of antibody blocking buffer was added to 
the wells and incubated for 1 hr.
Half of the 96-well plate wells were incubated with diluted phospho-p38 
antibody and the remaining half with total-p38 antibody. Some of the wells for 
each group were incubated with secondary antibody alone (negative 
controls). For negative control wells, cells were incubated with 40 pi antibody 
dilution buffer during the primary antibody incubation step. Blocking buffer 
was removed and the cells were washed 2X with 200 pi wash buffer. 40 pi of 
diluted primary antibody (or antibody dilution buffer for negative control wells) 
were added to the cells and the plate was sealed with sealing tape and 
incubated overnight at 4° C. This was followed by washing 3X, 5 min each, 
with 200 pi wash buffer. 100 pi diluted secondary antibody was added and the 
plate was covered and incubated for 1 hr at room temperature. During this 
incubation, developing solution was transferred to a secondary container, 
protected from light by covering it with aluminium foil.
The cells were washed 3X, 5 min each, with 200 pi wash buffer and then 2X, 
5 min each, with 200 pi 1X PBS. The PBS was removed and 100 pi of 
developing solution were added to each well. The plate was incubated for 20 
mins at room temperature, protected from light. Development of blue colour 
was monitored to avoid over-development. 100 pi of stop solution was added.
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This acidic solution turned the blue colour to yellow. Absorbance was read 
within 5 min at 450 nm.
Crystal Violet cell staining
After readings at 450 nm were complete, wells were washed 2X with 200 pi 
wash buffer and 2X with 200 pi 1X PBS. The plate was tapped on paper 
towels and air-dried at room temperature for 5 min. 100 pi of crystal violet 
solution were added to each well and incubated for 30 min at room 
temperature. The wells were washed 3X with 200 pi 1X PBS for 5 min each. 
100 pi of 1% SDS solution was added to each well and incubated on a shaker 
for 1 hr at room temperature. Absorbance was read at 570 nm. The measured 
absorbance at 450 nm was corrected for cell number by dividing the reading 
for a given well by the absorbance at 570 nm for that well.
2.2.11 Statistical analysis
All data was presented as mean ± S.E.M. (standard error of the mean). 
Statistical differences from appropriate controls were determined using 
Kruskal-Wallis non-parametric test followed by Dunn's post-hoc test or one­
way ANOVA followed by Boniferroni's post-hoc test and a p<0.05 was 
considered statistically significant. The GraphPad Prism statistical package 
was used (GraphPad Software, Inc).
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CHAPTER 3
CYTOTOXICITY ASSAYS IN CHONDROCYTE AND 
CARTILAGE EXPLANT CULTURES.
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3.1 Introduction
The MTT tetrazolium salt colorimetric assay previously described by 
Mossmann (1983) to measure cytotoxicity, cell proliferation and cell activation 
was used to examine the effects of cannabinoids and other inhibitors on 
cellular viability. MTT yellow solution is converted to blue formazan in living 
cells. The formazan crystals were dissolved using acid-isopropanol. The 
absorbance measured was proportional to mitochohdrial enzyme activity and 
viable cell numbers. CV solution was also used to verify the findings with the 
MTT assay. CV binds to cell nuclei and the absorbance of this stain at 550 
nm is proportional to cell numbers.
When cells are damaged, they become ‘leaky’ and this phenomenon is 
determined by measuring LDH in the extracellular medium. This enzyme is 
normally present in the cytosol, and cannot be measured extracellularly 
unless cell damage has occurred. Therefore LDH release assays were 
performed to quantify the membrane-damaging effects of the cannabinoids on 
chondroctes in cartilage explants.
3.2 Materials and methods
3.2.1 Materials: The endogenous cannabinoids, anandamide and N- 
arachidonyl glycine (N-AG); the synthetic cannabinoids ACEA, Win-55,212-2, 
HU-210 and JWH-133; and the antagonists, AM 281 and AM 630 which are 
also inverse agonists of cannabinoid receptors CBi and CB2 respectively, 
were studied along with their solvent controls. Absolute ethanol (1.0 - 0.05% 
final concentration) and dimethyl sulfoxide (DMSO) (1.0 - 0.05% final 
concentration) were used as the solvents according to instructions from the 
suppliers of the drugs. Different inhibitors were also studied, including: NS- 
398, inhibitor of cyclooxygenase 2 (COX-2); ODQ, inhibitor of NO-sensitive 
guanylyl cyclase; and pyrrolidine dithiocarbamate ammonium (PDTC), 
inhibitor of NF-kB.
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3.2.2 Bovine chondrocyte culture: Bovine articular chondrocytes were 
cultured as described in section 2.2.1. When the chondrocytes reached near 
confluence (about 7-10 days) they were stimulated with IL-1a (100 U/ml = 
0.06 nM) (Buttle et al., 1997) and were incubated with the drugs for 48 h in 
DMEM with the supplements except FBS
3.2.3 Cartilage expiant culture: Bovine nasal cartilage explants were 
cultured as described in section 2.2.2. The explants were stimulated with IL- 
1a (500 U/ml = 0.3 nM) (Buttle et al., 1997) and were incubated with the 
drugs for 4 days in DMEM with the supplements except FBS
3.2.4 MTT assay: After 48 h incubation of the chondrocytes stimulated or 
unstimulated with IL-1 in the presence of the drugs, the MTT assay was 
performed as described in section 2.2.3.1.
3.2.5 Crystal violet assay: The CV assay was carried on chondrocytes 
following the 48 hr-incubation in the presence or absence of IL-1 ± the drugs. 
For the rest of the assay procedure refer to section 2.2.3.2.
3.2.6 LDH release assay: conditioned media from bovine nasal cartilage 
explants incubated for 4 days in the presence or absence of IL-1 ± 
anandamide or Win-55,212-2 at 100 pM were used in the LDH release assay 
carried out as described in section 2.2.3.3.
3.2.7 Statistical Analysis: Kruskal-Wallis followed by Dunn's post-hoc test 
and ANOVA followed by Boniferroni's post-hoc test were used to determine 
statistical significance.
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3.3 Results
3.3.1 Anandamide and Win-55,212-2 cytotoxicity studies on bovine 
articular chondrocytes
Chondrocytes were incubated in the presence or absence of IL-1 a (0.06 nM) 
± anandamide or Win-55,212 at 1-100 pM. Their effects were compared with 
the appropriate vehicles, ethanol for anandamide and dimethyl sulfoxide 
(DMSO) for Win-55,212-2 at concentrations equivalent to those in the drug’s 
solution. These vehicle treatments served as controls. The cells were 
incubated for 48 hrs followed by the analyses of cytotocity of the drugs using 
the crystal violet (CV) assay and MTT assay.
Anandamide significantly (p<0.001) reduced cell viability at 100 pM as shown 
in both the CV and the MTT assays (Fig. 3.1 and 3.2). Win-55,212-2 
significantly affected cell viability negatively at 50 and 100 pM (p<0.05) as 
shown by the MTT and CV assays, respectively (Fig. 3.3 and 3.4).
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Figure 3.1: CV assay results showing the effect of 10-100 |j M anandamide in 
primary bovine articular chondrocytes. Chondrocytes were incubated for 48 
hrs in the presence or absence of IL-1 a +/- anandamide or vehicle (ethanol). 
Absorbance corresponded to the number of viable chondrocytes and results 
are expressed as mean (% of basal) ± s.e.m. (n=6) * p<0.05; *** p<0.001 
compared with vehicle control. Kruskal-Wallis followed by Dunn’s test was 
used to determine significance.
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Figure 3.2: MTT assay results showing the effect of 10-100 pM anandamide 
in primary bovine articular chondrocytes. Chondrocytes were incubated for 48 
hrs in the presence or absence of IL-1 a +/- anandamide or vehicle (ethanol). 
Absorbance corresponded to the number of viable chondrocytes. Results are 
expressed as mean ± s.e.m. (n=6) *** p<0.001 compared with vehicle control. 
ANOVA followed by Boniferroni post-hoc test was used to determine 
significance.
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Figure 3.3: CV assay results showing the effect of 10-100 pM Win-55,212-2 
in primary bovine articular chondrocytes. Chondrocytes were incubated for 48 
hrs in the presence or absence of IL-1 a +/- Win-55,212-2 or vehicle (DMSO). 
Absorbance corresponded to the number of viable chondrocytes and results 
are expressed as mean (% of basal) ± s.e.m. (n=6) * p<0.05 compared with 
vehicle control. Kruskal-Wallis followed by Dunn’s test was used to determine 
significance.
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Figure 3.4: MTT assay results showing the effect of 1-50 pM Win-55,212-2 in 
primary bovine articular chondrocytes. Chondrocytes were incubated for 48 
hrs in the presence or absence of IL-1 a +/- Win-55,212-2 or vehicle (DMSO). 
Absorbance corresponded to the number of viable chondrocytes. Results are 
expressed as mean ± s.e.m. (n=6) * p<0.05 compared with vehicle control. 
ANOVA followed by Boniferroni post test was used to determine significance.
3.3.2 Studies on the effects of anandamide and Win-55,212-2 on bovine 
nasal cartilage explants cytotoxicity (LDH release assay)
For this assay bovine nasal cartilage explants were cultured stimulated or 
unstimulated with IL-1 in the presence of anandamide and Win-55,212-2 at
100 pM or their appropriate vehicles for 4 days. Cytotoxicity of the 
cannabinoids was determined by the LDH release assay.
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Figure 3.5: The results of the LDH release studies on 100 pM anandamide 
and 100 pM Win-55,212-2 in bovine cartilage explants. The explants were 
incubated for 4 days in the presence or absence of anandamide/Win-55,212- 
2 or the vehicles (ethanol/DMSO) +/- IL-1 a. The results are expressed as 
mean (% of basal) ± s.e.m. (n=6)
IL-1 and the vehicles did not significantly reduce cell viability in the cartilage 
explant cultures compared with the basal. The cannabinoids, anandamide 
and Win-55212-2 also did not significantly affect viability of chondrocytes in
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this system at 100 pM compared with both the basal and vehicle controls (Fig. 
3.5).
3.3.3 Studies on synthetic cannabinoid HU-210 and antagonists AM 281 
and AM 630 on chondrocytes cytotoxicity.
Effects of synthetic cannabinoid, HU-210 and the cannabinoid receptor CBi 
and CB2 antagonists, AM 281 and AM 630, respectively on chondrocytes 
viability were studied. Bovine articular chondrocytes were incubated for 48 hrs 
in the presence or absence of IL-1 ± HU-210 (1-30 pM), AM 281 (10-100 pM), 
AM 630 (10-100 pM) or their vehicle (ethanol, 0.1% final concentration). Cell 
viability was determined by using the MTT assay.
IL-1 and vehicle (ethanol) for experiments did not affect chondrocytes 
viability. However, HU-210 appeared to significantly reduce cell viability from 
10 pM (Fig. 3.6a). The antagonists AM 281 and AM 630 did not affect cell 
viability even at the high concentration of 100 pM (Fig. 3.6b).
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Figure 3.6 a, b: MTT Assay results showing the effect of (a) HU-210 (1- 
30pM) and (b) antagonists, AM281 (10-1 00|jM) and AM630 (10-100pM) on 
IL-1a-stimulated bovine primary articular chondrocytes. Results expressed as
3.3.4 Cytotoxicity studies of cannabinoids ACEA, N-AG and JWH-133 
on bovine articular chondrocytes
Endocannabinoid N-arachidonylglycine (N-AG), synthetic cannabinoids ACEA 
(CBi receptor specific agonist) and JWH-133 (CB2 receptor specific agonist) 
were studied to determine whether they may affect chondrocyte viability. IL-1- 
stimulated chondrocytes were incubated with these cannabinoids at 10-50 pM 
or their vehicle (ethanol) at 0.1% final concentration, for 48 hrs and MTT 
assay was carried out on the chondrocytes.
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Figure 3.7: MTT Assay results showing the effect of ACEA (10, 30 and 50 
pM); N-AG (10, 25 and 50 pM); and JWH-133 (10, 30 and 50 pM) on IL-1a- 
stimulated bovine primary articular chondrocytes incubated for 48 hrs. The 
results are expressed as mean ± s.e.m. (n=6 ).
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The cannabinoids, ACEA, N-AG and JWH-133 at the concentrations up to 50 
pM did not significantly affect cell viability compared with the controls (Fig. 
3.7).
3.3.5 Cytotoxicity studies of the inhibitors ODQ and PDTC on bovine 
articular chondrocytes
Cytotoxic effects of ODQ, the inhibitor of NO-sensitive GC and PDTC, the 
inhibitor of NF-kB were studied on chondrocytes stimulated with IL-1 for 48 
hrs.
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Figure 3.8: MTT Assay results showing the effect of ODQ (100 pM); PDTC 
(10 and 100 pM) on IL-1a-stimulated bovine primary articular chondrocytes 
incubated for 48 hrs. The results are expressed as mean ± s.e.m. (n=6 ).
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ODQ and PDTC did not affect cell viability negatively but appeared to 
enhance proliferation when compared with basal, IL-1 and vehicle controls 
(Fig. 3.8).
3.4 Discussion
The cytotoxicity studies showed that most of the cannabinoids and inhibitors 
used are not toxic to the chondrocytes, except for anandamide, HU 210 and 
Win-55,212-2 which may be toxic to bovine chondrocytes at concentrations 
equal to or greater than 10 pM (Fig. 3.2 and Fig. 3.6a). Cannabinoids appear 
to be toxic at 1 0 0  pM in chondrocytes, although at the same concentrations 
showed no significant reduction of cell viability in cartilage explant cultures 
(Fig. 3.5). It appears that chondrocytes embedded in the ECM may be 
protected from the cytotoxic effects of the cannabinoids. The antagonists 
used did not induce cell, death even at a concentration of up to 100 pM (Fig.
3.6b). ODQ and PDTC also did not reduce cell viability.
High concentrations of cannabinoids were used in the cytotoxicity assays to 
establish the upper limits of the range of concentrations used. It was 
important to ensure that the results observed in other investigations such as 
reduction of inflammatory mediators’ expression and production were not due 
to reduced cell viability.
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CHAPTER 4
EFFECTS OF CANNABINOIDS ON IL-1-INDUCED NO 
PRODUCTION IN ARTICULAR CHONDROCYTES
n o
4.1 Introduction
Incubation of human articular chondrocytes with IL-1 results in the time- 
dependent expression of the enzyme induced NO synthase (iNOS), which 
appeared to be conserved between different cell types and across species 
(Charles et al., 1993) and this iNOS (= 131 kDa) was one of the first to be 
cloned and sequenced. Research on the biological roles of NO has revealed 
that it functions as an important signal and effector molecule in a variety of 
physiologic and pathologic settings (Stuehr, 1997). Superficial bovine 
cartilage explants and cells stimulated with IL-1, LPS, or TNF-a for 24 and 48 
hours were shown to produce, significantly, more NO than did deep explants 
and cells treated the same (Hayashi et al., 1997). This apparent increase of 
NO production at the cartilage surface-synovial fluid interface may play an 
important role in the modulation of cartilage damage in inflammatory arthritis 
(Hayashi et al., 1997). Articular chondrocytes are the major source of 
inducible nitric oxide synthase and nitric oxide during inflammation or infection 
of a joint (Murrell et al., 1996). In osteoarthritic tissue, iNOS is the enzyme 
that is responsible for the increased production of NO (Alderton et al., 2001). 
In articular chondrocytes and cartilage, NO plays a regulatory role in the 
activation of metalloproteinases (Murrell et al., 1995) and thus may be 
involved in cartilage catabolism. Inhibition of NO production in the cartilage 
tissue may be a potential target in the treatment of arthritis.
Cannabinoids have been shown to be capable of inhibiting iNOS transcription 
and NO production in macrophage cell line (RAW 264.7), rat microglial cells 
and neuronal cells at micromolar range concentrations (Hillard etal., 1999; 
Jeon et al., 1996 ; Waksman et al., 1999). Therefore the present study aimed 
at testing the hypothesis that cannabinoids may inhibit IL-1-induced NO 
production in articular chondrocytes by inhibiting iNOS expression in these 
cells.
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4.2 Materials and Methods
4.2.1 Cannabinoids and drugs: The endocannabinoids anandamide, N- 
Arachidonyl glycine (N-AG) and NADA; the synthetic cannabinoids ACEA, 
Win-55,212-2, Win-55,212-3, HU-210 and JWH-133; and the antagonists, 
AM281 and AM630 which are also inverse agonists of cannabinoid receptors 
CB'i and CB2 respectively, were studied along with their vehicle controls. 
Absolute ethanol (0.1% final concentration) and dimethyl sulfoxide (DMSO) 
(0 .1 % final concentration) were used as the solvent according to instructions 
from the suppliers of the cannabinoids. The same was true for the different 
inhibitors studied, namely: MK-8 8 6 , inhibitor of 5-lipooxygenase activating 
protein (FLAP); NS 398, inhibitor of cyclooxygenase 2 (COX-2); ODQ, 
inhibitor of NO-sensitive guanylyl cyclase; and pyrrolidine dithiocarbamate 
ammonium (PDTC), inhibitor of NF-kB. Their effects were investigated on 
unstimulated or IL-1a-stimulated chondrocyte NO production and iNOS 
expression at concentrations which were demonstrated to be non-toxic to 
chondrocytes.
4.2.2 Bovine chondrocyte culture: Bovine articular chondrocytes were 
cultured as described in section 2.2.1. After at least 5 days, chondrocytes 
were incubated with the drugs ± IL-1a (100U/ml = 0.06nM) for 48h in DMEM 
with the supplements except FBS.
4.2.3 NO production determination: NO was measured as nitrite in 
primary bovine articular chondrocyte conditioned media as described under 
section 2.2.4.
4.2.4 Immunoblotting: The immunoblot analysis was carried out as 
describe in section 2.2.7. The whole cell lysates were applied to SDS- 
polyacrylamide pre-cast 4-12 % NuPAGE® Bis-Tris mini-gels (Invitrogen). 
SeeBlue plus2 pre-stained protein standard (Invitrogen) was used for easy 
and clear band identification. Then the proteins were electroblotted onto 
invitrolon® polyvinyl id ene difluoride (PVDF) membranes. WesternBreeze®
112
Chromogenic Western Blot Immunodetection kit (Invitrogen) was used to 
detect primary antibodies immobilised on PVDF membrane, following the 
manufacturer’s instructions. Briefly, after blocking the membranes, they were 
incubated in primary antibody, rabbit polyclonal anti-inducible nitric oxide 
(iNOS) (1:500) (Alexis, UK) for 1 hr. After washing the membrane with the 
antibody wash, it was incubated in alkaline phosphatase-conjugated goat 
anti-rabbit secondary antibody for 30 min. After further washing with antibody 
wash and water, purple protein bands were visualized with chromogenic 
substrate [5-bromo-4-chloro-3-indolyl-1-phosphate (BCIP) and nitro blue 
tetrazolium (NBT)] for 1 hr.
4.2.5 Statistical Analysis: Kruskal-Wallis non-parametric test followed by 
Dunn's post-hoc test or one-way ANOVA followed by Boniferroni's post-hoc 
test were used to determine statistical significance. P-value of less than 0.05 
was considered statistically significant.
4.3 Results
4.3.1 Effect of Win-55,212 alone or in combination with CBi antagonist 
AM281
Bovine primary chondrocytes were stimulated with IL-1 a (0.06 nM) to produce 
NO. Effects of a non-selective cannabinoid receptor agonist, Win-55,212-2 
and effects of the antagonist which also acts as an inverse agonist at CBi 
cannabinoid receptor, AM 281, on IL-1-induced NO production were studied. 
AM 281 was expected to inhibit effects of Win-55,212-2, in treatments where 
these drugs were added together, to show that effects of Win-55,212-2 were 
mediated through the CB<i cannabinoid receptor. AM 281 was also expected 
to exhibit effects that were opposite to those produced by Win-55,212-2 when 
applied to the cells without Win-55,212-2.
Win-55,212-2 at concentrations 0.5-10 pM was used in this study. Win-
55,212-2 at 1-10 pM reduced the basal level of NO production whilst at 0.5 
pM increased this (Fig. 4.1a). Treatment of bovine articular chondrocytes with
IL-1 a (0.06 nM) significantly increased NO production in these experiments. 
Win-55,212-2 at 0.5 pM did not have any significant effect but at 1-10 pM 
significantly (p<0.001) reduced NO production compared to the vehicle 
control, and 5-10 pM reduced NO production to below basal levels. 
Chondrocytes unstimulated or stimulated with IL-1 a were also treated with 
100 pM AM 281 alone or in the presence of Win-55,212-2. AM 281 did not 
have any effect on unstimulated chondrocytes (Fig. 4.1a) but significantly 
reduced NO production in IL-1-stimulated chondrocytes compared with the 
vehicle controls (p<0.001) (Fig. 4.1b). Treatment of IL-1-stimulated 
chondrocytes with a combination of Win-55,212-2 and AM 281, reduced 
their NO production further, below the effect of each component alone, and to 
the extent that even 0.5 pM Win-55,212-2 in combination with AM 281 
reduced NO production to basal level (Fig. 4.1b).
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Figure 4.1a: Effects of Win-55,212-2 (0.5-10 pM) and CBi cannabinoid 
receptor antagonist/inverse agonist, AM 281 (100 pM), on basal NO 
production in bovine articular chondrocytes. The results are presented as 
mean ± s.e.m. (n=6 ). ** p<0 . 0 1  compared with appropriate vehicle controls.
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Figure 4.1b: Effects of Win-55,212-2 (0.5-10 pM) with or without CBi 
cannabinoid receptor antagonist/inverse agonist, AM 281 (100 pM), on IL-1a- 
induced NO production in bovine articular chondrocytes. The results are 
presented as mean ± s.e.m. (n=6 ). *** p<0 . 0 0 1  compared with appropriate 
vehicle controls.
4.3.2. Effect of Win-55,212-2 alone or in combination with CB2 
antagonist AM 630
Chondrocytes were unstimulated or stimulated with IL-1 a (0.06 nM) to 
produce NO. Effects of a non-selective cannabinoid receptor agonist, Win-
55,212-2 and effects of the antagonist which also acts as an inverse agonist 
at CB2 cannabinoid receptor, AM 630, on IL-1-induced NO production were
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studied. AM 630 was expected to inhibit effects of Win-55,212-2, in 
treatments where these drugs were added together, to show that effects of 
Win-55,212-2 were mediated through the CB-i cannabinoid receptor. AM 630 
was also expected to exhibit effects that were opposite to those produced by 
Win-55,212-2 when applied to the cells without Win-55,212-2.
Win-55,212-2 (1 and 10 pM) and 100 pM AM 630 with or without IL-1 a (0.06 
nM) were used in these experiments (Fig. 4.2a, b). In unstimulated 
chondrocytes, Win-55,212-2, at 1 pM had no effect on NO production but at 
10 pM significantly reduced basal NO production (Fig. 4.2a). AM 630 had no 
effect on basal NO production (Fig. 4.2a). When the chondrocytes were 
stimulated with IL-1 a, they produced significant amount NO. Win-55,212-2 at 
both concentrations significantly reduced this IL-1-induced NO production, 
with 10 pM Win-55,212-2 reducing NO production below basal level (Fig 
4.2b). AM 630 alone also reduced IL-1-induced NO production significantly 
compared to the vehicle control (Fig. 4.2b). 1 pM Win-55,212-2 combined with 
AM 630, reduced IL-1-induced NO production further, but not as markedly as 
that with AM 281, while 10 pM Win-55,212-2 in combination with AM 630 also 
reduced NO production significantly (p<0.001) compared with the vehicle 
control (Fig. 4.2b).
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Figure 4 .2 a: Effects of Win-55,212-2 (1-10 pM) and CB2 cannabinoid 
receptor antagonist/inverse agonist, AM 630 on basal NO production in 
bovine articular chondrocytes. Results presented as mean ± s.e.m. (n=6 ) ** 
p<0 . 0 1  compared with vehicle control.
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Figure 4.2b: Effects of Win-55,212-2 (1-10 pM) with or without CB2 
cannabinoid receptor antagonist/inverse agonist, AM 630 on IL-1a-induced 
NO production in bovine articular chondrocytes. Results presented as mean 
± s.e.m. (n=6 ) ***p<0 . 0 0 1  compared with vehicle control.
4.3.3. Effect of Win-55,212-3 compared with Win-55,212-2
The two enantiomers, Win-55,212-3 (inactive) and Win-55,212-2 (active) were 
used to carry out comparative studies of their effects on NO production in 
bovine articular chondrocytes stimulated by IL-1. These studies would help 
shed some light on whether cannabinoids such as Win-55,212 produced their 
effects in chondrocyte by acting via receptor(s).
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Figure 4.3: The Effect of Win-55,212-2 (active enantiomer) and Win-55,212-3 
(inactive enantiomer) on IL-1a-induced NO production in bovine articular 
chondrocytes. The results are presented as mean ± s.e.m. (n= 6 ). ***p<0.001 
compared with vehicle controls.
The inactive enantiomer, Win-55,212-3 did not have any significant effect on 
IL-1a-induced NO production (Fig. 4.3). The active enantiomer, Win-55,212-2 
at 1, 5 and 10 pM, however, reduced IL-1a-induced NO production to or near 
basal levels. These effect were statistically significant compared with the 
vehicle control (p<0 .0 0 1 ).
4.3.4 Effect of HU-210 on IL-1-induced NO production
The synthetic cannabinoid HU-210, one of the potent cannabinoids was 
studied to find out whether it has the capacity to modulate IL-1-induced NO 
production in chondrocytes. The chondrocytes were incubated with HU-210
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(1-10 pM) or its vehicle, ethanol (0.1% final concentration) for 48 hrs prior to 
nitrite assay.
HU-210 had no effect at 1 pM on IL-1-induced NO production but at 5 and 10 
pM appeared to significantly reduce the NO production in bovine articular 
chondrocytes (Fig. 4.4).
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Figure 4.4: The Effect of HU-210 on IL-1a-induced NO production in bovine 
articular chondrocytes. Results presented as mean ± s.e.m. (n=6 ). 
***p<0.001 compared with vehicle controls. ANOVA followed by Boniferroni’s 
post-hoc test was used to determine statistical significance.
4.3.5 Effects of other cannabinoids: anandamide and/or NADA; ACEA; 
N-AG; and JWH-133 on IL-1-induced NO production
Endocannabinoids, anandamide and NADA were studied alone or in 
combination on IL-1-induced NO production in bovine articular chondrocytes. 
NADA is also believed to have the ability to inhibit anandamide metabolism by
the fatty acid amide hydrolase (FAAH) (Bisogno et ai, 2000). Therefore 
addition of NADA to anandamide treatment would help to find out whether 
NADA modulates effects of anandamide. Effects of endocannabinoids, N-AG; 
the CBi cannabinoid receptor specific agonist, ACEA; and the CB2 
cannabinoid receptor specific agonist, JWH-133 were also studied on the IL- 
1-induced production of NO in chondrocytes.
Anandamide had no effect on IL-1-induced NO production in bovine 
chondrocytes (Fig. 4.5). NADA however appeared to reduce this production of 
NO significantly. Addition of NADA to anandamide treatments appeared not to 
make any significant difference (Fig. 4.5).
ACEA at all concentrations tested did not show any significant effects on NO 
production in articular chondrocytes (Fig. 4.6). However, N-AG from 10 pM 
appeared to significantly reduce NO production (Fig. 4.6). JWH-133 on the 
contrary, appeared to significantly increase NO production from 30 pM in 
what appeared to be a concentration dependent manner (Fig. 4.6).
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Figure 4.5: The effect of anandamide, NADA and combination of the two 
endocannabinoids on IL-1 a-induced NO production in bovine articular 
chondrocytes. Results presented as mean ± s.e.m. (n=6 ). **p<0.01; 
***p<0.001 compared with vehicle controls. ANOVA followed by Boniferroni’s 
post-hoc test was used to determine statistical significance.
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Figure 4.6: The Effect of ACEA, N-AG and JWH-133 (10-50 pM) on IL-1a- 
induced NO production in bovine articular chondrocytes. The results are 
presented as mean ± s.e.m. (n=6 ). *p<0.05; ***p<0.001 compared with 
vehicle control (ethanol). ANOVA followed by Boniferroni’s post-hoc test was 
used to determine statistical significance
4.3.6 Effects of Win-55,212 on IL-1-stimulated iNOS expression in 
chondrocytes
As mentioned earlier under section 4.1, iNOS is the enzyme responsible for 
the increased NO production in osteoarthritic tissue and its expression is 
induced by IL-1 in articular chondrocytes. Therefore bovine articular
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chondrocytes were stimulated with IL-1 in the presence of Win-55,212-2 to 
find out whether cannabinoids have the capacity to block the cytokine- 
induced expression of iNOS. The enzyme is approximately 131 kDa (Alderton 
et ai, 2001). Equal amounts of the sample were loaded, 30 pi per well with 
protein content of approximately 1 0  pg.
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Figure 4.7: Immunoblot analysis of iNOS expression in bovine articular 
chondrocytes. The cells were unstimulated or stimulated with IL-1a (0.06 nM) 
for 48 hrs in the presence or absence of Win-55,212-2. Lane 1 & 2: Marker; 
Lane 3: Basal; Lane 4: IL-1 a; Lane 5 & 6 : vehicle control (IL-1 +0.1 % 
DMSO); Lane 7 & 8 : IL-1 + Win-55,212-2 (1 pM); Lane 9 & 10: IL-1 + Win-
55,212-2 (5 pM).
Two bands appeared on the PVDF membrane at the end of the immunoblot 
assay (Fig. 4.7). The first band which was faint was close to the 191 kDa, 
whilst the other, the main band, stained more strongly and was above 97 kDa. 
Its position appeared to be consistent with the reported size of iNOS, which is 
about 131 kDa. The first band could be iNOS bound to other proteins or 
undenatured iNOS which migrated more slowly than the fully denatured 
iNOS. It is possible also to be just a product of non-specific binding, which 
was also appeared to be induced by IL-1.
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Expression of iNOS in this study appeared to be absent at basal levels and 
was significantly stimulated by IL-1 (Fig. 4.7; lanes 3 and 4, respectively). The 
vehicle (DMSO) appeared to slightly reduce iNOS expression (Fig. 4.7; lanes 
5 &6 ). Win-55,212-2 at 1 pM did not have any effect (Fig.4.7; lanes 7 & 8 ) 
whilst at 5 pM blocked the IL-1-induced expression of iNOS completely (Fig. 
4.7; lanes 9 & 10).
4.3.7 Effects of inhibitors MK-886, NS-398, ODQ, PDTC compared with 
Win-55,212-2 on IL-1-induced NO production in bovine articular 
chondrocytes
MK- 8 8 6  is the inhibitor of 5-LOX activating protein (FLAP), the enzyme that 
subsequently is responsible for LTB4 production. Its effect on NO production 
was studied to find out if 5-LOX activity affects NO production in chondrocytes 
and to compare the effects of MK- 8 8 6  with those of Win-55,212-2 and if its 
combination with Win-55,212-2 would affect the cannabinoid’s effect. The 
same was done for NS-398, the selective inhibitor of COX-2 activity; ODQ, 
the inhibitor of NO-sensitive GC; and PDTC, the inhibitor of NF-kB that 
subsequently inhibits iNOS mRNA expression. The aim was to try and identify 
the signal transduction pathways involved in the cytokine-induced NO 
production and determine whether Win-55, 212-2 affected any of those 
pathways to produce the effect it displayed.
MK- 8 8 6  reduced NO production significantly but did not augment the effect of 
Win-55,212-2 on NO production. NS-398 and ODQ did not show any effects. 
PDTC significantly reduced the production of NO and did not significantly 
affect the effect of Win-55,212-2 (Fig. 4.8).
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Figure 4.8: Effect of inhibitors (a) ODQ (100 pM); NS-398 (1 |j M ); PDTC (1 
|jM); MK- 8 8 6  (1 |jM); and Win-55,212-2 (1 pM) and combinations of these 
compounds on IL-1a-induced NO production in primary bovine articular 
chondrocyte culture. Results presented as mean ± s.e.m. (n=6 ). ***p<0.001 
compared with vehicle controls. ANOVA followed by Boniferroni’s post-hoc 
test was used to determine statistical significance
4.4 Discussion
Synthetic cannabinoids HU-210 and Win-55,212-2 as well as 
endocannabinoids NADA and N-AG appeared to exhibit anti-inflammatory 
effects because they significantly reduced or blocked completely IL-1-induced 
NO production in bovine articular chondrocytes. However it is not certain 
whether this is a true reflection of the effect of HU-210 on IL-1-induced NO 
production since HU-210 appeared to be cytotoxic at 10 pM. Win-55,212-2 
also blocked the IL-1-induced expression of iNOS. Thus its reduction of NO
production in chondrocytes may be at least in part through its ability to block 
iNOS expression.
The inverse agonists, AM 281 and AM 630, showed some unexpected effects 
on NO production in bovine articular chondrocytes. When applied alone, the 
inverse agonists would be expected to enhance NO production if their action 
was through the cannabinoid receptors but instead they reduced NO 
production. Also instead of inhibiting the effect of Win-55,212-2 on NO 
production they appeared to act synergistically when applied in combination 
with the cannabinoid. This implies that AM 281 and AM 630, in this case were 
not acting through the respective CB-i or CB2 cannabinoid receptors. 
However, AM 630 besides being an inverse agonist at CB2 receptors also 
behaves as a weak partial agonist at CBt receptors (Ross et a/., 2001). 
Therefore it is possible that AM 630 in this study was also acting as a partial 
agonist at the CBi cannabinoid receptor at the concentration used. It is also 
possible that these inverse agonists were acting via receptors other than the 
cannabinoid receptors or their effects were receptor independent. From these 
results, it is not possible to tell whether the effect of Win-55,212-2 was 
mediated through either CBi or CB2 cannabinoid receptors. However the 
study where Win-55,212-3, the inactive cannabinoid enantiomer, was 
compared with the active enantiomer, Win-55,212-2, suggested otherwise 
(section 4.3.3). Win-55,212-3 did not show any significant effects whilst Win-
55,212-2 significantly blocked the IL-1-induced NO production in 
chondrocytes. This stereo-specificity indicates that Win-55,212-2 produced its 
effects by acting through some receptor, possibly CBi, CB2 or an additional 
receptor yet to be identified.
NADA did not modulate the effects of anandamide, implying that lack of effect 
by anandamide may be due its low potency not its metabolism by FAAH. It is 
possible also that the concentration of NADA used was too low thus it did not 
work efficiently to protect anandamide in this system.
Inhibitors MK-8 8 6 , inhibitor of FLAP and PDTC, inhibitor of NF-kB significantly 
reduced the NO production induced by IL-1. MK- 8 8 6  reduced it to the level
comparable to the effect of Win-55,212-2 and it did not affect the activity of 
Win-55,212-2 when applied in combination. The results suggest that 5-LOX 
activation may enhance NO production induced by IL- 1  and it is possible that 
Win-55,212-2 may be acting in part as this inhibitor, blocking the 5-LOX 
pathway. PDTC, although it significantly reduced the production of NO, did 
not reduce it to basal levels as Win-55,212-2 did. The transcription factor, NF- 
kB is essential for activation of numerous genes for proteins involved in 
inflammation such as pro-inflammatory proteins; iNOS may be one of them. 
PDTC is capable of inhibiting expression of iNOS mRNA and this may be as a 
consequence of inhibition of NF-kB. Inhibition of iNOS results in reduced 
production of NO and this may explain the observed effects of PDTC. PDTC 
did not affect the effect of Win-55,212-2 and it is possible that the latter 
reduced NO production in part by acting as PDTC, inhibiting activation of NF- 
kB.
NO production by chondrocytes stimulated by IL-1 may be one of 
mechanisms that promote the breakdown of cartilage. In cytokine-stimulated 
chondrocytes, NO sustains nuclear translocation of NF-kB and thus keeps 
NF-xB-dependent transcription persistently switched on (Clancy et al., 2004). 
This may present a mechanism through which NO promotes cartilage 
degradation. Through this way NO may sustain or promote expression of 
proteinases responsible for the degradation of the extracellular matrix since 
NO plays a regulatory role in the activation of MMPs in articular chondrocytes 
and cartilage (Murrell et al., 1995). This is supported by the report that 
selective inhibition of NF-kB blocks inflammatory bone destruction (Jimi et al., 
2004).
NO production in early phases of arthritis, In vivo, may lead to chondrocyte 
apoptosis (Taskiran et al., 1994). Tawara et al. (1991) also report that IL-1 
significantly enhanced production of superoxides in chondrocytes. NO, in the 
presence of superoxide anions, was shown to induce chondrocyte apoptosis 
(Mathy-Hartert et al., 2005). Apoptotic death of articular chondrocytes 
contributes to articular cartilage degradation (Goggs et al., 2003).
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Endogenously synthesized NO also suppresses proteoglycan synthesis in 
articular chondrocytes (Hauselmann et al., 1994) and (Taskiran et al., 1994). 
Also IL-1-induced production of NO partially inhibits synthesis of type II 
collagen. This NO-dependent inhibition may occur at the post-translational 
level, where collagen is subject to several processing stages including 
hydroxylation by prolyl hydroxylase (Goggs et al., 2003). Inhibition of NO 
synthase was shown to strongly suppress the production of NO and partially 
relieve the inhibition of collagen synthesis in response to IL-1 whilst NO 
donors inhibited collagen production (Cao et al., 1997). The studies by Cao et 
al. (1997) suggested that inhibition of prolyl hydroxylase by NO might be 
responsible for the suppressive effect of this radical molecule on collagen 
synthesis since under-hydroxylated collagen monomers fail to anneal into 
stable triple helices and are degraded intracellularly. Thus inhibition of NO 
production by cannabinoids may blunt the inhibition of the synthesis of 
proteoglycan and type II collagen synthesis, thus maintaining the 
differentiated status of the chondrocytes and preventing loss of chondrocytes 
through apoptosis and maintaining the integrity of the cartilage.
NO is capable of inducing the inflammatory component of OA as well as 
tissue destruction. Therefore it could be responsible not only for the 
symptoms, but also for the disease process and thus is a most interesting 
target (Pelletier et al., 1998). In the same way, therefore, cannabinoids may 
have a potential as therapeutic agent in arthritic diseases; by reducing excess 
NO production, cannabinoids may be capable of reducing not only the 
symptoms but also the progression of disease, thus concurrently reaching two 
targets.
Conclusion
Cannabinoids have the capacity to inhibit IL-1a-induced NO production at 
micromolar concentrations in bovine articular chondrocytes. Win-55,212-2 
appeared to be the most potent compared with the rest of the cannabinoids 
tested. The attenuation of NO production may be partly through the capacity 
of the cannabinoids to block iNOS expression.
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CHAPTER 5
CANNABINOIDS AND THEIR EFFECT ON 
EICOSANOIDS PRODUCTION IN ARTICULAR 
CHONDROCYTES
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5.1 Introduction
Eicosanoids play a significant role not only in joint physiology, but also in the 
pathogenesis of joint disorders (Laufer, 2003). In response to IL-1, 
chondrocytes upregulate the production of PGE2, one of the factors that have 
been shown to induce a number of the cellular changes associated with OA 
(Hedbom and Hauselmann, 2002). The superinduction of PGE2 production 
coincides with the upregulation of cyclooxygenase-2 (COX-2) in OA-affected 
cartilage (Amin et al., 1997). PGE2 derived from COX-2 modulates cartilage 
proteoglycan degradation in human osteoarthritis explants (Hardy et al., 
2002). In addition, it has been identified that osteoarthritis subchondral 
osteoblasts can synthesize LTB4 , indicating a role of leukotrienes in bone 
remodeling associated with osteoarthritis (Laufer, 2003). LTB4  probably 
contributes to the up-regulation of important catabolic factors involved in the 
pathophysiology of OA, such as MMP (Martel-Pelletier et al., 2004). A 
therapeutic intervention that blocks lipoxygenase/cyclooxygenase pathways, 
thereby inhibiting production of prostaglandins and leukotrienes, may 
therefore be very attractive for the treatment of OA (Laufer, 2003). 
Cannabinoid effects on IL-1-induced PGE2 and LTB4 production in bovine 
primary articular chondrocytes were investigated.
5.2 Materials and Methods
5.2.1 Cannabinoids and drugs: N-Arachidonyl glycine (N-AG); the 
synthetic cannabinoids, ACEA, Win-55,212-2, HU-210 and JWH-133; and the 
antagonists, AM281 and AM630 which are also - inverse agonists of 
cannabinoid receptors CBi and CB2 respectively, were studied along with 
their solvent controls. Absolute ethanol (0.1% final concentration) and 
dimethyl sulfoxide (DMSO) (0.1% final concentration) were used as the 
solvent according to instructions from the suppliers of the cannabinoids. 
Different inhibitors were also studied, namely: MK-8 8 6 , inhibitor of FLAP; NS 
398, inhibitor of cyclooxygenase 2 (COX-2); ODQ, inhibitor of NO-sensitive 
guanylyl cyclase; and pyrrolidine dithiocarbamate ammonium (PDTC), 
inhibitor of NF-kB. Their effects were investigated on unstimulated or IL-1a-
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stimulated chondrocyte PGE2 and LTB4  production and COX-1 , COX- 2  and 
mPGES-2 expression at concentrations which were demonstrated to be non­
toxic to chondrocytes.
5.2.2 Bovine chondrocyte culture: Bovine articular chondrocytes were 
cultured as described in section 2.2.1. When the chondrocytes reached near * 
confluence (about 7-10 days) they were stimulated with IL-1 a (100 U/ml = 
0.06 nM) (Buttle et al., 1997) and were incubated with the drugs for 48 h in 
DMEM with the supplements except FBS.
5.2.3 PGE2 and LTB4  determination: After 48 hrs incubation of the
chondrocytes with the drugs or inhibitors, PGE2 and LTB4 production was 
measured using an ELISA (Alexis) according to the manufacturer’s 
instructions, refer to section 2.2.5.
5.2.4  ^ Immunoblotting: rabbit polyclonal COX-1 and COX-2 and mPGES-2 
(diluted 1:100) (Alexis Biochemical) were used. The rest of the immunoblot 
analysis was carried out as described under section 2.2.7.
5.2.5 Immunofluorescence: Polyclonal COX-2 (1:50) (Alexis Biochemical) 
was used to study expression of COX-2 in chondrocytes and the effect of 
Win-55,212-2 on this was determined. The immunofluorescence studies were 
carried out as described in section 2.2.9
5.3 Results
5.3.1 Effect of Win-55,212-2 on PGE2 production in chondrocytes
Chondrocytes were stimulated with IL-1 a (0.06nM) to produce PGE2. The 
cells were incubated with Win-55,212-2 at 1-10 pM for 48 hrs and PGE2 
production was measured. The effect of Win-55,212-2 was compared with its 
vehicle (DMSO, 0.1% final concentration)
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Win-55,212-2 did not show any effects at 1|jM but significantly (p<0.01) 
reduced IL-1-induced PGE2 production at 5 and 10pM, compared to the 
vehicle control in bovine chondrocyte cultures (Fig. 5.1).
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Figure 5.1: Effect of R-(+)-Win-55,212 on IL-1a-induced PGE2 production in 
primary bovine articular chondrocyte culture. The results are presented as 
mean ± s.e.m. (n=6). **p<0.01 compared with vehicle control. ANOVA 
followed by Boniferroni’s post-hoc test were used to determine statistical 
significance.
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5.3.2 Effect of HU-210 on PGE2 production in bovine chondrocytes
HU-210, a non-selective cannabinoid receptor agonist, was studied to find out 
its effect on the IL-1a-induced PGE2 production in bovine articular 
chondrocytes incubated for 48 hrs.
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Figure 5.2: Effect of HU-210 on IL-1a-induced PGE2 production in primary 
bovine articular chondrocyte culture. Results presented as mean ± SD. The 
treatments were run in duplicates and the experiment was performed once.
The cells in this experiment (Fig. 5.2) appeared to have high basal level of 
PGE2 and IL-1 slightly induced PGE2 production in these cells. Nonetheless, 
HU-210 appeared to enhance PGE2 production in a concentration-dependent 
manner.
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5.3.3 Effect of ACEA, N-AG and JWH-133 on PGE2 production in 
chondrocytes
The endocannabinoids, N-AG as well as the synthetic ACEA CB-\ cannabinoid 
receptor specific agonist and CB2 cannabinoid receptor specific agonist JWH- 
133 were studied to determine their effects on IL-1 a induced PGE2 production 
in chondrocytes. The chondrocytes were stimulated with IL-1 and incubated in 
the presence of the cannabinoids for 48 hrs.
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Figure 5.3: Effects of ACEA, N-AG and JWH-133 at 10, 30 and 50 pM on IL- 
1a-induced PGE2 production in primary bovine articular chondrocyte culture. 
Results presented as mean ± s.e.m (n=6). *p<0.05; **p<0.01; ***p<0.001; 
compared with vehicle control (ethanol). ANOVA followed by Boniferroni’s 
post-hoc test were used to determine statistical significance.
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ACEA significantly (p<0.05) reduced PGE2 production in bovine articular 
chondrocytes at 10 pM, did not show significant effect at 30 and 50 pM, albeit 
reduced PGE2 slightly (Fig. 5.3). N-AG apparently reduced PGE2 production 
at 30 and 50 pM in a concentration dependent manner in this system (Fig. 
5.3). JWH-133 appeared to slightly enhance PGE2 production at 10 pM, and 
slightly reduced its production at 30 pM and significantly reduced PGE2 
production at 50 pM (Fig. 5.3). This effect of JWH-133 also appears to be 
concentration dependent.
5.3.4 Effects of different inhibitors on PGE2 production in articular 
chondrocytes
MK-886, the inhibitor of 5-LOX activating protein (FLAP); NS-398, inhibitor of 
COX-2; ODQ, the inhibitor of NO-sensitive GC; and PDTC, the inhibitor of 
NF-kB were studied to determine their effects on the production of PGE2 
induced by IL-1 in bovine articular chondrocytes. The cells were treated for 48 
hrs. The aim was to find out the pathways involved in IL-1-induced PGE2 
production in chondrocytes.
All the inhibitors blocked the IL-1-induced production of PGE2 in 
chondrocytes, except for MK-886 which did not show any significant effects 
(Fig 5.4 and 5.5). MK-886 appeared to slightly block the inhibition of PGE2 
production by Win-55,212-2 (Fig. 5.5). When applied to the cells in 
combination with NS-398, MK-886 appeared not to affect the blockage of 
PGE2 production by NS-398, which appeared to be more potent, compared 
with Win-55,212-2 (Fig. 5.5). Addition of MK-886 and Win-55,212-2 to the NS- 
398 treatments did not alter its effects (Fig. 5.5). ODQ also blocked PGE2 
production in these cells and so did PDTC (Fig. 5.4 and 5.5).
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Figure 5.4: Effect of inhibitors (a) ODQ (30 and 100 yM); NS-398 (30 and 
100 pM) and PDTC (10 and 30 pM) on IL-1a-induced PGE2 production in 
primary bovine articular chondrocyte culture. The results are presented as 
mean ± s.e.m (n=6). ***p<0.001 compared with vehicle controls. ANOVAi 
followed by Boniferroni’s post-hoc test were used to determine statistical 
significance.
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Figure 5.5: Effect of inhibitors MK-886 (1 pM); NS-398 (1 jjM ); Win-55,212-2 
(1 |jM ), ODQ (100 jjM ) and combinations of these compounds on IL-1a- 
induced PGE2  production in primary bovine articular chondrocyte culture. The 
results are presented as mean ± s.e.m (n=6). ***p<0.001 compared with 
vehicle controls. ANOVA followed by Boniferroni’s post-hoc test were used to 
determine statistical significance.
5.3.5 Effects of Win-55,212-2 on IL-1-induced COX-1, COX-2 and 
mPGES-2 expression in bovine articular chondrocytes.
Expression of enzymes, COX-1,COX-2 and microsomal PGE2 synthase-2 
(mPGES-2) involved in the constitutive or inducible production of PGE2 in 
bovine articular chondrocytes stimulated by IL-1, and the effects of Win-
55,212-2 at 1 and 5 pM on the enzymes expression were studied.
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5.3.5.1 Immunofluorescence: COX-2 expression
Expression of COX-2 in bovine articular chondrocytes unstimulated or 
stimulated with IL-1 for 48 hrs and the effect of Win-55,212-2 at 5 pM on this 
was studied through indirect immunofluorescence.
Figure 5.6: Immunofluorescence analysis of COX-2 expression in bovine 
articular chondrocytes cultured for 7 days. The cells were unstimulated (B) or 
stimulated with IL-1a (0.06 nM) in the presence of: 0.1 % vehicle -  DMSO 
(C); 5 pM Win-55,212-2 (D). Negative control (A) (NGS used instead of 
primary antibody). Primary antibody against COX-2 was diluted 1:50 and 
FITC-conjugated secondary antibody was used to visualise COX-2 
expression.
In this experiment, the expression of COX-2, the inducible enzyme which 
produces PGE2, was not expected in the basal treatment but the 
chondrocytes appeared to have been stimulated in one way or the other (Fig.
5.6 B). IL-1 appeared to enhance the expression further (Fig. 5.6 C). Win-
55,212-2 at 5 pM blocked the expression of COX-2 in the cells (Fig. 5.6 D).
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S.3.5.2 immunoblot analysis on cyciooxygenase (COX) expression
9Expression of COX-2 in bovine articular chondrocytes was also studied 
through immunoblotting. Its expression was compared to the expression of 
COX-1 in these cells. COXs have their molecular weight around 64 kDa. The 
molecular weight of the enzymes depends on whether it is glycosylated or not 
(Percival etal., 1994).
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Figure 5.7: Immunoblot analysis of COX-1 and COX-2 expression in bovine 
articular chondrocytes. The cells were unstimulated or stimulated with IL-1 a 
(0.06 nM) for 48 hrs in the presence or absence of Win-55,212-2. Lane 1: 
Marker; Lane 2: Basal; Lane 3 & 4: IL-1 a; Lane 5 & 6: vehicle control (IL-1 + 
0.1 % DMSO); Lane 7 & 8: IL-1 + Win-55,212-2 (1 pM); Lane 9 & 10; IL-1 + 
Win-55,212-2 (5 pM).
The results indicated that expression of COX-2 was faint at 48 hrs following 
IL-1 stimulation in this system. This was not surprising because COX-2 
expression is time-dependent; it is maximal at 24 hrs (Kojima et al., 2004; 
Nedelec et al., 2001). Low levels, nonetheless, are still expressed at 48 hrs 
following stimulation. In the COX-2 blot (Fig. 5.7), the membrane was 
incubated for 2 hrs in substrate in an attempt to amplify the signal further. The 
bands appear to be where they would be expected with the COX-2 band 
appearing to be slightly above 64 kDa and the COX-1 band at 64 kDa. The 
blot shows no basal expression of COX-2 (Fig. 5.7, lane 2). IL-1 induced its 
expression. Win-55,212-2 at 1 pM (Fig. 5.7, lanes 7&8) did not significantly
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COX-2
COX-1
affect IL-1-induced COX-2 expression compared with the vehicle control (Fig. 
5.7, lanes 5&6). However, Win-55,212-2 at 5 pM blocked the IL-1-induced
expression of COX-2 (Fig. 5.7, lanes 9&10). COX-1 expression appeared not¥
to be affected by IL-1 or Win-55,212-2. It was constitutively expressed (Fig. 
5.7)
5.3.5.3 immunoblot analysis: mPGES-2 expression in
chondrocytes
Whole cell lysates from chondrocytes unstimulated or stimulated by IL-1 and 
incubated with or without Win-55,212-2, were analysed by immunoblotting for 
expression of one of the enzymes in the final step in the biosynthesis of PGE2 
-  mPGES-2. The molecular weight of mPGES-2 is approximately 60 kDa, 
consisting of a homo-dimer of approximately 30 kDa subunits (Wanatabe et 
al., 1999).
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Figure 5.8: Immunoblot analysis of microsomal PGE2 synthase-2 (mPGES-2) 
expression in bovine articular chondrocytes using rabbit anti-mPGES-2 
antibody. The cells were unstimulated or stimulated with IL-1 a (0.06 nM) for 
48 hrs in the presence or absence of Win-55,212-2. Lane 1 & 2: Marker; Lane 
3: Basal; Lane 4: IL-1a; Lane 5 & 6: vehicle control (IL-1 + 0.1 % DMSO);
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Lane 7 & 8: IL-1 + Win-55,212-2 (1 pM); Lane 9 & 10: IL-1 + Win-55,212-2 (5 
MM).
Three bands were visualised, one approximately 80 kDa, the second one 
appeared between 51 and 64 kDa and last one (the main band) was between 
28 and 39 kDa (Fig. 5.8). The band between 51 and 64 kDa possibly 
represented the homo-dimer, whilst the band below it (the main band), 
represented the protein subunit. It is not certain what the approximately 80 
kDa band represents. The mPGES-2 was expressed constitutively and was 
not affected by IL-1 or the drugs except at 5 pM Win-55,212-2 where the 
expression appeared to be reduced slightly (Fig. 5.8, lanes 9&10).
5.3.6 Effects of cannabinoids on LTB4 production in chondrocytes
Bovine articular chondrocytes were stimulated with IL-1 in the presence of 
cannabinoids and/or inhibitors. Production of LTB4 in these cells was 
measured and effects of the drugs were studied.
5.3.6.1 Effect of Win-55,212-2 and HU-210 on LTB4 production
Effects of non-selective cannabinoid receptors, HU-210 and Win-55,212-2 on 
IL-1 a (0.06nM) induced production of LTB4 in bovine articular chondrocytes. 
The cells appeared to constitutively produce LTB4 whilst IL-1 a appeared to 
reduce LTB4 production in these cells instead of stimulating its production 
(Fig. 5.9 and 5.10). These findings are not unprecedented, Tawara et al. 
(1991) also showed that chondrocytes spontaneously released LTB4 into 
culture medium and IL-1 p significantly inhibited LTB4 production by these 
cells.
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Figure 5.9: Effect of Win-55,212-2 on IL-1a-induced LTB4 production in 
primary bovine articular chondrocyte culture. Results presented as mean ± 
SD (n=3).
HU-210 at high concentration (10 pM) significantly increased LTB4 production 
in chondrocytes and appeared to attenuate the production of LTB4 at low 
concentration (1 pM) (Fig. 5.10). Win-55,212-2 on the other hand appeared to 
reduce LTB4 production in a concentration-dependent manner (Fig. 5.9).
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Figure 5.10: Effect of HU-210 (1, 5 and 10 jjM ) on IL-1a-induced LTB4 
production in primary bovine articular chondrocyte culture. Results presented 
as mean ± SD (n=3).
5.3.6.2 Effect of cannabinoids ACEA, N-AG and JWH-133 on LTB4
production
LTB4 production in IL-1 stimulated bovine articular chondrocytes was studied 
in the presence of endocannabinoid, N-AG; CBi cannabinoid receptor 
specific, ACEA; and CB2 cannabinoid receptor specific, JWH-133.
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ACEA and N-AG appeared to augment production of LTB4 in chondrocytes in 
a concentration-dependent manner (Table 5.1). N-AG significantly augmented 
LTB4 production.
Treatment
Average
(pg/ml) SD
Basal 0.001 0.0004
IL-1 a (0.06nM) 0.0004 0.0002
IL-1 + Vehicle 0.001 0.001
IL-1 + ACEA (10pM) 0.001 0.001
IL-1 + ACEA (30pM) 0.002 0.001
IL-1 + ACEA (50pM) 0.012 0.008
IL-1 + N-AG (10pM) 0.011 0.006
IL-1 + N-AG (30pM) 0.256 0.320
IL-1 + N-AG (50pM) 9.809 4.353
IL-1 + JWH-133 (10pM) 0.005 0.003
IL-1 + JWH-133 (30pM) 0.004 0.002
IL-1 + JWH-133 (50pM) 0.002 0.001
Table 5.1: Effect of ACEA, N-AG and JWH-133 (10, 30 and 50 pM) on IL-1a- 
induced LTB4 production in primary bovine articular chondrocyte culture. 
Results presented as mean ± SD (n=6).
5.3.6.3 Effect of ODQ, NS-398 and PDTC on LTB4 production
The effects of NO-sensitive GC inhibitor, ODQ; inhibitor of COX-2, NS-398; 
and NF-kB inhibitor, PDTC on production of LTB4 in bovine articular 
chondrocytes
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Figure 5.11: Effect of inhibitors ODQ (30 and 100 pM); NS-398 (30 and 100 
|jM); and PDTC (10 and 30 pM) on !L-1a-induced LTB4 production in primary 
bovine articular chondrocyte culture. Results presented as mean ± s.e.m. 
(n=6).
Inhibition of NO-sensitive GC by ODQ appeared to reduce LTB4 production in 
a concentration dependent-manner (Fig. 5.11). Inhibition of COX-2 by NS-398 
also blocked LTB4 production in chondrocytes (Fig. 5.11). On the contrary, 
inhibition of NF-kB by PDTC appeared to enhance LTB4 production in a 
concentration- dependent manner (Fig. 5.11).
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5.4 Discussion
All cannabinoids tested appeared to have the capacity to reduce the IL-1- 
induced production of PGE2 in bovine articular chondrocytes, except for HU- 
210 which appeared to augment the production in a concentration-dependent 
manner. Win-55,212-2 appeared to be the most potent of the cannabinoids 
and its effect was concentration-dependent.
Inhibition of NO-sensitive guanylate cyclase (GC) by ODQ significantly 
(p<0.001) reduced PGE2 production in articular chondrocytes. Suggesting 
that NO-sensitive GC pathway is involved in the IL-1-induced PGE2 
production in this system. COX-2 inhibition through NS-398, also significantly 
(p<0.001) reduced PGE2 production in these chondrocytes, at 1 pM it reduced 
PGE2 production to below basal levels. Thus IL-1-induced PGE2 production 
was through COX-2 activity. Inhibition of NF-kB by pyrrolidine 
dithiocarbamate (PDTC) significantly reduced IL-1 enhanced PGE2 production 
in these articular chondrocytes. This suggests that NF-kB is one of the 
mediators of IL-1-induced PGE2 production in these cells.
5-LOX inhibitor, MK-886, appeared to slightly enhance the IL-1-induced PGE2 
production in articular chondrocytes. Implying that blocking the 5-LOX 
pathway may enhance the induction of the COX pathway. This has also been 
reported by Martel-Pelletier etal. (2004).
IL-1 a up-regulated the production of PGE2 in articular chondrocytes and Win-
55,212-2 appeared to have the ability to attenuate the production of PGE2 by 
blocking COX-2 expression (Fig. 5.6-5.7). Win-55,212-2 in this study has 
been shown to be a specific COX-2 inhibitor since it did not affect expression 
of COX-1. It affected the expression of the constitutively produced mPGES-2 
slightly. This implies that the physiological roles of COX-1 and mPGES-2 may 
not be affected by use of the drug, thus may have fewer side effects, if any, 
compared to other COX-2 inhibitors that also affect COX-1 expression and 
other constitutively produced enzymes in this pathway.
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It has been reported that the induction of COX-2 expression and the 
subsequent increase in PGE2 production are essential for NO-induced 
chondrocyte apoptosis and that selective inhibition of COX-2 completely 
blocks this apoptotic phenomenon (Notoya et al., 2000). PGE2 produced in 
chondrocytes has been thought to induce apoptosis in these cells, linked with 
the cAMP-dependent pathway (Miwa et al., 2000) and since cannabinoids 
inhibit cAMP production by inhibiting adenylate cyclase (Howlett et al., 2002), 
cannabinoids could inhibit PGE2-dependent chondrocyte apoptosis by directly 
inhibiting PGE2 production and/or by inhibiting the cAMP-dependent pathway. 
Since apoptotic death of articular chondrocytes has been implicated in 
cartilage degradation (Goggs et al., 2003), its inhibition would protect the 
cartilage and could be one of the ways in which cannabinoids are able to 
protect cartilage from cytokine-induced degradation.
In studies done by Hardy et al. (2002), IL-1 induced cartilage proteoglycan 
degradation in OA synovial membrane-cartilage cocultures and this 
phenomenon corresponded to the induction of COX-2 protein expression and 
PGE2 production in this system. IL-1 neutralising antibody or the selective 
COX-2 inhibition attenuated both the IL-1-induced PGE2 production and 
cartilage proteoglycan degradation in these cocultures. Addition of PGE2 
reversed the inhibition of proteoglycan degradation caused by COX-2 
inhibition suggesting that induction of synovial COX-2-produced PGE2 is one 
mechanism by which IL-1 modulates cartilage proteoglycan degradation in 
OA. COX-2 inhibitors counteract some of the effects of IL-1 on human 
chondrocyte/cartilage metabolism. COX-2 inhibition was shown to be able to 
restore the proteoglycan synthetic response to TGF-p in IL-1 activated human 
chondrocytes. Thus these inhibitors may be used to minimize cartilage 
damage in arthritic and mechanically stressed joints (Studer and Chu, 2005).
High levels of PGE2  have been shown to up-regulate the expression and 
synthesis of Insulin-like growth factor-1 (IGF-1) binding proteins (IGFBPs) 
such as IGFBP-3, -4 and -5 (Di Battista et al., 1996; Sunic et al., 1998). 
These IGFBPs sequester IGF-1 thus reducing the anabolic stimulation of this 
tissue and contributing to the net loss of cartilage in inflammatory and
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degenerative arthritides (Niedel etal., 1997; Olney et al., 1996). Expression of 
these IGFBPs has also been reported to be elevated in osteoarthritic cartilage 
(Olney et al., 1996) and rheumatoid arthritis synovial fluid (Niedel et al., 
1997). Since PGE2  has been shown to be involved in the activation of the 
IGF-1/IGFBP axis, Di Battista et al (1997) suggested that PGE2 may be a 
rate-limiting step in cartilage repair processes. Cannabinoids, by inhibiting 
PGE2 production, may be interfering with this enhancement of expression of 
IGFBPs and enhancing IGF-1 bioavailability, thus protecting cartilage from 
resorption.
JWH-133 and Win-55,212-2 appeared to attenuate IL-1-induced LTB4 
production in a concentration-dependent manner whilst HU-210 enhanced it. 
ACEA and N-AG also enhanced LTB4 production in a concentration- 
dependent manner. Since N-AG also attenuated PGE2 production, it may be 
speculated that inhibition of the COX pathway enhanced the activation of the 
5-LOX pathway in this system. Other non-steroidal anti-inflammatory drugs 
(NSAIDs) also up-regulate the synthesis of LTB4, supporting the shunt 
hypothesis from COX to 5-LOX (Martel-Pelletier et al., 2004). Therefore these 
cannabinoids may be working in a similar way to the NSAIDs.
Inhibition of NO-sensitive GC by ODQ reduced LTB4 production suggesting 
that LTB4 production is dependent on cGMP production. Inhibition of COX-2 
by NS-398 also blocked LTB4 production in chondrocytes implying that COX 
pathway activation enhances LTB4 production as well. Inhibition of NF-kB by 
PDTC, on the contrary, appeared to enhance LTB4 production.
It is likely that LTB4 contributes to the up-regulation of important catabolic 
factors involved in the pathophysiology of OA, such as MMP (Martel-Pelletier 
et al., 2004). Therefore the effects of Win-55,212-2 and JWH-133 would be 
beneficial in treating OA.
The inhibition of prostaglandin synthesis has long been a basis for the 
treatment of OA, and other eicosanoids such as leukotrienes have also been 
implicated in the pathogenesis of osteoarthritis. Therefore selective inhibition
of prostaglandin pathways and/or inhibition of leukotriene activity may prove 
to be effective therapeutic strategies in osteoarthritis (Molloy and McCarthy, 
2005).
Conclusion
Cannabinoids, N-AG, JWH-133 and Win-55,212-2 attenuated PGE2 
production induced by IL-1 significantly. Cannabinoids significantly reduce 
PGE2  production in articular chondrocytes possibly through their ability to 
block COX-2 expression. Win-55,212-2 was shown to be a specific COX-2 
inhibitor since it did not affect expression of COX-1. Cannabinoids appear to 
have a potential as therapeutic agents in OA partly through this ability to block 
the COX-2 pathway.
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CHAPTER 6
EFFECTS OF CANNABINOIDS ON IL-1-INDUCED 
EXTRACELLULAR MATRIX DEGRADATION
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6.1 Introduction
A central pathological feature of the arthritic diseases is the resorption of 
cartilage. Chondrocytes, maintain cartilage tissue homeostasis, controlling the 
turnover rate of cartilage extracellular matrix (Steinmeyer and Daufeldt, 
1997). Active proteinases such as matrix metalloproteinases (MMPs) and 
aggrecanases degrade cartilage extracellular matrix (Cawston, 1998; Porter 
et al., 2005). The proteinases are inhibited by tissue inhibitors of 
metalloproteinases (TIMPs) (Steinmeyer and Daufeldt, 1997). In rheumatic 
conditions such as osteoarthritis and rheumatoid arthritis there is an 
imbalance between the proteinases and TIMPs that accounts at least in part 
for the observed cartilage destruction (Cawston, 1998; Steinmeyer and 
Daufeldt, 1997). Cartilage oligomeric matrix protein (COMP) and proteoglycan 
(mainly aggrecan) degradation occurs early in cartilage resorption process 
followed by collagen breakdown (Forslind et al., 1992; Little et al., 2002). 
Presence of COMP fragments in synovial fluid or serum is used as a marker 
for cartilage degradation (Neidhart et al., 1997; Saxne and Heinegard, 1992). 
Effects of cannabinoids on IL-1-induced extracellular matrix resorption were 
investigated in bovine nasal cartilage explant cultures and expression of 
proteinases in conditioned media from bovine articular chondrocyte cultures.
6.2 Materials and methods
6.2.1 Cannabinoids: Endocannabinoid anandamide (Sigma-Aldrich),
synthetic cannabinoids HU-210 (Tocris), Win-55,212-2 (active enantiomer) 
(Sigma-Aldrich) and Win-55,212-3 (inactive enantiomer) (Sigma-Aldrich) were 
studied along with solvent controls, ethanol and DMSO (0.1% final 
concentration) (Sigma, UK). Their effects were investigated on unstimulated 
or IL-1cc-stimulated cartilage breakdown.
6.2.2 Cartilage proteoglycan breakdown (sGAG assay): The cartilage 
explants were prepared and incubated overnight in complete medium, after 
which, the explants were unstimulated or stimulated to resorb with IL-1 a (500
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U/ml = 0.3 nM) in the presence of anandamide or Win-55,212-2 (5-50 pM) for 
4 days; HU-210 (0-15 pM) for 21 days and Win-55,212-2 or Win-55,212-3 (0- 
10 pM) for 28 days in DMEM without FBS. The rest of the assay was carried 
out as described in section 2.2.6.3.
6.2.3 Cartilage collagen breakdown (hydroxyproline assay): some of the 
conditioned culture media used in the sGAG assay above was set aside for 
this assay. Collagen degradation was determined as described under section 
2.2.6.1.
6.2.4 COMP release assay: COMP release was determined using an 
animal COMP ELISA as described in section 2.2.6.2.
6.2.5 Statistical Analysis: Statistical significance was determined using 
Kruskal-Wallis non-parametric test followed by Dunn's post-hoc test and a 
p<0.05 was considered statistically significant.
6.2.6 Zymography: This was carried out using manufacturer’s pre-cast gels, 
buffers and instruction up to developing stage. Briefly, the zymogram gelatin 
gels which were 10% Tris-Glycine gels with 0.1% gelatin incorporated as 
substrate were used. Conditioned media from bovine articular chondrocyte 
cultured was obtained as described in section 2.2. The cells were stimulated 
with IL-1 in the presence or absence of Win-55,212-2 for 48 hrs. For the rest 
of the procedure refer to section 2.2.8.
6.3 Results
6.3.1 Preliminary studies on the effects of cannabinoids on IL-1 - 
induced matrix degradation in bovine nasal cartilage (BNC).
The endocannabinoid anandamide and synthetic cannabinoid Win-55,212-2 
were used in the preliminary studies on IL-1-induced cartilage degradation 
measured as the release of sulphated GAGs in 4-day cartilage explant 
cultures.
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Explants were treated with IL-1 a (0.3nM) to induce matrix resorption. Effects 
of anandamide and Win-55,212-2 on IL-1-induced matrix release were 
studied. IL-1 a (0.3nM) significantly induced proteoglycan breakdown in bovine 
nasal cartilage (BNC) explants. Anandamide (10 and 50 pM) (Fig. 6.1) and 
Win-55,212-2 (5, 10 and 50 pM) (Fig. 6.2) significantly reduced IL-1 induced 
proteoglycan degradation in BNC cultured for 4 days. Their effects appeared 
to be concentration-dependent. Win-55,212-2 appeared to be the more potent 
than anandamide, although these were two different experiments.
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Figure 6.1: Effects of anandamide (5-50pM) on 4 day IL-1a-induced sGAG 
release in bovine nasal cartilage explants. Results expressed as mean ± 
s.e.m. (n=6). * p<0.05; **p<0.01 compared with vehicle control. Kruskal-Wallis
154
followed by Dunn’s post-hoc test was used to determine statistical 
significance.
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Figure 6.2: Effects of Win-55,212-2 (5-50pM) on 4 day IL-1a-induced sGAG 
release in bovine nasal cartilage explants. Results expressed as mean ± 
s.e.m. (n=6). * p<0.05; *** p<0.001 compared with vehicle control. Kruskal- 
Wallis followed by Dunn’s post-hoc test was used to determine statistical 
significance.
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Having shown that the cannabinoids were able to reduce matrix breakdown 
induced by IL-1, longer duration cultures of the BNCs were carried out with 
the intention of studying the effects of cannabinoids on proteoglycan and 
collagen degradation to the point where the cartilage explants in the control 
wells were completely resorbed through IL-1 induced pathways.
6.3.2 Effect of HU-210 and Win-55,212-2 on IL-1a-induced proteoglycan 
degradation in bovine nasal cartilage explants
Bovine cartilage explants were incubated for up to 21 or 28 days stimulated 
with IL-1 in the presence and absence of HU-210, the active enantioner Win-
55,212-2 and the inactive enantiomer Win-55,212-3. The conditioned media 
from these cultures were used to determine the release of proteoglycan 
measured as sGAGs. The effects of the enantiomers were compared to 
determine whether cannabinoids may be blocking proteoglycan breakdown 
via any receptor(s).
HU-210 (5-15 pM) reduced sGAG release at days 7-14 with approximately 
20% difference compared with the vehicle controls. HU-210 at 15 pM 
significantly (p<0.05) reduced sGAG release at day 7 (Fig. 6.3). By day 7, 
about 80 % of the proteoglycan had been lost through IL-1 induced 
mechanisms.
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Figure 6.3: The effect of HU-210 on IL-1-induced proteoglycan degradation in 
bovine nasal cartilage explants. Results expressed as mean ± s.e.m. (n=6). * 
p<0.05 compared with vehicle control.
The inactive enantiomer, Win-55,212-3, did not show any effect on sGAG 
release when compared to the vehicle control whilst Win-55,212-2 at 5 and 
10pM significantly (p<0.001) reduced sGAG release compared with the 
vehicle control and the reduction was to basal levels (Fig. 6.4). Actually, Win-
55,212-2 kept sGAG release to basal levels through out the culture period. By 
the end of day 7, approximately 80 % of the proteoglycan had been lost in the 
IL-1 treatment; over 40 % had been lost in the vehicle and Win-55,212-3 
treatments.
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Figure 6.4: The effect of Win-55,212-2 compared with its inactive enantiomer, 
Win-55,212-3 on IL-1a-induced proteoglycan degradation in bovine nasal 
cartilage explant cultures. Results expressed as mean ± s.e.m. (n=6). *** 
p<0.001 compared with vehicle control. Kruskal-Wallis followed by Dunn’s 
post test was used to determine statistical significance.
6.3.3 Effects of cannabinoids on IL-1a-induced collagen degradation in 
bovine nasal cartilage explants
The conditioned media from bovine cartilage explant stimulated with IL-1 in 
the presence or absence of HU-210; and the enantiomers, Win-55,212-2 
(active) and Win-55,212-3 (inactive) were used to determine the release of 
collagen measured as HPro. The effects of the enantiomers were compared 
to determine whether cannabinoids may be blocking collagen breakdown via 
any receptor(s).
At 5 pM, HU-210 showed no effect at day 7 but later slightly reduced 
hydroxyproline release by up to 20% compared with the vehicle control at
days 14 and 21. At 10 and 15 pM, however, HU-210 significantly reduced 
hydroxyproline release at day 7 (p<0.01 and p<0.05 respectively) and at days 
14 and 21 (p<0.001 and p<0.01 respectively) (Fig. 6.5). Only about 20 % of 
the collagen in the explants trated with IL-1 had been lost by the end of day 7. 
By day 21, the explants in the IL-1 and vehicle controls were completely 
resorbed.
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Figure 6.5: The effect of HU-210 on IL-1-induced collagen breakdown in 
bovine nasal cartilage explants. Results expressed as mean ± s.e.m. (n=6). * 
p<0.05; **p<0.01; *** p<0.001 compared with vehicle control. Kruskal-Wallis 
followed by Dunn’s test was used to determine statistical significance.
The inactive enantiomer Win-55,212-3 did show some inhibitory effects on 
hydroxyproline release although the effects were not significantly different 
compared with those of vehicle control. However at 5-10 pM, Win-55,212-2 
significantly (p<0.001) reduced hydroxyproline release compared to the 
vehicle control (Fig. 6.6). Less than 20 % of the explants’ collagen had been 
lost through IL-1-induced mechanisms by the end of day 7. By day 28, the
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explants were completely resorbed in the IL-1 and vehicle control (DMSO) 
treatments.
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Figure 6.6: The effect of Win-55,212-2 compared with its inactive enantiomer, 
Win-55,212-3 on IL-1a-induced collagen degradation in bovine nasal cartilage 
explant cultures. Results expressed as mean ± s.e.m. (n=6). *** p<0.001 
compared with vehicle control. Kruskal-Wallis followed by Dunn’s test was 
used to determine statistical significance.
6.3.4 Effect of cannabinoids on IL-1-induced COMP release in articular 
cartilage
The release of COMP was measured in conditioned media from BNC 
explants that were stimulated with IL-1 and treated with Win-55,212-2 for 28 
days. The effect of Win-55,212-2 was studied on the release of COMP.
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Figure 6.7: The effect of Win-55,212-2 (1, 5 and 10 pM) on IL-1-induced 
COMP degradation in bovine nasal cartilage explants. The results are 
expressed as mean ± s.e.m. (n=6).
Win-55,212-2 appeared to consistently inhibit the release of COMP 
throughout the culture period. Win-55,212-2 kept the release of COMP to 
basal levels (Fig. 6.7). This implies that Win-55,212-2 blocked IL-1-induced 
matrix breakdown completely. However, the results show that basal release 
of COMP was almost in a linear fashion, ending with 100% release at day 28, 
just as the rest of treatments in which COMP release was induced by IL-1 a. 
This is an anomaly, basal levels of release of COMP should have been much 
lower than the levels observed. The results observed could be attributed to 
loss of remaining COMP in the explants digested with papain solution, since 
no COMP residues were detected in the digests. Papain digestion of COMP 
may be responsible for the loss of the protein. Because the calculations were 
done as a percent of total COMP, loss of COMP in the digests distorted the 
results.
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6.3.5 The effect of cannabinnoid, Win-55,212-2 on proteases expression
The effects of Win-55,212-2 on expression of proteases in condition mediatfrom articular chondrocyte culture were investigated using 10% zymogram 
gelatin gels. Presence of proteases is readily visualised as clear bands in the 
lanes against the blue background. Clear bands represent the bands where 
proteases digested the gelatin. This study would enable identification of 
gelatinases such as matrix metalloprotinase-2 and -9 (MMP-2 and MMP-9) 
and other proteinases that can digest gelatin.
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Figure 6.8: 10% Gelatin zymogram gels were used to detect proteases that 
can utilise gelatine as substrate in bovine articular chondrocyte conditioned 
media. The cells were unstimulated or stimulated with IL-1 and incubated for 
48 h in the presence or absence of Win-55,212-2 (1-10 pM) or its vehicle. 
Lane 1 & 2: Markers; Lane 3: Blank; Lane 4: Basal; Lane 5: IL-1a (0.06nM); 
Lane 6: Vehicle control; Lane 7: IL-1+ Win-55,212-2 (10pM); Lane 8; IL-1 + 
Win-55,212-2 (5pM); Lane 9: IL-1+ Win-55,212-2 (1pM)
The conditioned media contained a number of proteases which may include 
the well-known gelatinases, MMP-2 and MMP-9 apparently in their inactive 
and/or active forms (Fig. 6.8). The molecular weights for the active MMP-2, 
pro-MMP-2, active MMP-9 and pro-MMP-9 are about 65, 72, 92 and 100 kDa, 
respectively. MMP-9, active form does not appear to be expressed in this
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system, however there appears to be a faint band at above 97 kDa, which 
could be the pro-MMP-9. Win-55,212-2 appears to reduce expression of this 
form of gelatinase in a concentration-dependent manner (Fig 6.8, lanes 7, 8 & 
9). There is a faint band above and a clear pronounced band around 64 kDa. 
The one above 64 kDa may be the Pro-MMP-2 which appeared not to be 
affected by presence of IL-1 or Win-55,212-2 and was not as highly 
expressed as the one around 64 kDa which may be the active form of MMP-2 
(Fig. 6.8). Expression of the “active MMP-2” appears to be slightly enhanced 
by presence of IL-1, but was attenuated by Win-55,212-2 at 5 and 10 pM. 
Other protease activities were around 45 kDa and below (Fig. 6.8), it is 
possible that these may represent MMP-1/MMP-3 as suggested elsewhere 
(Collen et a/., 2003). The molecular weights for pro-MMP-1, MMP-1, pro- 
MMP-3 and MMP-3 are: 51 or 53 kDa, 41 or 44 kDa, 43 or 45 kDa, and 57 
kDa, respectively (Fuchs et a/., 2004). These may vary depending on 
glycosylation state. The expression of these proteases was not affected by IL- 
1 stimulation but was abrogated by Win-55,212-2 in what appeared to be a 
concentration-dependent manner, with significant effects from 5 pM. With 
zymography, it is dfficult to identify the proteases with accuracy and certainty 
especially for those proteases with nearly similar molecular weights (Fuchs et 
ah, 2004).
Conditioned media from explant cultures were also tested but there was a 
problem (results not shown). The presence of released matrix components 
such as glycosaminoglycans appeared to impede migration of the enzymes 
and caused smearing of gels. No clear bands were visualised in conditioned 
media from days 7-14 cultures, but slightly clearer bands were seen in 
conditioned media from days 21-28 (data not shown). The bands became 
clear in days 21-28 culture media, particularly in lanes for IL-1a (0.3nM), 
vehicle control as well as 1 pM Win-55,212-2, showing proteases expression. 
The lanes for basal and 5 pM Win-55,212-2 showed little, if any expression of 
the proteases. This suggested that by day 21, the conditioned media in the 
lanes that showed clear protease activity bands had less presence of the 
degraded components of the matrix. This further indicated that there was 
accerelated and enhanced matrix resorption in those treatments during the 14
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days of culture. The smearing of gels that was seen was more associated 
with the conditioned media from the IL-1, vehicle control and 1 pM Win-
55,212-2 treatments.
6.4 Discussion
The results show that synthetic cannabinoids have the potential to protect 
against IL-1a-induced cartilage breakdown as evidenced by inhibition of 
cartilage matrix degradation in bovine nasal cartilage explants. The synthetic 
cannabinoids significantly inhibited proteoglycan degradation early in the 
process of cartilage resorption and potently inhibited collagen breakdown 
later in the process (see Figures 6.1-.6.6). HU-210 and Win-55,212-2 
significantly inhibited IL-1-induced proteoglycan and collagen breakdown in 
bovine cartilage explants. Win-55,212-2 was also capable of blocking IL-1 
induced COMP release in this system. Win-55,212-2 was able to reduce 
matrix degradation to about basal levels at the concentrations tested, thus 
showing ability to abrogate completely the degradative effects of IL-1 in 
cartilage. This effect of Win-55,212-2 may be partly due to its ability to reduce 
expression of proteinases. Generally, the proteinases expressed in the 
conditioned media were constitutively expressed. However these results 
suggest that Win-55,212-2 blocked cartilage breakdown by attenuating 
expression of proteases. The MMPs are a unique family of enzymes that are 
responsible for catabolism of extracellular matrix, working in concert; these 
proteases can degrade all components of the extracellular matrix (Ellis et at., 
1994; Flannery etal., 2000).
In the system used, proteoglycan release appeared to occur earlier in the 
cartilage resorption process; IL-1 induced the release of approximately 80 % 
of the proteoglycan in the explants by the end of day 7. For COMP it was 
approximately 40 % and for collagen only about 20 % by the end of the first 
week of culture.
The effects of the cannabinoids in these studies appeared to be generally 
concentration-dependent. The stereo-specificity exhibited by the effects Win-
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55,212-2, the active enantiomer at cannabinoid receptors, on these cartilage 
resorption assays suggests that Win-55,212-2 was acting via CBi and/or CB2 
cannabinoid receptor(s).
It is not known for certain, how the cartilage resorbed in the presence of IL-1 
in the assays studied. However, it was shown in chapters 4 and 5 that IL-1 
significantly stimulated production of the inflammatory mediators, NO and 
PGE2  respectively. The mediators appear to be partly responsible for the 
effects of IL-1 observed. They have been reported to induce apoptosis in 
chondrocytes (Miwa et al., 2000 and Notoya et a/., 2000). Blanco et al. (1998) 
carried out studies to determine the kind of cell death which occurred in 
cartilage from patients with OA. These studies revealed that chondrocytes in 
OA cartilage undergo apoptosis. This mechanism of cell death plays an 
important role in the pathogenesis of OA (Blancho et al., 1998). Chondrocyte 
loss has profound effects on matrix composition; on the other hand, matrix 
composition has an equally profound effect on chondrocytes viability (Lo and 
Kim, 2004). Chondrocyte apoptosis has been described in studies of the 
pathogenesis of various arthritides and collagen framework degradation has 
been shown to induce apoptosis of chondrocytes in human cartilage (Kim et 
al., 2001). Therefore, collagen degradation appears to be a physiologically 
relevant pro-apoptotic signal and, quite likely, a key mediator of chondrocyte 
apoptosis in diseases such as osteoarthritis (Lo and Kim, 2004). Therefore 
the possibility of induction of chondrocyte apoptotic death by matrix 
breakdown can not be ruled out in this present study. It is possible that IL-1- 
induced activation of proteases that started the degradation of the matrix. 
This in turn, stimulated chondrocytes death and, this in turn led to 
compromised extracellular matrix integrity, triggering a vicious cycle. 
Whichever starts, remains to be elucidated.
Conclusion
Cannabinoids blocked proteoglycan, COMP and collagen degradation 
induced by IL-1 a in bovine nasal cartilage explants. Although IL-1 a 
completely resorbed cartilage explants in 3 -  4 weeks time, cannabinoids
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protected the cartilage explants from the IL-1-induced breakdown. This could 
be partly through inhibition of proteinase expression. Finally cannabinoids 
could be acting through some receptor(s).
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CHAPTER 7
THE MODE OF ACTION OF CANNABINOIDS IN
CHONDROCYTES
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7.1 Introduction
The p38 MAPK signalling transduction pathway plays an essential role in 
regulating many cellular processes including inflammation, cell differentiation, 
cell growth and death. Activation of p38 often through extracellular stimuli 
such as bacterial pathogens and cytokines, mediates signal transduction into 
the nucleus to turn on the responsive genes (Ono and Han, 2000).
MAPK p38 is strongly activated by pro-inflammatory stimuli, and has been 
studied largely in the context of inflammation (Clark et al., 2003). Activation of 
p38 MAPK has been implicated in the catabolic and anti-anabolic actions of 
IL-1 (Studer et al., 2004). Activation of p38 plays an important role in the 
induction and expression of inflammatory mediators such as COX-2 and 
iNOS (Ono and Han, 2000). Inhibition of this pathway may be a versatile anti­
inflammatory strategy and this accounts for the intense interest of the 
pharmaceutical industry in the development of p38 MAPK inhibitors (Clark et 
al., 2003)..
Another important way to block induction and expression of mediators of 
inflammation and tissue resorption such as NO, PGE2 and pro-inflammatory 
cytokines, would be to target the transcription factors responsible for induction 
of the genes of these mediators in the nucleus. NF-kB is one such 
transcription factor that could be targeted. This would allow the specific 
control of the overexpression of a number of genes that occur in many 
arthritic conditions like OA (Pelletier, 2004). The NF-xB/Rel family of 
transcription factors consists of five known proteins: p65, p50, p52, c-Rel and 
RelB. All NF-kB proteins possess a conserved amino-terminal domain that 
contains the DNA-binding and dimer-forming domains, as well as the nuclear 
localization signal (NLS). Active NF-kB molecules exist as dimers, mostly in 
the form of p65/RelA and p50 (Schwartz et al., 1999). In unstimulated cells, 
NF-kB is sequestered in the cytoplasm by the inhibitor of kappaB (IkB) 
proteins, thus it exists as a heterotrimer of p50, p65 and IkB. IkB prevents 
nuclear translocation and DNA binding of NF-kB by masking its NLS 
(Shishodia and Aggarwal, 2004). In response to proinflammatory stimuli, IkB 
is phosphorylated (Clancy et al., 1998). The phosphorylation leads to
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ubiquitination and degradation of IkB, thus unmasking the NLS and allowing 
NF-kB to translocate to the nucleus where the NF-kB dimers bind to the 
promoter region of targeted genes and regulates their transcription (Clancy et 
al., 1998; Schwartz et al., 1999). The composition of the dimer and the cell 
type in which it is functioning are thought to contribute to the transcriptional 
specificity of NF-kB (Schwartz et al., 1999).
Cannabinoids appear to be acting through receptor(s) in the systems used in 
this study, as evidenced by effects that are apparently concentration- 
dependent and the stereo-specificity of effects of Win-55,212-2. Therefore 
expression of cannabinoid receptors in chondrocytes was studied. The effects 
of Win-55,212-2 on IL-1 induced activation of the p38 MAPK pathway as well 
as activation of the NF-kB were studied in bovine articular chondrocytes.
7.2 Materials and methods
7.2.1 Materials: MK-886, inhibitor of 5-lipooxygenase (5-LOX); NS 398, 
inhibitor of cyclooxygenase 2 (COX-2); ODQ, inhibitor of NO-sensitive 
guanylyl cyclase; and pyrrolidine dithiocarbamate ammonium (PDTC), 
inhibitor of NF-kB; PGE2 and LTB4 ELISA kits (Alexis Biochemical); FACE® 
MAPK p38 kit; rabbit polyclonal anti-cannabinoid receptors - CB1 (H-150) and 
CB2 (H-60) (Santa Cruz); rabbit polyclonal anti-NF-xB p65 (1:100) 
(SantaCruz) and fluorescein isothiocyanate (FITC)-conjugated secondary 
goat anti-rabbit IgG (Santa Cruz) diluted (1:100) were used in this study.
7.2.2 Bovine chondrocyte culture: Chondrocytes stimulated with IL-1 in 
the presence or absence of Win-55,212-2 (0-10 pM) were cultured as 
describe in section 2.2.1.
7.2.3 FACE™ p38 MAPK: This Fast-activated cell-based ELISA for p38 
MAPK was carried out as described under section 2.2.10
7.2.4 Immunofluorescence: Chondrocytes were plated on 8-well chamber 
slides and incubated for 5 days in complete medium (for cannabinoid receptor
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immunofluorescence) or incubated for a further 48 hours stimulated with IL-1 a 
(0.06nM) in the presence of Win-55,212-2. The rest of the procedure was 
carried out as described in section 2.2.9. Rabbit polyclonal anti-cannabinoid 
receptors - CBi (H-150) and CB2 (H-60) (Santa Cruz) and rabbit polyclonal 
anti-NF-xB p65 (1:100) (SantaCruz) were used. Fluorescein isothiocyanate 
(FITC)-conjugated secondary goat anti-rabbit IgG (Santa Cruz) diluted (1:100) 
in PBS with NGS was used to label the cells. Normal goat serum was used as 
a negative control. Cells were mounted in SlowFade anti-fade fluorescent 
mounting medium (Molecular Probes).
7.2.5 Immunoblotting: whole cell lysates were obtained from chondrocytes 
incubated with or without IL-1 a stimulation in the presence or absence of 
cannabinoid, Win-55,212-2 (1 or 5 pM) for 48 hrs. The procedure was carried 
out as described in section 2.2.7. Briefly, after blocking, the membranes were 
incubated in primary antibodies - rabbit polyclonal anti-cannabinoid receptor-1 
and -2 (CBi and CB2) (Sigma-Aldrich) for 1 hr. After washing the membranes 
were incubated in alkaline phosphatase-conjugated goat anti-rabbit 
secondary antibody for 30 min followed by visualized of purple protein bands 
with chromogenic substrate [5-bromo-4-chloro-3-indolyl-1-phosphate (BCIP) 
and nitro blue tetrazolium (NBT)] for at least 1 hr. This was followed by 
imaging.
7.2.6 Statistical Analysis: Statistical siginificance was determined using 
one-way ANOVA followed by Boniferroni's post test and a p<0.05 was 
considered statistically significant.
7.3 Results
7.3.1 Effect of Win-55,212-2 on IL-1-induced activation of p38 Mitogen- 
Activated Protein Kinase (MAPK) in bovine articular chondrocytes
Chondrocytes were cultures in 96 well-plates until at or near to confluence. 
The chondrocytes were stimulated with IL-1 and incubated with Win-55,212-2 
at 1-10 pM for 15 minutes. Activation of p38 MAPK in IL-1-stimulated
chondrocytes was studied and the effects of cannabinoid Win-55,212-2 were 
determined. Expression of total p38 MAPK was also determined and effects 
of Win-55,212-2 on this were studied as well.
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Figure 7.1: The effect of Win-55,212-2 (1, 5 and 10 pM) on IL-1-induced 
activation of p38 MAPK in bovine articular chondrocytes incubated for 15 min. 
Results expressed as mean ± s.e.m. (n=6).
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IL-1 a stimulated phosphorylation of p38 MAPK in these chondrocytes (Fig. 
7.1). Win-55,212-2 at 1-10 pM did not show any significant effect on IL-1 - 
stimulated phosphorylation of p38 MAPK (Fig. 7.1). Total p38 MAPK was not 
significantly affected by any of the treatments in these cells at 15 min 
following stimulation by IL-1 (Fig. 7.1).
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Figure 7.2: The effect of Win-55,212-2 (1, 5 and 10 pM) on IL-1-induced 
activation of p38 MAPK in bovine articular chondrocytes incubated for 30 min. 
Results expressed as mean ± s.e.m. (n=6).
IL-1 a induced the phosphorylation of p38 MAPK in these cells stimulated for 
30 min (Fig. 7.2). The vehicle appeared to slightly enhance the 
phosphorylation; however, Win-55,212-2 at the concentrations tested equally 
inhibited the IL-1-induced phosphorylation of p38 MAPK (Fig. 7.2). The total 
p38 MAPK was not affected by the IL-1 or Win-55,212-2 but appeared to be 
slightly inhibited by the vehicle (Fig. 7.2).
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7.3.2 Win-55,212-2 and NF-kB activation in bovine articular
chondrocytes
fBovine articular chondrocytes were plated onto chamber slides and were 
used in the study of effects of Win-55,212-2 on IL-1a-induced NF-kB 
activation using indirect immunofluorescence. A primary antibody against the 
p65 subunit of the NF-kB dimers was used.
11
Figure 7.3: Immunofluorescence analysis of NF-kB activation in bovine 
articular chondrocytes cultured for 7 days. The cells were unstimulated (B) or 
stimulated with IL-1 a (0.06 nM) in the presence of: 0.1 % vehicle -  DMSO 
(C); 5 pM Win-55,212-2 (D). (A) Negative control (NGS used instead of 
primary antibody). Primary antibody against NF-kB p65 was diluted 1:100 and 
FITC-conjugated secondary antibody was used to visualise NF-kB activation.
Under basal conditions, NF-kB was expressed mainly in the cytoplasm (Fig.
7.3 B). Stimulation with IL-1 a activated the NF-kB in chondrocytes as 
evidenced by the translocation of the transcription factor into the nuclei shown
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by strong staining of the nuclei, little staining in the cytoplasm (Fig. 7.3 C). 
Win-55,212-2 (5 pM) attenuated the IL-1-induced activation of NF-kB in 
bovine articular chondrocytes (Fig. 7.3 D) as shown by reduced nuclei 
staining and and general expression.
7.3.3 Cannabinoid receptor expression in bovine articular 
chondrocytes
The bovine articular chondrocytes were studied to determine expression of 
cannabinoid receptors using immunofluorescence and immunoblot analyses.
Figure 7.4: Immunofluorescence analysis of CBi and CB2 cannabinoid 
receptors in bovine articular chondrocytes cultured for 7 days. A & C: 
negative controls (NGS used instead of primary antibody); B: CBi receptor 
expression; D: CB2 receptor expression. Primary antibodies against the 
receptors were diluted 1:100. FITC-conjugated secondary antibody was used 
to visualise the receptor’s expression.
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In this immunofluorescence analysis, the chondrocytes showed punctate 
expression of the cannabinoid receptors, CBi and CB2 (Fig. 7.4). The 
expression of these receptors appeared to be constitutive. The expression of 
the two cannabinoid receptors CBi and CB2 by chondrocytes was confirmed 
also by immunoblot analyses (Fig. 7.5 and 7.6). These are unprecedented 
findings.
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Figure 7.5: Immunoblot assay performed using anti-cannabinoid receptor-1 
(CBi) antibody from rabbit (diluted 1:250 as outlined by the manufacturer) in 
bovine chondrocyte lysate. Lanes 1: Marker; Lane 2: Basal; Lane 3: IL-1a 
(0.06nM); Lanes 4: Vehicle control; Lanes 5 & 6: IL-1 + Win-55,212-2 (1pM); 
Lanes 7 & 8: IL-1 +Win-55,212-2 (5pM); Lane9 & 10: IL-1 +Win-55,212-2 
(5pM)
The antibody against CBi cannabinoid receptor, when used in immunoblot 
recognises a major band of 60 kDa, according to information from the 
manufacturer. In this study, the antibody recognised a major band around 64 
kDa. The bands observed were faint though, suggesting either low affinity for 
the antibody in this species or low expression of receptors.
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Figure 7.6: Immunoblot assay performed using anti-cannabinoid receptor-2 
(CB2 ) antibody from rabbit (diluted 1:500) in bovine chondrocyte lysate. Lanes 
1: Marker; Lane 2: Basal; Lane 3: IL-1 a (0.06nM); Lanes 4 (30 pi) & 5 (15 pi): 
Vehicle control; Lanes 6 (30 pi) & 7 (15 pi): IL-1 + Win-55,212-2 (1pM); Lanes 
8 (30pl) & 9 (15 pi): IL-1 +Win-55,212-2 (5pM); Lane 10: Marker
The immunoblot for CB2 cannabinoid receptors showed a major band at 30 
kDa and a minor (faint) band at 97 kDa.
7.4 Discussion
The p38 MAP kinase inhibitors have been shown to be efficacious in several 
disease models, including inflammation, arthritis and other joint diseases. In 
all cases, p38 activation in key cell types correlated with disease initiation and 
progression. Treatment with p38 MAP kinase inhibitors attenuated both p38 
activation and disease severity (Lee et al., 2000). A number of compounds 
that inhibit p38 MAPK have been developed and their potential as therapeutic 
agents in inflammation, arthritis, septic shock, and myocardial injury is 
currently being explored (Studer et al., 2004). Compounds that potently inhibit 
p38 MAPK have been found to be capable of inhibiting IL-1 induction of iNOS 
in bovine chondrocytes and thus blocking NO synthesis (Studer et al., 2004).
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This effect may also protect cartilage from the damaging actions of NO. It is 
possible that inhibition of activation of p38 MAPK by Win-55,212-2 
consequently blocked the induction and expression of COX-2 and iNOS, 
resulting in inhibition of PGE2 and NO production respectively. Therefore this 
ability of Win-55,212-2 to reduce p38 MAPK activation suggests that it has 
the potential as an effective therapeutic agent for arthritis.
In chondrocytes, NO is a key regulator of the signaling pathways downstream 
of IL-I, involving NF-kappa B (NF-kB) activation and leading to the expression 
of genes that are involved in the pathophysiology of arthritic diseases 
(Mendes et al., 2002). NO is not per se involved in the immediate cytokine- 
stimulated activation of NF-kB in chondrocytes, but rather sustains nuclear 
translocation and this persistent activation of NF-kB may be responsible for 
NO sustained catabolic processes that lead to cartilage resorption in arthritic 
diseases (Clancy et al., 2004). The ability of Win-55,212 to block NO 
production implies that this drug may also be capable of modulating the 
signalling pathways downstream of IL-1, including the activation of NF-kB. In 
this study, Win-55,212-2 appeared to reduce NF-kB nuclear translocation 
stimulated by IL-1 (Fig. 7.3). This could be partly through its ability to 
abrogate NO production but also could be partly through direct effects on the 
NF-kB activation mechanisms. It is possible that the effects produced by the 
cannabinoids are partly through their capability to attenuate NF-kB activation.
Cannabinoids have been shown to inhibit significantly NO production as well 
as block iNOS expression in chondrocytes (Chapter 4). The transcription of 
iNOS has been reported to be partially under the control of cAMP-dependent 
NF-kB (Berdyshev, 2000). Win-55,212-2 appeared to reduce activation of the 
transcription factor (Fig. 7.3 D), suggesting that cannabinoids may have the 
capacity to inhibit activation of NF-kB in chondrocytes. It has been suggested 
therefore that cannabinoids might be regulating the NF-KB-dependent iNOS 
transcription via cannabinoid receptor-mediated downregulation of PKA 
activity (Berdyshev, 2000).
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It is possible that the cannabinoids are producing the cartilage protective 
effects via cannabinoid receptor(s). The cannabinoid receptor inactive 
enantiomer, Win-55,212-3, did not inhibit NO production and did not 
significantly protect cartilage from degradative effects of IL-1, although it 
slightly inhibited collagen degradation at 10 pM. The stereoselectivity 
suggests that Win-55,212-2 could be acting through some receptor(s). The 
bovine articular chondrocytes used were shown, for the first time, to 
constitutively express both CBi and CB2 cannabinoid receptors (Figure 7.4- 
7.6). Since Win-55,212-2 is a non-specific cannabinoid receptor agonist, it is 
therefore not possible to tell exactly at which receptor it is acting without 
carrying out further studies. The use of AM 281 and AM 630 (CBi and CB2 
cannabinoid receptor antagonists, respectively) did not help solve this 
dilemma because these antagonists did not antagonise but instead enhanced 
Win-55,212-2’s effects and did not act as inverse agonists in the system 
tested, as would be expected.
Conclusion
Win-55,212-2 reduced IL-1 induced p38 MAPK and NF-kB activation and this 
may be responsible for the other effects of Win-55,212-2 observed. It has 
been shown also, for the first time that chondrocytes express both CBi and 
CB2 cannabinoid receptors. Although the chondrocytes express cannabinoid 
receptors, it is still not yet clear which receptor the cannabinoids may be 
acting through. As suggested earlier, there is a possibility that cannabinoids 
such as Win-55,212-2 may have another target other than the two known 
cannabinoid receptors.
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CHAPTER 8 
GENERAL DISCUSSION AND SUMMARY
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Cannabinoids and IL-1a-induced NO production in chondrocytes
IL-1 stimulates the production of NO in bovine articular chondrocytes. 
Cannabinoids generally appeared to have the ability to inhibit NO production 
induced by IL-1 a at concentrations that were not toxic, in bovine articular 
chondrocytes (Chapter 4). Figure 8.1 below shows the proposed IL-1-induced 
NO production pathway in these cells and possible targets for cannabinoids. 
IL-1 has been shown to stimulate activation of NF-kB, which translocates to 
the nucleus (Section 7.3.2) and activates transcription of a number of genes, 
one of which is iNOS (Berdyshev, 2000). In this study PDTC, inhibitor of NF- 
kB, significantly inhibited NO production in chondrocytes, suggesting that NF- 
kB activation enhances activation of iNOS and consequently NO production in 
these cells. Win-55,212-2 appeared to reduce the transcription factor’s 
activation and its effects on NO and PGE2 were similar to those of PDTC. 
Cannabinoids attenuated NO production partly through their ability to block 
iNOS expression as shown by the effect Win-55,212-2. NO activates NO- 
sensitive soluble guanylyl cyclase (sGC) which leads to increased production 
of the second messenger, cGMP. This cGMP may be responsible, at least in 
part, for some of the effects of IL-1 observed in chondrocytes and cartilage. 
The inhibition of sGC by ODQ, for instance, significantly inhibited PGE2 and 
LTB4 production in chondrocytes. Cannabinoids, therefore, by inhibiting NO 
production inhibited sGC activation and its subsequent production of cGMP. 
In summary, Cannabinoids interfered with NF-kB activation, iNOS expression 
and subsequent NO production which led to inhibition of activation of sGC 
and subsequent cGMP production in chondrocyte stimulated by IL-1.
Inhibition of PGE2 (using NS-398, COX-2 inhibitor) and LTB4 (using MK-886, 
5-LOX activating protein -  FLAP inhibitor) production also inhibited NO 
production in chondrocytes indicating cross-talk (Chapter 4). The possibility of 
cannabinoids inhibiting NO production through inhibition, at least in part, of 
the COX-2 and 5-LOX pathways may not be ruled out.
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Figure 8.1: Proposed schematic representation of IL-1-induced NO 
production pathway in chondrocytes and possible cross-talk with PGE2  and 
LTB4 production pathways
The main reactive oxygen species (ROS) produced by chondrocytes are NO 
and superoxide anion (O2 ') that generate derivative radicals, including 
peroxynitrite (ONOO") and hydrogen peroxide (H2 O2). ONOO- is one the 
radicals thought to be responsible for the cell apoptosis that leads to cartilage 
degradation (Henrotin et al. 2003). Cannabinoids may also be working as 
antioxidant thus protecting cartilage degradation.
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Cannabinoids and eicosanoid production in chondrocytes
Cannabinoids had varied effects on eicosanoids, PGE2 and LTB4 production 
in bovine articular chondrocytes stimulated with IL-1. Whilst PGE2 was 
significantly enhanced by the cytokine, LTB4 production appeared to be 
reduced by it, suggesting that IL-1 is not one of the factors that induce LTB4 
production in chondrocytes (Chapter 5). Some of the cannabinoids tested 
significantly reduced PGE2 production induced by IL-1. This was partly due to 
specific blockade of expression of COX-2, since COX-1 and mPGES-2 which 
are constitutively expressed were not significantly affected by Win-55,212-2. 
However some of the cannabinoids enhanced PGE2 production. Again some 
of the cannabinoids reduced LTB4 production whilst some enhanced its 
production. Win-55,212-2 reduced both eicosanoids showing a high potential 
as an anti-inflammatory agent.
IL-1 treatment of chondrocytes has been shown to result in a dramatic dose- 
dependent increase in intracellular phospholipase A2 (PLA2) activity and 
subsequent secretion of this enzyme extracellularly (Gilman et al., 1987). 
This is followed by an enhanced release of free arachidonic acid. The 
arachidonic acid liberated was subsequently metabolized exclusively to 
PGE2 ; no significant increases in the production of other eicosanoids were 
observed including LTB4 (Gilman et al., 1987). However, soluble PLA2 has 
also been shown to correlate with augmention of LTB4 secretion at 
inflammatory sites (Lam et al., 1990). This may possibly be through 
stimulation of the PLA2 pathway via factors other than IL-1. In an arthritic 
tissue, the inhibition of both the COX-2 pathway and the 5-LOX pathway may 
thus prove to be therapeutically more beneficial than blockade of one of the 
pathways (Laufer, 2001).
IL-1 stimulated production of PGE2 in bovine articular chondrocytes (Chapter 
5) and Figure 8.2 below, shows the proposed IL-1-induced PGE2 production 
pathway in these cells and possible targets for cannabinoids’ action. IL-1 
activates PLA2 which liberates arachidonic acid from phospholipids in the 
plasma membrane. COX-2 utilises arachidonic acid to produce PGG2
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followed by PGH2 . Then mPGES utilises PGH2 to produce PGE2 . 
Cannabinoids have been shown in this study, to inhibit COX-2 expression and 
subsequent PGE2 production. They may also significantly reduce the 
production of PGE2 by inhibiting the mPGESs, especially the inducible 
mPGES-1.
IL-1 a
»“ V  NF-kB
Arachidonic acid
>  sGC
LTB4
COX-2 and mPGES
A
PGE:
KEY
Inhibition and possible targets for 
cannabinoids
Activation/stimulation
Figure 8.2: Proposed schematic representation of IL-1-induced PGE2 
production pathway in chondrocytes and possible cross-talk with NO and 
LTB4 production pathways
Inhibition of 5-LOX activating protein (FLAP) by MK-886 also inhibited PGE2 
production, suggesting cross-talk between these two pathways. Inhibition of 
PGE2 production by cannabinoids may possibly, in part, be through their 
ability to reduce LTB4 production. IL-1 has also been shown to activate NF-kB 
mediated PGE2 production through expression of COX-2 and mPGES (Catley
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et a/., 2003). Since the cannabinoid Win-55,212-2 has been shown to inhibit 
activation of NF-kB in chondrocytes in this study (Chapter 7), it is possible 
that some of the effects of cannabinoids shown on PGE2 production were due 
to NF-kB inhibition. Inhibition of NO-sensitive GC also inhibited PGE2 
production, another indication of possible cross-talk between PGE2 and NO 
production pathways. Thus inhibition of NO production by cannabinoids may, 
in part, inhibit PGE2 production.
k-i«
AA FLAP
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5-LOX <
KEY
..................^  Inhibition and possible targets for
cannabinoids
■" Activation/stimulation
Figure 8.3: Proposed schematic representation of induced LTB4 production 
pathway in chondrocytes stimulated with IL-1 a and possible cross-talk with 
PGE2 and NO pathways
In bovine articular chondrocytes, IL-1 was shown to inhibit production of LTB4 
(Chapter 5) and Figure 8.3 shows the proposed LTB4 production pathway in 
bovine articular chondrocytes stimulated with IL-1. It is possible that IL-1 
inhibited 5-LOX or its activating protein (FLAP), thus blocking LTB4
184
production. There appears to be cross-talk between the LTB4 pathway and 
NO and PGE2 pathways since inhibitors of NO-sensitive GC, ODQ and 
inhibitor of COX-2, NS-398 reduced LTB4 production (Chapter 5). 
Cannabinoids also inhibited LTB4 production. This could be due to their ability 
to block the NO and PGE2 pathways or through direct effects on FLAP and/or 
5-LOX.
Cross-talk between the iNOS and COX pathways has been reported by a 
number of researchers (Kanematsu et a/., 1997; Manfield et al., Uno et al., 
2004), suggesting that activation of one pathway modulates the other 
pathway negatively or positively. This implies that pharmacological agents 
designed to inhibit iNOS or COX-2 may influence both pathways (Legrand et 
al., 2001). The present study also suggests that the 5-LOX pathway is also 
involved in the cross-talk. Therefore pharmacological agents that inhibit all 
three pathways may be more effective than those that inhibit just one of the 
pathways. Since cannabinoids, such as Win-55,212-2 exhibited the capacity 
to inhibit all three, COX-2, iNOS and 5-LOX pathways, this places them in a 
favourable position as possible therapeutic agents in arthritis.
Cartilage protection from cytokine-induced degradation
Cannabinoids were found to able to inhibit IL-1-induced extracellular matrix 
degradation in bovine nasal articular cartilage. Cannabinoids blocked the 
induced release of COMP and significantly inhibited proteoglycan and 
collagen breakdown. Win-55,212-2 blocked IL-1-stimulated matrix 
degradation completely, allowing only basal degradation. This could be 
partially due to canabinoids1 ability to block iNOS, COX-2 and LTB4 
production as well as inhibition of p38 MAPK and NF-kB activation.
Possibility of existence of additional cannabinoid receptor(s)
This study has shown for the first time that chondrocytes express both CBi 
and CB2 cannabinoid receptors. To test if the effects of cannabinoids were 
mediated through receptors, enantiomeric pair, Win-55,212-3 and Win-
55.212-2 was used to check for the stereoselectivity of the effects of the 
cannabinoids. Unlike the high-affinity cannabinoid receptor agonist Win-
55.212-2, the low-affinity enantiomer Win-55,212-3 did not exert any 
significant inhibitory effects on the parameters tested: NO production 
(Chapter 4) and extracellular matrix degradation (Chapter 6). This 
enantiomeric stereo-specificity suggests that effects of Win-55,212-2 were 
receptor mediated. Since Win-55,212-2 is a non selective cannabinoid 
receptor agonist, selective antagonists/ inverse agonists, AM 281 and AM 630 
at CBi and CB2  receptors, respectively, were used to check the involvement 
of these receptors in the effects exhibited by Win-55,212-2. Both antagonists 
did not block the effects of Win-55,212-2, suggesting that effects of Win-
55.212-2 were mediated by neither CBi nor CB2 receptor. These findings 
imply presence of another cannabinoid receptor yet to be identified in 
chondrocytes. A number of researchers have suggested the possibility of 
existence of new cannabinoid receptor(s). Facchinetti et al. (2002) showed 
the stereoselectivity of Win-55,212 effects in microglial cells as well as 
inability of selective antagonists of CBi (SR141716A and AM251) and CB2 
(SR144528) cannabinoid receptors to affect the effect of Win-55,212-2, 
suggesting the existence of yet unidentified cannabinoid receptor(s) in brain 
microglia. Also anandamide and Win-55,212-2 were shown to be active in 
CBi knockout mouse brain membranes via a common G protein-coupled 
receptor with a distinct CNS distribution, also implying the existence of an 
unknown cannabinoid receptor subtype in the brain (Breivogel et al., 2001). 
Although anandamide and vanilloid agonists share pharmacological effects, 
the actions of anandamide in CBi knockout mice appeared not to be 
mediated by vanilloid VR(1) receptors (Wiley and Martin, 2002). While not yet 
conclusive, these results suggest the possibility of additional cannabinoid 
receptor(s) in the brain and periphery.
Win-55,212-2 appeared to be the most efficacious cannabinoid agonist in the 
present studies on chondrocytes and cartilage. Win-55,212-2 high potency 
has also been reported elsewhere (Breivogel et al., 2001) and it has been 
proposed that this may be explained by the existence of this extra G protein- 
coupled target for Win-55,212-2.
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For a sumary of effects of cannabinoids as observed using the synthetic 
cannabinoid, Win-55,212-2 at concentration that were not cytotoxic, please 
refer to the Table 8.1 below.
Table 8.1: Summary of the effects of Win-55,212-2
Bovine articular chondrocytes stimulated by IL-1a {0.06 nM)
Parameter
NO production
iNOS expression
PGE2 production
COX-1 expression
COX-2 expression
mPGES expression
LTB4 production
Phosphorylation of p38 MAPK
Total p38 MAPK
NF-kB activation
Proteinase expression
Effect
significantly inhibited 
blocked
significantly inhibited
unaffected
blocked
slight inhibition
inhibited
inhibited
no effect
inhibited
reduced
Bovine nasal cartilage explants stimulated with IL-1a (0.3 nM) 
Parameter Effect
Collagen breakdown significantly inhibited
COMP release blocked completely
Proteoglycan breakdown significantly inhibited
Further work
Further studies are required to allow a full understanding of the effects of 
cannabinoids on chondrocyte metabolism and whether they have potential as 
anti-arthritic drugs. Suggestions for future work include:-
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• studies of the effects of cannabinoids on IL-1 -stimulated human 
chondrocytic cell lines or primary human chondrocytes/explants 
derived from human cartilage, though tissue supply may be 
problematic;
• studies of the effect of cannabinoids on cartilage and synovium co­
cultures unstimulated or stimulated with IL-1, studying parameters 
such as sGAG release, hydroxyproline release and production of pro- 
inflammatory cytokines such as TNF;
• further studies of cannabinoid receptor expression on chondrocytes in 
order to determine the receptors involved in the observed actions of 
cannabinoids including:-
o receptor binding studies;
o studies on receptor knockdown using siRNA and its effects on 
cannabinoid action;
• determination of the effect of cannabinoids on the expression of 
specific proteinases such as MMP-1,-2,-3 and -9 and aggrecanases as 
well as expression of inhibitors of these proteinases in cartilage explant 
and chondrocyte cultures.
These studies would help to further evaluate the role of cannabinoids in 
preventing cartilage breakdown.
Conclusion
It would be worthwhile to consider Win-55,212-2 and other cannabinoids with 
similar potency and efficacy for further studies or trials in arthritic disorders. 
The use of nonpsychoactive cannabinoids such as ajulemic acid, cannabidiol 
and dexanabinol as well as CB2 cannabinoid receptor agonists may allow the 
dissociation of unwanted psychoactive effects from potential therapeutic 
benefits. The existence of other cannabinoid receptors may provide potential 
therapeutic targets that are independent of CB1 receptors and thus devoid of 
the adverse effect associated with the central cannabinoid receptors. 
Elucidation of the most appropriate route of delivery, eliminating smoking,
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may increase the efficacy of the cannabinoids and may evade or reduce 
adverse effects. This thesis suggests that cannabinoids may protect cartilage 
from degradation, partly through their ability to modulate production of pro- 
inflammatory mediators, NO and PGE2 .
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